,NCT Number,Title,Interventions,Phases,Official Title
0,NCT02266147,studi of sd101 in combin with local lowdos radiat in patient with untreat lowgrad bcell lymphoma,['sd-101'],"['1', '2']",a phase 12 nonrandomized openlabel multicenter dose escal and expans studi of intratumor inject of sd101 in combin with local lowdos radiat in patient with untreat lowgrad bcell lymphoma
1,NCT02055924,bruton tyrosin kinas btk inhibit in bcell lymphoma,"['ibrutinib', 'immunochemotherapies']",['1'],a phase ib studi of ibrutinib combin with rdhap or rdhaox in patient with bcell lymphoma
2,NCT02395601,a studi evalu cpi1205 in patient with bcell lymphoma,['cpi-1205'],['1'],a phase 1 studi of cpi1205 a small molecul inhibitor of ezh2 in patient with bcell lymphoma
3,NCT00162656,treatment of matur bcell lymphomaleukaemia,"['half cyclophosphamide', 'without copadm3', 'mini cyve', 'without 3 maintenance courses', 'lmb b', 'lmb c']",['3'],treatment of matur bcell lymphomaleukaemia a sfop lmb 96ccg 5961ukccsg nhl 9600 cooper studi
9,NCT02433795,bendamustin plus rituximab br for relaps or progress margin zone bcell lymphoma mzbcl,"['bendamustine', 'rituximab']",['2'],a phase ii studi of bendamustin plus rituximab br in patient with relaps or progress margin zone bcell lymphoma mzbcl
19,NCT02060656,phase ii studi compar lrgem to rgemp in secondlin treatment of diffus larg bcell lymphoma legend,"['gemcitabine', 'methylprednisolone', 'rituximab', 'cisplatin', 'lenalidomide']",['2'],a randomis phase ii studi compar lenalidomid plus rituximab gemcitabin and methylprednisolon lrgem to rituximab gemcitabine methylprednisolon and cisplatin rgemp in secondlin treatment of diffus larg bcell lymphoma dlbcl
20,NCT01068392,oxaliplatin and prednisolon oxp for patient with relaps or refractori margin zone bcell lymphomamzl,"['oxaliplatin', 'prednisolone']",['2'],a phase ii studi of oxaliplatin and prednisolon oxp for patient with relaps or refractori margin zone bcell lymphoma
21,NCT02531308,metformin in combin with standard induct therapi for larg bcell lymphoma dlbcl,"['metformin', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone', 'pegfilgrastim']",['2'],a phase ll studi evalu the efficaci and safeti of metformin in combin with standard induct therapi rmchop for previous untreat aggress diffus larg bcell lymphoma
26,NCT00097929,an investig drug studi with suberoylanilid hydroxam acid in relaps diffus larg bcell lymphoma 0683013,"['mk0683', 'vorinostat', 'suberoylanilide hydroxamic acid ']",['2'],a phase ii clinic trial of oral suberoylanilid hydroxam acid saha in patient with relaps diffus larg bcell lymphoma dlbcl
27,NCT01226849,feasibl studi of ad bortezomib to rice chemotherapi to treat relapsed refractori diffus larg bcell lymphoma,"['bortezomib', 'rituximab', 'ifosphamide', 'etoposide', 'carboplatin']",['1'],an openlabel pilot studi to investig feasibl and safeti of use bortezomib rituximab ifosfamide carboplatin etoposid as salvag regim in previous treat patient with diffus larg bcell lymphoma
29,NCT00801216,highdos sequenti chemoimmunotherapi for bcell lymphoma with central nervous system involv,"['high-dose sequential chemotherapy', 'autologous transplant']",['2'],highdos sequenti chemotherapi and rituximab rhds in patient with system bcell lymphoma with central nervous system involv at diagnosi or relaps
30,NCT00761384,high dose absorb dose adjust 90yibritumomab with peripher blood stem cell pbsc support in bcell lymphoma,['90y-ibritumomab'],"['1', '2']",a prospect studi with individu adjust high dose 90yibritumomab tiuxetan treatment with peripher blood stem cell support to improv outcom for patient with refractoryrecurr bcell lymphoma stage iiiv
31,NCT00965289,highdos chemotherapi with rituximab for adult with aggress larg bcell lymphoma,['rituximab'],['2'],frontlin highdos chemotherapi hdt combin with rituximab for adult with aggress larg bcell lymphoma dlbcl  goelam 074 trial
35,NCT02733380,chidamid combin with vddt regimen in the relaps and refractori diffus larg b cell lymphoma,"['chidamide', 'vinorelbine', 'liposomal doxorubicin or mitoxantrone', 'dexamethasone', 'thalidomide']",['2'],the efficaci and safeti of chidamid combin with vddt regimen（vinorelbine，liposom doxorubicin，dexamethason and thalidomide） in relaps and refractori patient with diffus larg b cell lymphoma
40,NCT00906841,studi of 90ydotahll2 as a consolid therapi after rchop in patient with diffus larg bcell lymphoma,['90y-dota'],['2'],phase ii studi of evalu of fraction radioimmunotherapi with 90ydotahll2 as a consolid therapi after first line of chemotherapi in patient older than 60 with dissemin diffus larg bcell lymphoma
41,NCT01626352,studi of bendamustin and ofatumumab in elder patient with newli diagnos diffus larg bcell lymphoma who are poor candid for rchop chemotherapi,"['bendamustine', 'ofatumumab']",['2'],phase ii studi of bendamustin and ofatumumab in elder patient with newli diagnos diffus larg bcell lymphoma who are poor candid for rchop chemotherapi
44,NCT01402440,studi of aeb071 a protein kinas c inhibitor in patient with cd79mutant diffus larg bcell lymphoma,['aeb071'],['1'],an openlabel singlearm phase i studi of aeb071 a protein kinas c inhibitor in patient with cd79mutant diffus larg bcell lymphoma
45,NCT01854606,safeti and efficaci of aeb071 and everolimus in patient with cd79mutant or abc subtyp diffus larg bcell lymphoma,"['aeb071', 'everolimus']",['1'],an openlabel singlearm phase ibii studi of aeb071 a protein kinas c inhibitor and everolimus mtor inhibitor in patient with cd79mutant or abc subtyp diffus larg bcell lymphoma
49,NCT02227251,a phase 2b openlabel studi of selinexor kpt330 in patient with relapsedrefractori diffus larg bcell lymphoma dlbcl,['selinexor'],['2'],selinexor kpt330 in patient with relapsedrefractori diffus larg bcell lymphoma dlbcl
51,NCT00169468,associ of velcad to rchop in the treatment of b cell lymphoma,['rituximab '],['2'],phase ii studi of the associ of velcad to rchop in the treatment of b cell lymphoma
54,NCT01046825,matur bcell lymphoma and leukemia studi iii,"['copad', 'cop', 'copd m3', 'cym', 'cop', 'copadm8', 'cyve']","['2', '3']",matur bcell lymphoma and leukemia studi iii
56,NCT00895661,high dose rituximab for initi treatment of indol bcell lymphoma,['rituximab'],['2'],phase ii trial of increas dose rituximab plus mainten rituximab for initi system treatment of indol bcell lymphoma
61,NCT01799083,lower dose decitabin base therapi in patient with refractori andor chemotherapi resist solid tumor or b cell lymphoma,['decitabine'],"['1', '2']",phase 12 studi of decitabin alon andor in combin with chemotherapi andor cytokin induc killer cell transfus in patient with relaps or refractori solid tumor and b cell lymphoma
62,NCT01499303,studi to learn if 200mg test drug fostamatinib help peopl with larg bcell lymphomaa type of blood cancer,['fostamatinib'],['2'],phase ii trial to evalu the efficaci of fostamatinib in patient with relaps or refractori diffus larg bcell lymphomadlbcl
65,NCT01622439,valproat as first line therapi in combin with rituximab and chop in diffus larg bcell lymphoma,"['valproate', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone']","['1', '2']",valproat as first line therapi in combin with rituximab and chop in diffus larg bcell lymphoma
67,NCT01805557,phase ii random studi with rdhap  bortezomib as induct therapi in relapsedrefractori diffus larg bcell lymphoma dlbcl patient elig to transplantation brdhap versus rdhap,"['r-dhap', 'br-dhap']","['2', '3']",phase ii random studi with rdhap  bortezomib as induct therapi in relapsedrefractori diffus larg bcell lymphoma dlbcl patient elig to transplantation brdhap versus rdhap
69,NCT01278602,reshap follow by autolog transplant for refractori or relaps diffus larg bcell lymphoma,['r-eshap'],['2'],a multicent phase ii studi of reshap follow by autolog transplant as salvag treatment for patient with refractori or relaps diffus larg bcell lymphoma
70,NCT00138086,yttrium90 ibritumomab tiuxetan zevalin with beam in relaps low grade bcell lymphoma,"['zevalin', 'beam']",['2'],target intensif by a new prepar regimen for patient with lowgrad bcell lymphoma util standarddos yttrium90 ibritumomab tiuxetan zevalin radioimmunotherapi rit combin with highdos beam follow by autolog stem cell transplant asct
78,NCT01289210,vtx2337 in combin with radiotherapi in patient lowgrad bcell lymphoma,"['vtx-2337', 'radiotherapy']","['1', '2']",a phase iii studi of intratumor inject of the small molecul tlr8 agonist vtx2337 in combin with local radiat in lowgrad bcell lymphoma
83,NCT02595242,safeti and efficaci studi of cnop chemotherapi in diffus larg b cell lymphoma,"['cyclophosphamide', 'vincristine', 'prednisone']",['1'],safeti and efficaci studi of mitoxantron hydrochlorid liposom inject plus cyclophosphamidevincristin and prednison cnopin diffus larg b cell lymphoma
84,NCT01466868,studi of mk 2206 in patient with relaps or refractori diffus larg b cell lymphoma,['mk2206'],['2'],a phase ii studi of mk 2206 in patient with relaps or refractori diffus larg b cell lymphoma
85,NCT01238692,a phase ii studi of oral panobinostat lbh589 and rituximab to treat diffus larg b cell lymphoma dlbcl,"['lbh589', 'rituximab']",['2'],a random phase ii studi of oral panobinostat lbh589 with or without rituximab to treat relaps or refractori diffus larg b cell lymphoma
86,NCT00001271,a phase i studi of continu infus immunotoxin iggrfb4smptdga in refractori cd22 posit bcell lymphoma,['igg-rfb4'],['1'],a phase i studi of continu infus immunotoxin iggrfb4smptdga in refractori cd22 posit bcell lymphoma
87,NCT01949818,treatment of diffus larg b cell lymphoma,"['yangzhengxiaoji capsule combined with chop regimen', 'chop regimen']",['4'],a randomized control mutiplecent clinic research on the treatment with yangzhengxiaoji capsul combin chemotherapi for iiiiv diffus larg b cell lymphoma
90,NCT01676558,a phase ii studi of 131irituximab for relapsedrefractori diffus larg b cell lymphoma dlbcl,['131i-rituximab'],['2'],a phase ii studi of 131irituximab for elder or poor perform status patient with diffus larg b cell lymphoma dlbcl or for adult patient with relaps or refractori dlbcl
93,NCT01282476,panobinostat with rituximab for relapsedrefractori diffus larg b cell lymphoma,['panobinostat with rituximab'],['2'],panobinostat in combin with rituximab for relapsedrefractori diffus larg b cell lymphoma
94,NCT01766583,a phase ib studi of the btki cc292 combin with lenalidomid in adult patient with relapsedrefractori bcell lymphoma,"['cc-292', 'lenalidomide']",['1'],a phase ib studi of the btki cc292 combin with lenalidomid in adult patient with relapsedrefractori bcell lymphoma
96,NCT01556035,lenalidomid in relaps or refractori primarycutan larg bcell lymphoma legtyp  multicentr prospect phase ii singl arm trial of the french studi group of cutan lymphoma,['lenalidomide'],['2'],a multicentr prospect phase ii singl arm trial evalu the benefit of therapi with lenalidomid revlimid® in relaps or refractori primarycutan larg bcell lymphoma legtype after first line treatment by chemotherapi plus rituximab for the french studi group of cutan lymphoma gfelc
97,NCT02449265,efficaci of consolid involvedsit radiotherapi for patient with limitedstag diffus larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone']",['3'],efficaci of consolid involvedsit radiotherapi follow suffici chemotherapi for patient with limitedstag diffus larg bcell lymphoma wuhan univers cancer center nhl03 trial
98,NCT02449278,the palliat benefit of involvedsit radiotherapi for patient with advancedstag diffus larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone']",['3'],the palliat benefit of involvedsit radiotherapi follow effect chemotherapi for patient with advancedstag diffus larg bcell lymphoma wuhan univers cancer center  nhl04 trial
99,NCT02692248,ibrutinib in patient with refractoryrelaps nongcb diffus larg bcell lymphoma noncandid to autolog stem cell transplant,"['ibrutinib', 'rituximab', 'gemcitabine', 'oxaliplatin', 'dexamethasone']",['2'],multicentr phase ii trial to evalu the efficaci and safeti of ibrutinib in combin with rituximab gemcitabine oxaliplatin and dexamethason follow by ibrutinib mainten in patient with refractoryrelaps nongcb diffus larg bcell lymphoma non candid to asct
100,NCT02412267,studi of ofatumomab in combin with icechemotherapi in patient with diffus larg bcell lymphoma dlbcl,['o-ice '],['2'],an openlabel nonrandom phase 2 studi of ofatumomab o in combin with ice ifosfamide carboplatin etoposidechemotherapi in patient with relapsedrefractori diffus larg bcell lymphoma dlbcl
102,NCT01197560,studi of lenalidomid to evalu safeti and effect in patient with diffus larg bcell lymphoma dlbcl,"['lenalidomide', 'gemcitabine', 'oxaliplatin', 'rituximab', 'etoposide']","['2', '3']",a phase 23 multicenter randomized openlabel studi to compar the efficaci and safeti of lenalidomid revlimid ® versus investig choic in patient with relaps or refractori diffus larg bcell lymphoma
103,NCT01054781,intensifi 1st cycl rituximab plus 8th cycl of rchop chemotherapi in patient with advanc or bulki cd20 diffus larg bcell lymphoma dlbcl,['rituximab'],['2'],openlabelled multicent phase ii studi of intensifi 1st cycl rituximab plus 8th cycl of rchop chemotherapi in patient with advanc or bulki cd20 diffus larg bcell lymphoma dlbcl
105,NCT00776802,gcs100le in combin with etoposid and dexamethason in relaps or refractori diffus larg bcell lymphoma,"['gcs-100', 'etoposide']","['1', '2']",phase 12 studi of gcs100 in combin with etoposid and dexamethason in relaps or refractori diffus larg b cell lymphoma
106,NCT02329080,new combin of chemoimmunotherapi for system bcell lymphoma with central nervous system involv,"['methotrexate', 'rituximab', 'cytarabine', 'thiotepa', 'liposomial cytarabine', 'etoposide', 'ifosfamide', 'carmustine']",['2'],an intern phase ii trial assess toler and efficaci of sequenti methotrexatearacytinbas combin and rice combination follow by hd chemotherapi support by asct in patient with system bcell lymphoma with cns involv at diagnosi or relaps marietta regimen
108,NCT02340936,clinic trial to determin dose secur and efficaci or lenalidomid and rituximab lreshap in patient with diffus larg bcell lymphoma,"['lr-eshap ', 'lr-eshap ', 'lr-eshap ', 'lr-eshap ']","['1', '2']",national openlabel multicentr phase iii studi of combin reshap with lenalidomid as salvag therapi for patient with relaps or refractori diffus larg bcell lymphoma candid to stemcel transplant
110,NCT01164267,multicent phase ii studi to evalu the clinic activ and the safeti profil of everolimus in margin zone bcell lymphoma mzl,['everolimus'],['2'],a multicent phase ii studi to evalu the clinic activ and the safeti profil of everolimus rad001 in margin zone bcell lymphoma mzl eudract number 200901172514
111,NCT02142049,ibrutinib and lenalidomid with dose adjust epochr in subject with relapsedrefractori diffus larg bcell lymphoma,"['ibrutinib', 'part 1']","['1', '2']",a multicent studi of ibrutinib and lenalidomid in combin with daepochr in subject with relaps or refractori diffus larg bcell lymphoma
112,NCT00486759,a studi of bevacizumab avastin in combin with rituximab mabthera and chop cyclophosphamide hydroxydaunorubicin doxorubicin oncovin vincristine prednisone chemotherapi in patient with diffus larg bcell lymphoma,"['bevacizumab', 'rituximab', 'chop', 'placebo']",['3'],a multicenter randomized doubleblind placebocontrol phase iii trial compar the efficaci of bevacizumab in combin with rituximab and chop rchop  bevacizumab versus rituximab and chop rchop in previous untreat patient with cd20posit diffus larg bcell lymphoma dlbcl
114,NCT01481129,akt inhibitor mk2206 in treat patient with relaps or refractori diffus larg bcell lymphoma,['akt inhibitor mk2206'],['2'],a phase 2 studi of mk2206 in patient with relaps or refractori diffus largeb cell lymphoma
117,NCT01741792,clinic studi with blinatumomab in patient with relapsedrefractori diffus larg bcell lymphoma dlbcl,['blinatumomab'],['2'],an open label multicenter exploratori phase 2 studi to evalu the efficaci and safeti of the bispecif tcell engag bite® blinatumomab in patient with relapsedrefractori diffus larg bcell lymphoma dlbcl
119,NCT02471911,kpt330 plus rice for relapsedrefractori aggress bcell lymphoma,"['kpt-330', 'rituximab', 'etoposide', 'carboplatin', 'ifosfamide', 'dexamethasone']",['1'],a phase i investigatoriniti studi of selinexor kpt330 plus rice in patient with relaps or refractori aggress bcell lymphoma
122,NCT01481272,ofatumumab with ivac salvag chemotherapi in diffus larg b cell lymphoma patient,"['ofatumumab', 'etoposide', 'ifosfamid', 'mesna', 'cytarabine', 'methotrexate', 'leukovorin', 'granulocyte-colony stimulating factor']",['2'],a phase ii trial on ofatumumab with ivac salvag chemotherapi in diffus larg b cell lymphoma patient progress or relaps after prior rchop treatment not suitabl for autolog stem cell transplant
123,NCT01470456,combin of sar3419 and rituximab in relapsedrefractori diffus larg bcell lymphoma,"['sar3419', 'rituximab']",['2'],an open label multicent phase ii studi of intraven sar3419 an anticd19 antibodymaytansin conjugate in combin with rituximab in patient with relaps or refractori diffus larg bcell lymphoma
124,NCT01004991,phase iii trial of rchop  azacytidin in diffus larg b cell lymphoma,"['cyclophosphamide', 'vincristine', 'doxorubicin', 'prednisone', 'azacytidine']","['1', '2']",phase iii trial of azacytidin  rchop in diffus larg bcell lymphoma
127,NCT01472887,sar3419 as singl agent in relapsedrefractori diffus larg bcell lymphoma dlbcl patient,['sar3419'],['2'],an open label nonrandom phase 2 studi evalu sar3419 an anticd19 antibodi  maytansin conjugate administ as singl agent by intraven infus to patient with relaps or refractori cd19 diffus larg bcell lymphoma
128,NCT00169169,efficaci studi of rituximab after asct in highrisk diffus larg bcell lymphoma,"['acvbp', 'ace', 'rituximab']",['3'],randomis phase 3 studi of rituximab in highrisk patient with diffus larg bcell lymphoma who receiv a firstlin consolid chemotherapi with autolog stem cell transplant asct
129,NCT00790036,phase iii studi of rad001 adjuv therapi in poor risk patient with diffus larg bcell lymphoma dlbcl of rad001 versus match placebo after patient have achiev complet respons with firstlin rituximabchemotherapi,"['everolimus', 'everolimus placebo']",['3'],a randomized doubleblind placebocontrolled multicent phase iii studi of rad001 adjuv therapi in poor risk patient with diffus larg bcell lymphoma dlbcl of rad001 versus match placebo after patient have achiev complet respons with firstlin rituximabchemotherapi
131,NCT01423539,a studi of navitoclax in addit to bendamustin and rituximab in patient with relaps diffus larg bcell lymphoma navigate,"['bendamustine', 'navitoclax', 'rituximab']",['2'],a phase ii multicenter randomized controlled openlabel studi of bendamustin  rituximab with or without navitoclax in patient with relaps diffus larg bcell lymphoma
132,NCT00836173,rituximab ifosfamide carboplatin and etoposid rice follow by gallium nitrate rituximab and dexamethason gard for relaps or refractori diffus larg bcell lymphoma,"['rice', 'gard treatment']",['2'],a phase ii studi evalu three cyslc of ifosfamide carboplatin etoposide and rituximab rice follow by two cycl of gallium nitrate rituximab and dexamethason gard for relaps or refractori diffus larg bcell lymphoma ma
134,NCT01678404,131irituximab for relaps or refractori margin zone bcell lymphoma,['131i-rituximab'],['2'],a phase ii studi of 131irituximab for patient with relaps or refractori margin zone bcell lymphoma
136,NCT02112526,acp196 a btk inhibitor for treatment of de novo activ bcell abc subtyp of diffus larg bcell lymphoma,['acp-196'],['1'],an openlabel phase 1b studi of acp 196 in subject with relaps or refractori de novo activ bcell abc subtyp of diffus larg bcell lymphoma
137,NCT00869999,everolimus plus rituximab for relapsedrefractori diffus larg b cell lymphoma,"['everolimus', 'rituximab']",['2'],everolimus in combin with rituximab for relapsedrefractori diffus larg b cell lymphoma
138,NCT00978432,epigenet modul in relapsedrefractori diffus larg bcell lymphoma dlbcl,"['rad001', 'lbh589', 'doublet ']",['2'],a phase 2 studi to evalu the efficaci of epigenet modul in relapsedrefractori diffus larg bcell lymphoma dlbcl
139,NCT01562990,phase ibii studi of the efficaci and safeti of the rcmc544rgemox combin in diffus lage bcell lymphoma at first or second relaps,"['rituximab', 'cmc544', 'gemcitabine', 'oxaliplatine']","['1', '2']",a multicenter phase ibii open label singl arm studi of inotuzumab ozogamicin plus rituximab rcmc544 altern with gemcitabineoxaliplatin plus rituximabrgemoxin patient age from 18 to 80 year with cd20 and cd22 posit diffus larg bcell lymphoma dlbcl in relaps afterrefractori to 1st or 2nd line treatment who are no candid for autolog transplant
140,NCT01502982,dose dens chemotherapi and rituximab for young high risk diffus larg bcell lymphoma patient cry04,['r-choep14x6+hd'],['2'],choep14  rituximab with cns prophylaxi in patient less than 65 year with diffus larg bcell lymphomafollicular lymphoma grade iii stage iiiv with risk factor age adjust ipi ≥ 2 a phase ii studi
141,NCT00831597,bendamustin combin with rituximab for patient with relaps or refractori diffus larg bcell lymphoma,"['bendamustine', 'rituximab']",['2'],bendamustin combin with rituximab for patient with relaps or refractori diffus larg bcell lymphoma
142,NCT01066429,daedoch14r in poorprognosi diffus larg bcell lymphoma,"['dexamethasone', 'dose']",['2'],treatment with infusion doseadjust etoposidevincristinedoxorubicinbolus cyclophosphamidedexamethason and rituximab daedoch14r in patient with poorprognosi diffus larg bcell lymphoma
144,NCT00474188,a studi to evalu lenalidomid combin with dexamethason in relaps or refractori diffus larg bcell lymphoma,"['cc-5013 ', 'dexamethasone']",['2'],a phase ii multicenter singlearm openlabel studi to evalu the safeti and efficaci of lenalidomid revlimid ® in combin with dexamethason in subject with relaps or refractori diffus larg bcell lymphoma
145,NCT01287741,a studi of obinutuzumab in combin with chop chemotherapi versus rituximab with chop in particip with cd20posit diffus larg bcell lymphoma goya,"['rituximab', 'obinutuzumab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone']",['3'],a phase iii multicenter openlabel random trial compar the efficaci of ga101 ro5072759 in combin with chop gchop versus rituximab and chop rchop in previous untreat patient with cd20posit diffus larg bcell lymphoma dlbcl
147,NCT00169143,studi of racvbp regimen support by pegfilgrastim in highrisk diffus larg bcell lymphoma,"['rituximab', 'acvbp regimen', 'pegfilgrastim']",['2'],studi of racvbp regimen support by pegfilgrastim in previous untreat patient age from 18 to 60 year with highrisk diffus larg bcell lymphoma ageadjust ipi or 2
148,NCT00788606,rchopb bevacizumab for diffus larg b cell lymphoma,"['bevacizumab', 'rituximab']",['2'],feasibl studi of rchop plus bevacizumab in patient with diffus larg b cell lymphoma dlbcl
149,NCT02077166,ibrutinib in combin with lenalidomid and rituximab in particip with relaps or refractori diffus larg bcell lymphoma,"['ibrutinib', 'lenalidomide', 'rituximab']","['1', '2']",a multicent openlabel phase 1b2 studi of the bruton tyrosin kinas btk inhibitor ibrutinib in combin with lenalidomid and rituximab in subject with relaps or refractori diffus larg bcell lymphoma
150,NCT00918463,a studi to evalu the safeti and efficaci of dasatinib sprycel in subject with relaps or refractori diffus larg bcell lymphoma dlbcl,['dasatinib'],['2'],a phase ii singleinstitution singlearm openlabel studi to evalu the safeti and efficaci of a singl agent dasatinib sprycel in subject with relaps or refractori diffus larg bcell lymphoma
152,NCT02271945,safetyefficaci of medi551 in combin with immunomodul therapi in subject with aggress bcell lymphoma,"['medi-551 12 mg', 'medi0680 2', 'medi0680 10 mg']","['1', '2']",a phase 1b2 openlabel studi to evalu the safetyefficaci of medi551 in combin with immunomodul therapi in subject with relaps or refractori aggress bcell lymphoma
153,NCT00440583,the respons studi of yt90zevalin in patient with diffus larg bcell lymphoma after 6 cycl of chop,['chemotherapy followed by zevalin'],['2'],yt90 zevalin  combin chemotherapi in treat patient with stage iistag iiior stage iv diffus larg bcell lymphoma
154,NCT02670616,studi of ibrutinib in combin with rituximabchop in epsteinbarr virusposit diffus larg bcell lymphoma,"['ibrutinib', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisolone']",['2'],phase ii studi of ibrutinib in combin with rituximabchop in epsteinbarr virusposit diffus larg bcell lymphoma 54179060lym2003 nick name ivori study
155,NCT01040871,studi of the combin of velcade rituximab cyclophosphamide doxorubicin and prednison or rituximab cyclophosphamide doxorubicin vincristine and prednison in patient with newli diagnos nongermin center bcell subtyp of diffus larg bcell lymphoma,"['velcade', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'prednisone', 'vincristine']",['2'],a randomized openlabel multicent phase 2 studi of the combin of velcade rituximab cyclophosphamide doxorubicin and prednison or rituximab cyclophosphamide doxorubicin vincristine and prednison in patient with newli diagnos nongermin center bcell subtyp of diffus larg bcell lymphoma
156,NCT02420210,bendamustine obinutuzumab and dexamethason in older patient with diffus larg bcell lymphoma,"['bendamustine hydrochloride', 'dexamethasone']",['2'],multicent phase ii studi of the bendamustine obinutuzumab and dexamethason bod regimen in unfit elder ≥ 70 year of age diffus larg bcell nonhodgkin lymphoma dlbcl patient
158,NCT00118209,rituximab and combin chemotherapi in treat patient with diffus larg bcell nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone', 'etoposide', 'filgrastim', 'pegfilgrastim']",['3'],phase iii random studi of rchop v doseadjust epochr with molecular profil in untreat de novo diffus larg bcell lymphoma
159,NCT00209014,phase ii trial of thalidomid in refractoryrelaps diffus larg bcell lymphoma and hodgkin diseas,['thalidomide'],['2'],phase ii trial of thalidomid in refractoryrelaps diffus larg bcell lymphoma and hodgkin diseas
163,NCT02679196,the safety pharmacokinet and pharmacodynam effect of ka2237 pi3 kinas p110βδ inhibitor in b cell lymphoma,['ka2237'],['1'],an open label ascend dose studi evalu the safetytolerability pharmacokinet and pharmacodynam effect of ka2237 in patient with b cell lymphoma
164,NCT02594163,studi of rituximab and bendamustin with or without brentuximab vedotin for cd30 posit diffus larg bcell lymphoma,"['brentuximab vedotin', 'rituximab', 'bendamustine']",['2'],a randomized open label phase 2 studi of rituximab and bendamustin with or without brentuximab vedotin for relaps or refractori cd30posit diffus larg bcell lymphoma
165,NCT02596971,a studi of atezolizumab in combin with either obinutuzumab plus bendamustin or obinutuzumab plus  cyclophosphamide doxorubicin vincristine and prednison chop in particip with follicular lymphoma fl or rituximab  chop in particip with diffus larg bcell lymphoma dlbcl,"['atezolizumab', 'bendamustine', 'cyclophosphamide', 'doxorubicin', 'obinutuzumab', 'prednisone', 'vincristine', 'rituximab']","['1', '2']",a phase ibii studi evalu the safeti and efficaci of atezolizumab in combin with either obinutuzumab plus bendamustin or obinutuzumab plus chop in patient with follicular lymphoma or rituximab plus chop in patient with diffus larg bcell lymphoma
166,NCT00575406,multicentr studi to determin the cardiotox of rchop compar to rcomp in patient with diffus larg bcell lymphoma,"['rituximab', 'cyclophosphamide', 'doxorubicin', 'liposomal doxorubicin', 'vincristin', 'prednisolone']",['2'],multicentr studi to determin the cardiotox of rchop rituximab cyclophosphamide doxorubicin vincristin and prednisolone compar to rcomp rituximab cyclophosphamide liposom doxorubicin vincristin and prednisolone in patient with diffus larg bcell lymphoma nhl14
167,NCT01195714,studi of minichop plus ofatumumab to treat cd 20 diffus larg bcell lymphoma in patient age over 80 year,['ofatumumab'],['2'],phase ii studi of minichop plus ofatumumab o in non previous treat patient age over 80 year with cd 20 diffus larg bcell lymphoma
169,NCT01852435,rceop90rceop70 versus rchop50 in the treatment of diffus larg bcell lymphoma and follicular lymphoma grade 3b,"['r-ceop', 'r-ceop', 'r-chop']",['3'],a multicenter prospective random phase iii studi of the safeti and efficaci of rceop90rceop70 versus rchop50 in the treatment of diffus larg bcell lymphoma and follicular lymphoma grade 3b
175,NCT00931918,studi to assess the effect of rchop with or without velcad in previous untreat nongermin center bcelllik diffus larg bcell lymphoma patient,"['bortezomib', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone']",['2'],an openlabel randomized phase 2 studi to assess the effect of rchop with or without velcad in previous untreat nongermin center bcelllik diffus larg bcell lymphoma patient
177,NCT00316511,studi of lnddp aroplatin in patient with advanc solid malign or bcell lymphoma,['aroplatin'],['1'],a phase 1 multicenter dose escal and pharmacokinet studi of lnddp aroplatin in patient with advanc solid malign or bcell lymphoma
178,NCT01786018,thiotepa busulfan and fludarabin for pt with refractoryear relaps aggress bcell non hodgkin lymphoma,"['thiotepa', 'busulfan', 'fludarabin', 'immunosuppression', 'cyclosporine', 'methotrexate', 'atg']",['2'],allogen transplant after a condit with thiotepa busulfan and fludarabin for the treatment of refractoryear relaps aggress bcell non hodgkin lymphomas a phase ii multicent trial
180,NCT00147121,rituximabstandard chop vs rituximabbiweek chop for untreat stage iiiiv lowgrad bcell lymphoma jcog0203,"['rituximab', 'standard chop', 'rituximab', 'bi']","['2', '3']",rituximab  standard chop r･schop vs rituximab biweek chop r･bichop rctphase iiiii for stage iiiiv lowgrad bcell lymphoma lowbnhlrsbichopp23 jcog0203
181,NCT02600897,a studi of obinutuzumab polatuzumab vedotin and lenalidomid in relaps or refractori follicular lymphoma fl and rituximab in combin with polatuzumab vedotin and lenalidomid in relaps or refractori diffus larg bcell lymphoma dlbcl,"['lenalidomide', 'obinutuzumab', 'polatuzumab vedotin', 'rituximab']",['1'],a phase ibii studi evalu the safeti and efficaci of obinutuzumab in combin with polatuzumab vedotin and lenalidomid in patient with relaps or refractori follicular lymphoma and rituximab in combin with polatuzumab vedotin and lenalidomid in patient with relaps or refractori diffus larg bcell lymphoma
182,NCT00434629,safeti and efficaci of bexxar therapi in the treatment of relapsedresidu bcell lymphoma after autolog transplant,['bexxar'],['1'],a phase i studi of bexxar® tositumomab and 131itositumomab radioimmunotherapi in patient with relaps or residu cd20 antigenexpress bcell lymphoma follow autolog hematopoiet stem cell transplant
183,NCT02542111,a studi of bortezomib plus gdp in the treatment of refractori and relaps nongcb dlbcl,"['bortezomib', 'gemcitabine', 'dexamethasone', 'cisplatin']",['2'],a phase ii studi of the efficaci and safeti of bortezomib plus gdp in the treatment of refractori and relaps nongcb diffus larg bcell lymphoma
184,NCT00499018,dose dens chemotherapi  rituximab intensifi high dose chemoimmunotherapi with support of peripher autolog stem cell in diffus larg bcell lymphoma,"['rituximab', 'ciclofosfamide', 'doxorubicina', 'vincristina', 'prednisone', 'pegfilgrastim', 'mitoxantrone', 'ara-c', 'lenograstim', 'bcnu', 'vp-16']",['3'],a randomis multicentr phase iii studi for the treatment of young patient with high risk ipi 23 diffus larg bcell lymphoma dose dens chemotherapi  rituximab  intensifi high dose chemoimmunotherapi with support of peripher autolog stem cells
185,NCT01724021,a studi of particip prefer with subcutan versus intraven mabtherarituxan in particip with cd20 diffus larg bcell lymphoma or cd20 follicular nonhodgkin lymphoma grade 1 2 or 3a,"['cyclophosphamide', 'hydroxydaunorubicin', 'oncovin', 'prednisone', 'cyclophosphamide', 'vincristine', 'prednisone', 'bendamustine', 'rituximab']",['3'],a randomized openlabel mutlicentr studi to evalu patient prefer with subcutan administr of rituximab versus intraven rituximab in previous untreat patient with cd20 diffus larg bcell lymphoma or cd20 follicular nonhodgkin lymphoma grade 1 2 or 3a
186,NCT01788189,lenalidomide mtx arac and rituximab in relaps aggress bcell lymphoma,['lenalidomide'],"['1', '2']",lenalidomid in conjunct with methotrexate leucovorin cytarabin and rituximab for the treatment of relaps or refractori cd20posit aggress lymphomas an openlabel multicent phase iii trial
188,NCT01453205,a phase 2 multicenter randomized openlabel studi of medi551 in adult with relaps or refractori diffus larg bcell lymphoma dlbcl,"['medi-551 2 mg', 'rituximab', 'ice', 'dhap', 'medi-551 4 mg']",['2'],a phase 2 random openlabel studi of medi551 in adult with relaps or refractori dlbcl
190,NCT00038571,proteasom inhibitor ps341 relaps or refractori b cell lymphoma previous treat with chemotherapi,['ps341 '],['2'],phase ii studi of proteasom inhibitor ps341 for patient with relaps or refractori b cell lymphoma previous treat with chemotherapi
191,NCT02660710,rituximab plus chop chemotherapi for diffus larg bcell lymphoma,['r-chop'],['2'],lccc 1335 a singlearm phase iii clinic trial of rituximab plus chop chemotherapi for diffus larg bcell lymphoma in malawi
192,NCT00849654,studi of the safeti and toler of pci32765 in patient with recurr b cell lymphoma,['pci-32765'],['1'],phase i doseescal studi of bruton tyrosin kinas btk inhibitor pci32765 in recurr b cell lymphoma
198,NCT01414855,a studi of obinutuzumab ro5072759 ga101 in combin with chop chemotherapi in patient with previous untreat advanc diffus larg bcell lymphoma gather,"['obinutuzumab', 'cyclophosphamide', 'doxorubicin', 'prednisone', 'vincristine']",['2'],a phase ii openlabel multicent studi of efficacy safety and biomark in patient with previous untreat advanc diffus larg bcell lymphoma treat with ga101 ro5072759 in combin with chop chemotherapi
200,NCT02229981,earli phase evalu of abc294640 in patient with refractoryrelaps diffus larg bcell lymphoma or kaposi sarcoma,['abc294640'],"['1', '2']",an earlyphas clinic trial evalu abc294640 in patient with refractoryrelaps diffus larg bcell lymphoma or kaposi sarcoma
201,NCT02570542,impact of cd34 cell dose on progressionfre surviv follow highdos therapi and autolog stem cell transplant for relaps and refractori diffus larg bcell lymphoma dlbcl,"['plerixafor', 'carmustine', 'etoposide', 'cytarabine', 'melphalan']",['2'],a multicent random phase ii studi of the impact of cd34 cell dose on progressionfre surviv follow highdos therapi and autolog stem cell transplant for relaps and refractori diffus larg bcell lymphoma dlbcl
202,NCT00867087,studi evalu inotuzumab ozogamicin cmc544 plus rituximab in diffus larg bcell nonhodgkin lymphoma,"['inotuzumab ozogamicin ', 'rituximab']",['2'],an openlabel singlearm phase 2 studi of inotuzumab ozogamicin plus rituximab in subject with relapsedrefractori cd22posit diffus larg bcell lymphoma elig for autolog stem cell transplant
203,NCT01965119,pilot studi of ruxolitinib in relaps or refractori hodgkin lymphoma and primari mediastin larg bcell lymphoma,['ruxolitinib'],['2'],pilot studi of ruxolitinib in relaps or refractori hodgkin lymphoma and primari mediastin larg bcell lymphoma
204,NCT00338494,dose escal studi of clofarabin in patient with relaps or refractori low grade or intermediategrad bcell lymphoma,['clofarabine'],['1'],dose escal studi of clofarabin in patient with relaps or refractori low grade or intermedgrad bcelltcel lymphoma
205,NCT00216164,rituximab and gemcitabin for patient with relaps or refractori diffus larg bcell lymphoma,"['rituximab', 'gemcitabine']",['2'],phase ii studi of rituximab and gemcitabin in patient with relaps or refractori diffus larg bcell lymphoma hoosier oncolog group lym0364
206,NCT01325701,safeti and efficaci studi of a btk inhibitor in subject with relaps or refractori diffus larg bcell lymphoma,['ibrutinib'],['2'],a multicenter openlabel phase 2 safeti and efficaci studi of the bruton tyrosin kinas btk inhibitor pci32765 in subject with relaps or refractori or de novo diffus larg bcell lymphoma dlbcl
209,NCT01535989,studi of inotuzumab ozogamicin  temsirolimus in patient with relaps or refractori cd22 bcell nhlymphoma,"['inotuzumab ozogamicin', 'temsirolimus']",['1'],a phase i studi of inotuzumab ozogamicin cmc544 in combin with temsirolimus cci779 in patient with relaps or refractori cd22posit bcell non hodgkin lymphoma
210,NCT02219737,ibrutinib and combin chemotherapi in treat patient with relaps or refractori diffus larg bcell lymphoma,"['carboplatin', 'etoposide', 'ibrutinib', 'ifosfamide']",['1'],a phase i studi combin ibrutinib with rituximab ifosfamide carboplatin and etoposid rice in patient with relaps or primari refractori diffus larg bcell lymphoma dlbcl
213,NCT00054665,ps341 alon and ps341 plus epoch chemotherapi to treat nonhodgkin lymphoma,"['ps-341', 'etoposide', 'doxorubicin', 'vincristine', 'cyclophosphamide', 'prednisone', 'filgrastim']",['2'],ps341 and ps341  epoch chemotherapi and molecular profil in relaps or refractori diffus larg bcell lymphoma
214,NCT01854372,rituximabhypercvad rhcvad altern with rituximabmethotrexatecytarabine rmc in newli diagnos patient with diffus larg bcell lymphoma with mycrearrangement,"['r-hcvad', 'r']",['2'],rituximabhypercvad rhcvad altern with rituximabmethotrexatecytarabine rmc in newli diagnos patient with diffus larg bcell lymphoma with mycrearrangement a phase 2 multicenter open label studi ctrc 1153
215,NCT01510184,studi of zevalin versus observ in patient at least 60 yrs old with newli diagnos diffus larg bcell lymphoma in petneg complet remiss after rchop or rchoplik therapi,['zevalin '],['3'],a phase 3 openlabel multicenter random studi of sequenti zevalin ibritumomab tiuxetan versus observ in patient at least 60 year of age with newli diagnos diffus larg bcell lymphoma in petneg complet remiss after rchop or rchoplik therapi
216,NCT01991184,a studi of gdc0853 in patient with resist bcell lymphoma or chronic lymphocyt leukemia,['gdc-0853'],['1'],an openlabel phase i doseescal studi evalu the safeti and toler of gdc0853 in patient with relaps or refractori bcell nonhodgkin lymphoma and chronic lymphocyt leukemia
219,NCT01976585,in situ vaccin for lowgrad lymphoma combin of intratumor flt3l and polyiclc with lowdos radiotherapi,"['rhuflt3l', 'poly-iclc']","['1', '2']",a phase iii studi of intratumor inject of rhuflt3lcdx301 and polyiclc in combin with lowdos radiotherapi in lowgrad bcell lymphoma
221,NCT00799513,trial on lenalidomid given as mainten therapi for relaps diffus larg b cell lymphoma,['lenalidomide'],['2'],a phase ii trial to evalu the safeti and activ of singleag lenalidomid given as mainten therapi after respons to secondlin therapi in patient with relaps dlbcl not elig for highdos chemotherapi and asct
223,NCT01846390,romidepsin gemcitabine dexamethason and cisplatin in the treatment of peripher tcell and diffus larg bcell lymphoma,"['gemcitabine', 'dexamethasone', 'cisplatin', 'romidepsin']",['1'],a phase i studi of romidepsin gemcitabine dexamethason and cisplatin combin therapi in the treatment of peripher tcell and diffus larg bcell lymphoma
224,NCT00386321,yt90 zevalin and combin chemotherapi zchopin treat patient with stage ii stage iii or stage iv diffus larg bcell lymphoma,['yttrium 90 '],['2'],yt90zevalin plus chop zchop
225,NCT01582776,studi of obinutuzumab combin to lenalidomid for the treatment of relapsedrefractori follicular and aggress bcell lymphoma,"['lenalidomide', 'ga101']","['1', '2']",a phase ibii studi of obinutuzumab combin to lenalidomid for the treatment of follicular and relapsedrefractori aggress dlbcl and mcl bcell lymphoma
226,NCT00553943,phase ii studi to evalu the combin of rituximab and depocyte® in the c5r chemotherapi protocol in patient between the age of 18 and 60 year with primari cerebr nonhodgkin lymphoma and system diffus larg bcell lymphoma with neuromening invas at diagnosi,"['rituximab', 'cytarabine']",['2'],prospect multicentr phase ii studi to evalu the combin of rituximab and depocyte® by intrathec inject in the c5r chemotherapi protocol in patient between the age of 18 and 60 year with primari cerebr nonhodgkin lymphoma and system diffus larg bcell lymphoma with neuromening invas at diagnosi
227,NCT01523834,oral panobinostat adult patient dlbcl relapsedrefractori stem cell transfus asct or not elig for asct,['panobinostat'],['2'],a phase ii studi of oral panobinostat in adult patient with diffus larg bcell lymphoma relapsedrefractori after highdos chemotherapi with autolog stem cell transfus asct or not elig for asct
228,NCT00400478,a multicentre random phase iii studi of rituximab as mainten treatment versus observ in patient with aggress bcell lymphoma nhl13,['rituximab'],['3'],a multicentre random phase iii studi of rituximab as mainten treatment versus observ alon in patient with aggress bcell lymphoma nhl13
229,NCT00717925,studi evalu safeti and toler of inotuzumab ozogamicin cmc544 in japanes patient with bcell nonhodgkin lymphoma nhl,['inotuzumab ozogamicin '],['1'],a phase 1 studi of cmc544 administ as a singl agent in subject with bcell nonhodgkin lymphoma
230,NCT02054559,rchop alon vs rchop plus radiotherapi for local cd20 dlbcl,['r-chop'],['3'],random phase iii trial compar rchop alon and rchop plus radiotherapi for local cd20 diffus larg bcell lymphoma dlbcl
233,NCT01679119,treatment of patient with diffus larg b cell lymphoma who are not suitabl for anthracyclin contain chemotherapi,"['cyclophosphamide', 'vincristine', 'prednisolone', 'rituximab', 'inotuzumab ozogamicin', 'gemcitabine']",['2'],a randomis phase ii trial of inotuzumab ozogamicin plus rituximab  cvp iorcvp vs gemcitabin plus rituximab  cvp gemrcvp for the first line treatment of patient with dlbcl who are not suitabl for anthracyclin contain chemotherapi
234,NCT01925612,studi of brentuximab vedotin combin with rchop or rchp in frontlin treatment of patient with diffus larg bcell lymphoma dlbcl,"['brentuximab vedotin', 'rituximab', 'vincristine', 'cyclophosphamide', 'prednisone', 'doxorubicin']",['2'],a phase 2 studi of brentuximab vedotin in combin with standard of care treatment rituximab cyclophosphamide doxorubicin vincristine and prednison rchop or rchp rituximab cyclophosphamide doxorubicin and prednisone as frontlin therapi in patient with diffus larg bcell lymphoma dlbcl
237,NCT01670370,trial of rgemox regimen in previous untreat elder patient with dlbcl,['r-gemox'],['2'],a prospective singlearm openlabel phase 2 studi to evalu efficaci and safeti of rgemox regimen as firstlin treatment in elder patient with diffus larg bcell lymphoma dlbcl
238,NCT01653067,storm temsirolimus rituximab and dhap for relaps and refractori diffus larg bcell lymphoma,"['rituximab', 'temsirolimus', 'dhap', 'intravenous']",['2'],a phase ii trial to evalu the safety feasibl and efficaci of a salvag therapi consist of temsirolimus ad to the standard therapi rdhap for the treatment of patient with relaps or refractori dlbcl  the storm trial
241,NCT01516567,intergroup trial for children or adolesc with primari mediastin larg bcell lymphoma daepochrituximab evalu,"['etoposide', 'doxorubicin', 'vincristine', 'cyclophosphamide', 'rituximab']",['2'],intergroup trial for children or adolesc with bcell nhl or bal evalu of rituximab efficaci and safeti in high risk patient  phase ii trial of daepochrituximab in pmlbl
242,NCT01279902,abbrevi rchop in complet excis stage i or ii dlbcl,"['rituximab', 'chop immunochemotherapy']",['2'],phase 2 studi of abbrevi 3 cycl of rituximab plus chop cyclophosphamide adriamycin vincristine and prednisolone immunochemotherapi in patient with complet excis stage i or ii cd20 diffus larg bcell lymphoma
243,NCT01859819,treatment for advanc bcell lymphoma,"['rituximab', 'it cytarabine']",['2'],reduc burden of oncolog therapi in advanc bcell lymphoma reboot ably in children adolesc and young adult with cd20 matur bcell lymphoma
244,NCT00498914,studi of ym155 in refractori diffus larg bcell lymphoma dlbcl subject,['ym155'],['2'],a phase ii multicenter openlabel studi of ym155 in refractori diffus larg bcell lymphoma dlbcl subject
245,NCT02252146,dose escal studi in patient with relaps or refractori dlbcl and myd88 l265p mutat,['imo-8400'],"['1', '2']",phase iii openlabel multipledose doseescal studi to evalu the safeti and toler of imo8400 in patient with relaps or refractori diffus larg bcell lymphoma and presenc of the myd88 l265p mutat
252,NCT02423291,a studi of sgn35 brentuximab vedotin of patient with relaps or refractori pmlbcl,['brentuximab vedotin'],['2'],a phase ii studi of sgn35 brentuximab vedotin of patient with relaps or refractori primari mediastin larg bcell lymphoma pmlbcl
258,NCT00204659,phase ii studi with rituximab and cyclophosphamide doxorubicin vincristine prednison chop in patient with gastric diffus larg bcell nonhodgkin lymphoma,"['rituximab', 'chop chemotherapy']",['2'],phase ii studi with rituximab and chop in patient with gastric diffus larg bcell nonhodgkin lymphoma
263,NCT01693614,safeti and efficaci of bkm120 in relaps and refractori nhl,['buparlisib'],['2'],an openlabel phase ii studi of bkm120 in subject with relaps and refractori diffus larg bcell lymphoma mantl cell lymphoma and follicular lymphoma
264,NCT02617485,mabioncd20® compar to mabthera® in lymphoma patient,"['rituximab', 'doxorubicin', 'vincristine', 'cyclophosphamide', 'prednisone']",['3'],randomized parallelgroup doubleblind compar bioequival trial of mabioncd20 mabion sa compar to mabthera rituximab by hoffmanla roche in patient with diffus larg bcell lymphoma
270,NCT00466258,linfotargam treatment with chemotherapi plus rituximab and high activ antiretrovir therapi in patient with diffus larg b cell lymphoma and infect with the human immunodefici virus hiv,"['r-chop', 'highly active antiretroviral therapy', 'central nervous system ', 'prophylaxis of opportunistic infections', 'support treatment']",['4'],linfotargam firstlin treatment with dosedens chemotherapi plus rituximab rchop14 and high activ antiretrovir therapi haart in patient with diffus larg b cell lymphoma dlbcl and infect with the human immunodefici virus hiv
272,NCT01659099,ga in newli diagnos diffus larg b cell lymphoma,"['ga101', 'rituximab', 'doxorubicin', 'cyclophosphamide', 'prednisone', 'bleomycin', 'vindesin', 'vincristine']",['3'],random phase iii studi use a petdriven strategi and compar ga101 or rituximab associ to a chemotherapi deliv everi 14 day acvbp or chop in dlbcl cd20 lymphoma untreat patient from 18 to 60 present with 1 or more advers prognost factor of the ageadjust ipi
273,NCT02549651,medi4736 alon and in combin with tremelimumab or azd9150 in adult subject with relapsedrefractori dlbcl d4190c00023,"['medi4736', 'tremelimumab', 'azd9150']",['1'],a phase 1b studi to evalu the safeti and efficaci of medi4736 as monotherapi and in combin with tremelimumab or azd9150 in subject with relaps or refractori diffus larg bcell lymphoma
274,NCT01914718,doseadjust epochr in myc posit dlbcl,['da-epoch'],['2'],doseadjust epochr in patient with diffus larg bcell lymphoma a phase ii studi
277,NCT02323230,a studi of dpxsurvivac vaccin therapi in patient with recurr survivinexpress dlbcl,['cyclophosphamide'],['2'],phase 2 studi of an immunotherapeut vaccine dpxsurvivac with low dose cyclophosphamid in patient with recurr survivinexpress diffus larg bcell lymphoma dlbcl
278,NCT02399085,a studi to evalu the safeti and efficaci of lenalidomid with mor00208 in patient with rr dlbcl,"['mor00208', 'lenalidomide']",['2'],a phase ii singlearm openlabel multicentr studi to evalu the safeti and efficaci of lenalidomid combin with mor00208 in patient with relaps or refractori diffus larg bcell lymphoma rr dlbcl
280,NCT01965977,bortezomib mainten in high risk dlbcl,['bortezomib'],['2'],openlabel multicent phase ii studi of bortezomib for mainten therapi in patient with high risk diffus larg b cell lymphoma
283,NCT01804127,interim petct guid cycl number of rchop in dlbcl,['r-chop'],['2'],interim petct guid cycl number of rchop in patient with diffus larg bcell lymphoma a exploratori phase ii studi studi
285,NCT02456207,a pharmacokinet studi compar sct400 and rituximab in patient with bcell nonhodgkin lymphoma,"['sct400', 'rituximab']",['2'],a phase ii multicenter random and open studi to evalu and compar the pk pd and safeti of sct400 with rituximab in patient with cd20 bcell nonhodgkin lymphoma
288,NCT02670317,phase ii studi about combin chop21 obinutuzumab and ibrutinib in untreat young high risk dlbcl patients,"['obinutuzumab', 'ibrutinib', 'chop']",['2'],multicent phase ii singl arm openlabel studi on the feasibility safeti and efficaci of combin of chop21 supplement with obinutuzumab and ibrutinib in untreat young high risk diffus larg bcell lymphoma dlbcl patients
290,NCT00085696,velcade® bortezomib with rituximab in subject with relaps or refractori indol bcell lymphoma,"['velcade', 'rituximab']",['2'],a phase 2 studi of velcade® bortezomib with rituximab in subject with relaps or refractori indol bcell lymphoma
291,NCT02658968,studi of betalutin for treatment of relaps or refractori nonhodgkin lymphoma lymrit3705,['betalutin'],['1'],a phase 1 dose find studi of lutetium 177lulilotomab satetraxetan betalutin® in patient with relapsedrefractory diffus larg bcell lymphoma not elig for autolog stem cell transplant
293,NCT01933516,gp2013 in japanes patient with cd20 posit low tumor burden indol bcell nonhodgkin lymphoma,['gp2013'],['1'],phase i trial to assess the safeti and pharmacokinet of gp2013 monotherapi administ week in japanes patient with cd20 posit low tumor burden indol bcell nonhodgkin lymphoma
296,NCT01704963,a studi to evalu the bruton tyrosin kinas btk inhibitor pci32765 in patient with recurr matur bcell neoplasm,['pci-32765'],['1'],a phase 1 studi of the bruton tyrosin kinas btk inhibitor pci32765 in subject with recurr matur bcell neoplasm
297,NCT02128061,efficaci of lenalidomid in combin with subcutan rituximab  minichop in dlbcl patient of 80 yo or,"['lenalidomide', 'rituximab']",['3'],subcutan rituximabminichop versus subcutan rituximabminichop  lenalidomid r2minichop in diffus larg b cell lymphoma for patient of 80 year old or more a multicentr phase iii studi of the lysa associ
298,NCT01856192,rituximab and combin chemotherapi with or without lenalidomid in treat patient with newli diagnos stage iiiv diffus larg b cell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'lenalidomide', 'prednisone', 'vincristine sulfate']",['2'],random phase ii open label studi of lenalidomid rchop r2chop vs rchop rituximab cyclophosphamide doxorubicin vincristin and prednisone in patient with newli diagnos diffus larg b cell lymphoma
299,NCT00998946,studi of pralatrex to treat patient with relaps or refractori bcell nonhodgkin lymphoma,['pralatrexate injection'],['2'],a phase 2 singlearm openlabel multicent studi of pralatrex in patient with relaps or refractori bcell nonhodgkin lymphoma
301,NCT00902525,zevalin twice in aggress nonhodgkin lymphoma,['90y-ibritumomab tiuxetan'],['2'],two repeat dose of yttrium90 ibritumomab tiuxetan zevalin® as salvag treatment for patient with relaps or refractori aggress bcell lymphoma a phase ii study
303,NCT02388581,firstlin antibiot therapi for earlystag hp gastric pure dlbcl,"['lansoprazole', 'amoxicillin', 'clarithromycin', 'metronidazole']",['2'],multicentre prospect studi of firstlin antibiot therapi for earlystag h pyloriposit gastric pure de novo diffus larg bcell lymphoma and potenti predict factor for treatment outcom
305,NCT00577629,chemotherapi with monoclon antibodi and radioimmunotherapi for highrisk bcell nonhodgkin lymphoma,"['cyclophosphamide', 'etoposide', 'rituximab', 'cytarabine', 'doxorubicin', 'tositumomab']",['2'],doseintens chemotherapi combin with monoclon antibodi therapi and target radioimmunotherapi for untreat patient with highrisk bcell nonhodgkin lymphoma
306,NCT02134262,gene therapi for bcell nonhodgkin lymphoma use cd19 car gene transduc t lymphocyt,['cyclophosphamide or bendamustine'],"['1', '2']",clinic research of gene therapi for refractori bcell nonhodgkin lymphoma use autolog t cell express a chimer antigen receptor specif to the cd19 antigen
307,NCT02700022,a phase i studi of alisertib  repoch for treatment of mycposit aggress bcell lymphoma,['alisertib'],['1'],a phase iib studi of alisertib plus repoch for treatment of mycposit aggress bcell lymphoma
309,NCT00299494,studi evalu inotuzumab ozogamicin cmc544 administ in combin with rituximab in subject with nonhodgkin lymphoma nhl,"['inotuzumab ozogamicin', 'rituximab']","['1', '2']",a phase 12 studi of cmc544 administ in combin with rituximab in subject with follicular or diffus larg bcell nonhodgkin lymphoma
310,NCT00924326,car t cell receptor immunotherapi for patient with bcell lymphoma,"['fludarabine', 'cyclophosphamide']","['1', '2']",an assess of the safeti and feasibl of administ tcell express an anticd19 chimer antigen receptor to patient with bcell lymphoma
312,NCT00211276,a studi of ontak in patient with relaps or refractory bcell non hodgkin lymphoma,['ontak '],['2'],a phase ii multicent studi of ontak in patient with relaps or refractory bcell nonhodgkin lymphoma
313,NCT00073749,studi evalu cmc544 in bcell nonhodgkin lymphoma,['inotuzumab ozogamicin '],['1'],a phase 1 studi of cmc544 administ as a singl agent in subject with bcell non hodgkin lymphoma
315,NCT01569750,a studi combin ibrutinib with rituximab cyclophosphamide doxorubicin vincristine and prednison in patient with cd20posit bcell non hodgkin lymphoma,"['part 1', 'cohort 1', 'part 1', 'cohort 2', 'part 1', 'cohort 3', 'part 2', 'cohort 1', 'part 2', 'cohort 2']",['1'],a phase 1b studi combin ibrutinib with rituximab cyclophosphamide doxorubicin vincristine and prednison rchop in subject with cd20posit bcell non hodgkin lymphoma nhl
316,NCT00515138,a pilot studi of standarddos rituximab ifosfamide carboplatin and etoposid rice plus bortezomib velcade in a doseescal fashion for patient with relaps or primari refractori aggress bcell nonhodgkin lymphoma who are candid for autolog stem cell transplant,"['rituximab', 'ifosfamide', 'carboplatin', 'etoposide', 'bortezomib']",['1'],a pilot studi of standarddos rituximab ifosfamide carboplatin and etoposid rice plus bortezomib velcade in a doseescal fashion for patient with relaps or primari refractori aggress bcell nonhodgkin lymphoma who are candid for autolog stem cell transplant
319,NCT02361346,pk pd safety toler of multipl dose regimen of mt3724 for the treatment of patient with relaps nonhodgkin bcell lymphoma and bcell chronic lymphocyt leukemia,['mt-3724'],['1'],pharmacokinetics pharmacodynamics safeti and toler of multipl dose regimen of mt3724 for the treatment of patient with relaps nonhodgkin bcell lymphoma and bcell chronic lymphocyt leukemia
321,NCT01148108,studi of canfosfamid in refractori or relaps mantl cell diffus larg b cell lymphoma and multipl myeloma,['canfosfamide hcl for injection'],['2'],phase 2 studi of canfosfamid hcl for inject telcyta® tlk286in refractori or relaps mantl cell lymphoma mcl diffus larg b cell lymphoma dlbcl and multipl myeloma mm
322,NCT00556127,rituximab in addit to chemotherapi with autolog stem cell transplant as treatment diffus larg bcell lymphoma,"['rituximab', 'epirubicin', 'cyclophosphamide', 'vincristine', 'prednisone', 'granulocyte-colony', 'mitoxantrone', 'cytarabine ara', 'dexamethasone', 'carmustine bcnu', 'etoposide', 'melphalan']",['2'],programma di terapia per pazienti affetti da linfoma diffuso a grandi cellul b cd20 posit
324,NCT02282358,studi of mocetinostat in select patient with mutat of acetyltransferas gene in relaps and refractori diffus larg bcell lymphoma and follicular lymphoma,['mocetinostat'],"['1', '2']",an openlabel phase ii studi of mocetinostat in select patient with mutat of acetyltransferas gene in relaps and refractori diffus larg bcell lymphoma and follicular lymphoma
325,NCT01478542,optimal60  dr chop improv of therapi of elder patient with cd20 dlbcl use rituximab optim and liposom vincristin,"['conventional vincristine', 'liposomal vincristine', 'ricover-scheme rituximab', 'optimised rituximab']",['3'],improv of outcom and reduct of toxic in elder patient with cd20 aggress bcell lymphoma by an optimis schedul of the monoclon antibodi rituximab substitut of convent by liposom vincristine and fdgpet base reduct of therapi in combin with vitamin d substitut
326,NCT00768339,a phase 12 multicenter openlabel studi of aeg35156 in patient with relaps or refractori chronic lymphocyt leukemia and indol bcell lymphoma,['aeg35156 antisense iv infusion'],"['1', '2']",aeg35156204 a phase 12 multicenter openlabel studi of the xlink inhibitor of apoptosi xiap antisens aeg35156 in patient with relaps or refractori chronic lymphocyt leukemia and indol bcell lymphoma
327,NCT01990144,rituximab plus bendamustin as front line treatment in frail elder 70 years patient with dlbcl a phase ii multicent studi of the fil,['bendamustine+rituximab'],['2'],rituximab plus bendamustin as front line treatment in frail elder 70 years patient with diffus larg bcell nonhodgkin lymphoma a phase ii multicent studi of the fondazion italiana linfomi fil
328,NCT02674750,studi to evalu the efficaci and safeti of cudc907 in patient with rr dlbcl includ patient with myc alter,['cudc-907'],['2'],openlabel phase 2 studi to evalu the efficaci and safeti of cudc907 in patient with relapsedrefractori diffus larg bcell lymphoma includ patient with myc alter
329,NCT02564744,studi to evalu the efficaci and toler debio 1562 in combin with rituximab in patient with relaps andor refractori dlbcl and other form of nhl,"['debio 1562', 'rituximab']",['2'],a phase 2 studi to evalu the efficaci and toler of debio 1562 in combin with rituximab in patient with relaps andor refractori diffus larg bcell lymphoma and other form of nonhodgkin lymphoma
330,NCT02495454,ga101minichop regimen for the treatment of elder unfit patient with diffus larg bcell nonhodgkin lymphoma,['ga101'],['2'],ga101minichop regimen for the treatment of elder unfit patient with diffus larg bcell nonhodgkin lymphoma a phase ii studi of the fondazion italiana linfomi fil
331,NCT01092182,phase ii studi of doseadjust epochrituximab in adult with untreat burkitt lymphoma and cmyc diffus larg bcell lymphoma,"['epoch-r', 'epoch-rr']",['2'],phase ii studi of doseadjust epochrituximab in adult with untreat burkitt lymphoma cmyc posit diffus larg bcell lymphoma and plasmablast lymphoma
333,NCT01241734,studi of lenalidomid in combin with rice with lenalidomid mainten postauto transplant for dlbcl,['revlimid'],"['1', '2']",phase iii studi of lenalidomid in combin with rituximab ifosfamide etoposide and carboplatin ricer
335,NCT01691898,a studi of pinatuzumab vedotin dcdt2980s combin with rituximab or polatuzumab vedotin dcds4501a combin with rituximab or obinutuzumab in particip with relaps or refractori bcell nonhodgkin lymphoma nhl,"['obinutuzumab', 'pinatuzumab vedotin', 'polatuzumab vedotin', 'rituximab']","['1', '2']",a randomized openlabel multicenter phase ii trial evalu the safeti and activ of pinatuzumab vedotin dcdt2980s in combin with rituximab or polatuzumab vedotin dcds4501a in combin with rituximab and a nonrandom phase ibii evalu of polatuzumab vedotin in combin with obinutuzumab in patient with relaps or refractori bcell nonhodgkin lymphoma
338,NCT00724971,studi evalu the safeti and toler of combin therapi inotuzumab ozogamicin cmc544 and rituximab,"['inotuzumab ozogamicin ', 'rituximab ']",['1'],a phase 1 studi of inotuzumab ozogamicin cmc544 administ in combin with rituximab in subject with bcell nonhodgkin lymphoma
339,NCT01234467,bendamustin  rituximab in older patient with previous untreat diffus larg bcell lymphoma,"['bendamustine', 'rituximab']",['2'],a phase ii trial of bendamustin in combin with rituximab in older patient with previous untreat diffus larg bcell lymphoma
340,NCT01471210,safety tolerability pharmacokinetics and immunoregulatori studi of urelumab bms663513 in subject with advanc andor metastat solid tumor and relapsedrefractori bcell nonhodgkin lymphoma,['urelumab '],['1'],a phase 1 studi of the safety tolerability pharmacokinet and immunoregulatori activ of urelumab bms663513 in subject with advanc andor metastat solid tumor and relapsedrefractori bcell nonhodgkin lymphoma bnhl
341,NCT01415765,mln4924 compar with mln4924 plus chemotherapi for larg bcell lymphoma,"['mln4924', 'etoposide', 'prednisone', 'vincristine', 'cyclophosphamide', 'doxorubicin', 'rituximab', 'filgrastim']","['1', '2']",phase iii studi of mln4924 alon follow by doseadjust epochrituximab  mln4924 with gene express profil and mutat analysi in relapsedrefractori de novo diffus larg bcell lymphoma
345,NCT01944943,phase ii studi of vismodegib in patient with refractori or relaps bcell lymphoma or chronic lymphocyt leukemia,['vismodegib'],['2'],phase ii studi of vismodegib in patient with refractori or relaps bcell lymphoma or chronic lymphocyt leukemia
346,NCT01361191,earli treatment stratif base on pet scan respons to chemotherapi in patient with diffus larg bcell lymphoma,['r-megachop'],['2'],earli treatment stratif base on pet scan respons to rmegachop follow by rmegachop or rife plus peripher autolog stem cell transplant pbsct in patient with poor prognosi dlbcl
349,NCT02049541,studi of bkm120  rituximab in patient with relaps or refractori indol bcell lymphoma,['pi3k inhibitor bkm120'],['1'],a phase i studi of bkm120 and rituximab in patient with relaps or refractori indol bcell lymphoma
351,NCT02592876,treatment studi of denintuzumab mafodotin sgncd19a plus rice versus rice alon for diffus larg bcell lymphoma,"['denintuzumab mafodotin', 'rituximab', 'ifosfamide', 'carboplatin', 'etoposide']",['2'],a randomized openlabel phase 2 studi of denintuzumab mafodotin sgncd19a plus rituximab ifosfamide carboplatin and etoposid 19arice chemotherapi vs rice in the treatment of patient with relaps or refractori diffus larg bcell lymphoma dlbcl who are candid for autolog stem cell transplant
353,NCT00946023,optim donor selection nonmyeloabl bmt for bcell lymphoma with posttransplant cy and rituximab,"['fludarabine', 'cyclophosphamide', 'tacrolimus', 'mycophenolate mofetil', 'rituximab']",['2'],nonmyeloabl bmt with posttranspl cyclophosphamide rituximab and optim donor select for bcell lymphoma
355,NCT01009970,studi with rituximab cyclophosphamide doxorubicin liposom myocet® vincristine prednisone rcomp to treat nonhodgkin lymphoma,"['rituximab', 'cyclophosphamide', 'vincristine', 'prednisone', 'doxorubicin']",['2'],multicent studi of phase ii with rituximab cyclophosphamide doxorubicin liposom myocet ® vincristine prednisone rcomp in nonhodgkin lymphoma diffus larg b cell in cardiopath patient
357,NCT02044276,a compar studi on efficaci and safeti of lipegfilgrastim in comparison to pegfilgrastim in elder patient with aggress b cell nonhodgkin lymphoma at high risk for rchop21induc neutropenia,"['lipegfilgrastim', 'pegfilgrastim']",['3'],a randomized phase iiib openlabel twoarm multicenter compar studi on efficaci and safeti of lipegfilgrastim lonquex teva in comparison to pegfilgrastim neulasta® amgen in elder patient with aggress b cell nonhodgkin lymphoma at high risk for rchop21induc neutropenia  avoid neutropenia
358,NCT00842595,efficaci  safeti of treatment r nimp for relaps aggress lymphoma,"['rituximab', 'vinorelbine', 'ifosfamide', 'mitoxantrone', 'prednisone']",['2'],phase ii studi of treatment of relaps agress lymphoma
359,NCT00841945,treatment of aggress local lymphoma,"['rituximab', 'doxorubicin', 'vincristine', 'prednisone']",['3'],phase iii studi of the interest of radiotherapi after 4 or 6 cycl of chop 14 rituximab regimen of chemotherapi  patient with agress local lymphoma
363,NCT00586391,cd19 chimer receptor express t lymphocyt in bcell non hodgkin lymphoma all  cll,['ipilimumab'],['1'],phase i studi of cd19 chimer receptor express t lymphocyt in bcell non hodgkin lymphoma acut lymphocyt leukemia and chronic lymphocyt leukemia
364,NCT01959698,carfilzomib rituximab ifosfamide carboplatin and etoposid in treat patient with relaps or refractori stage iiv diffus larg bcell lymphoma,"['carboplatin', 'carfilzomib', 'etoposide', 'ifosfamide']","['1', '2']",phase iii studi of carfilzomib plus rituximab plus ifosfamid plus carboplatin plus etoposid crice in patient with relapsedrefractori diffus larg bcell lymphoma dlbcl
366,NCT00599170,rituximab plus chop with sargramostim in patient with newli diagnos diffus larg bcell lymphoma,['rituximab'],['2'],rituximab plus chop given everi two week with sargramostim in patient with newli diagnos diffus larg bcell lymphoma
367,NCT01397825,mln8237 in patient with relaps or refractori aggress bcell lymphoma treat with rituximab  vincristin,"['alisertib ', 'rituximab', 'vincristine']","['1', '2']",a multicenter phase 12 studi of mln8237 an oral aurora a kinas inhibitor in patient with relaps or refractori aggress bcell lymphoma treat with rituximab and vincristin
371,NCT01613300,studi of ofatumumab as part of the scheme of reduc intens condit in high risk nonhodgkin lymphoma b patient,['ofatumumab'],['2'],ofatumumab as part of the reduc intens condit regimen ric for patient with high risk b non hodgkin lymphoma undergo allogen hematopoiet cell transplant
372,NCT01718691,efficaci and safeti studi of syb l0501 in combin with rituximab in patient with untreated lowgrad b cell nonhodgkin lymphoma and mantl cell lymphoma,"['syb l', 'rituximab']",['2'],phase ii clinic studi of syb l0501 in combin with rituximab in patient with untreated lowgrad bcell nonhodgkin lymphoma and mantl cell lymphoma multicenter openlabel
376,NCT00324467,tailor treatment for b cell nonhodgkin lymphoma base on pet scan result mid treatment,"['cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone', 'ondansetron', 'dexamethasone', 'diphenhydramine', 'acetaminophen', 'ifosfamide', 'mesna ', 'mesna ', 'carboplatin', 'etoposide', 'rituximab']",['2'],phase ii trial investig tailor firstlin therapi for advanc stage diffus larg bcell nonhodgkin lymphoma base on midtreat positron emiss tomographi pet scan result
379,NCT00455897,choprituximab augment with gmcsf in patient with previous untreat diffus larg b cell nonhodgkin lymphoma,"['gm-csf', 'chop', 'rituximab']",['2'],phase ii trial of choprituximab augment with granulocytemacrophag coloni stimul factor gmcsf in patient with previous untreat diffus larg b cell nonhodgkin lymphoma
380,NCT02012088,clinic trial to evalu rcomp versus rchop in newli diagnos patient with nonlocalis diffus larg bcell lymphoma dlbclfollicular lymphoma grade iiib,"['rcomp', 'rchop']",['2'],phase ii randomised multicentr studi with two treatment arm rcomp versus rchop in newli diagnos elder patient ≥60 years with nonlocalis diffus larg bcell lymphoma dlbclfollicular lymphoma grade iiib
381,NCT01235793,the addit of temozolomid to condit for autolog transplant in relaps  refractori cns lymphoma,['temozolomide'],['2'],a phase 2a studi of the addit of temozolomid to a standard condit regimen for autolog stem cell transplant in relaps and refractori central nervous system cns lymphoma
382,NCT02443077,ibrutinib befor and after stem cell transplant in treat patient with relaps or refractori diffus larg bcell lymphoma,"['carmustine', 'cyclophosphamide', 'cytarabine', 'etoposide', 'ibrutinib', 'melphalan']",['3'],a random doubleblind phase iii studi of ibrutinib dure and follow autolog stem cell transplant versus placebo in patient with relaps or refractori diffus larg bcell lymphoma of the activ bcell subtyp
384,NCT02628405,rice and lenalidomid in treat patient with firstrelapseprimari refractori diffus larg bcell lymphoma,"['carboplatin', 'etoposide', 'ifosfamide', 'lenalidomide']","['1', '2']",phase iii openlabel studi of rice rituximabifosfamidecarboplatinetoposide with lenalidomid r2ice in patient with firstrelapseprimari refractori diffus larg bcell lymphoma dlbcl
385,NCT01516580,intergroup random trial for children or adolesc with bcell non hodgkin lymphoma or bacut leukemia rituximab evalu in high risk patient,"['vincristine', 'cyclophosphamide', 'methotrexate', 'doxorubicin', 'cytarabine', 'ara', 'rituximab', 'vincristine', 'cyclophosphamide', 'methotrexate', 'doxorubicin', 'cytarabine', 'ara']",['3'],intergroup trial for children or adolesc with bcell non hodgkin lymphoma or bacut leukemia evalu of rituximab efficaci and safeti in high risk patient  phase iii trial
387,NCT01148446,rchop versus rminiceop in elder patients65with dlbcl,"['cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone', 'epirubicin', 'vinblastine', 'rituximab', 'g-csf']",['3'],a random phase iii random studi to compar rchop versus rminiceop in elder patient 65 years with diffus larg b cell lymphoma dlbcl
391,NCT01939730,rituximab  gmcsf in patient with follicular bcell lymphoma,"['rituximab', 'gm-csf']",['2'],rituximab idecc2b8 plus gmcsf in patient with follicular bcell lymphoma
397,NCT02431988,evalu of car19 tcell as an optim bridg to allogen transplant,"['cyclophosphamide', 'fludarabine']",['1'],cobalt evalu of car19 tcell as an optim bridg to allogen transplant
399,NCT02272686,ibrutinib post stem cell transplant sct in doublehit bcell lymphoma,['ibrutinib'],['2'],target bruton tyrosin kinas btk with ibrutinib after autolog stem cell transplant in doublehit bcell lymphoma
400,NCT01458366,bendamustin in combin with ofatumumab carboplatin and etoposid for refractori or relaps aggress bcell lymphoma,"['bendamustine', 'ofatumumab', 'carboplatin', 'etoposide']","['1', '2']",phase iii studi of bendamustin in combin with ofatumumab carboplatin and etoposid for refractori or relaps aggress bcell lymphoma
402,NCT01897571,openlabel multicenter phase 12 studi of tazemetostat ezh2 histon methyl transferas hmt inhibitor as a singl agent in subject with adv solid tumor or with bcell lymphoma and tazemetostat in combin with prednisolon in subject with dlbcl,['tazemetostat'],"['1', '2']",an openlabel multicenter phase 12 studi of tazemetostat ezh2 histon methyl transferas hmt inhibitor as a singl agent in subject with advanc solid tumor or with bcell lymphoma and tazemetostat in combin with prednisolon in subject with diffus larg b cell lymphoma
403,NCT00333008,a dose studi of doxil in a dose dense 14 day cdoprituximab regimen for patient with diffus larg bcell nonhodgkin lymphoma nhl 60 year or with compromis cardiac status,"['doxil', 'cyclophosphamide', 'vincristine', 'prednisone', 'rituximab', 'pegfilgrastim']",['2'],phase ii dose studi of doxil in a dose dense 14 day cdoprituximab regimen for patient with diffus larg bcell nhl  60 year or with compromis cardiac status
404,NCT01181999,rituximab augment follow rchop induct chemotherapi in extrem elder patient with diffus larg b cell lymphoma,['rituximab'],['2'],phase ii trial of rituximab r augment follow rchop cyclophosphamide doxorubicin vincristine and prednisolone induct chemotherapi in extrem elder patient with diffus larg b cell lymphoma dlbcl
405,NCT00168740,treatment of relaps lowgrad or follicular lymphoma with rituximab also known as rituxan idecc2b8 idec102,['rituximab'],['3'],pivot phase iii multicent studi to evalu the safeti and efficaci of onc week time four dose of idecc2b8 idec102 in patient with relaps lowgrad or follicular bcell lymphoma
408,NCT02151903,openlabel extens studi of deimmun dileu16il2 immunocytokin administ in patient with bcell nhl,['di-leu16'],"['1', '2']",an openlabel extens studi of deimmun dileu16il2 immunocytokin administ in patient with bcell nonhodgkin lymphoma nhl
410,NCT00379574,bortezomib plus chop everi 2 week for advanc stage dlbcl,"['bortezomib', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisolone', 'lenograstim']","['1', '2']",a phase iii studi of bortezomib plus chop everi 2 week in patient with advanc stage diffus larg bcell lymphoma
411,NCT02541565,pembrolizumab and combin chemotherapi in treat patient with previous untreat diffus larg bcell lymphoma or grade 3b follicular lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['1'],mk3475 in combin with standard rchop therapi for previous untreat diffus larg bcell lymphoma
413,NCT01874288,phase iii studi of deimmun dileu16il2 immunocytokin administ subcutan in patient with bcell nhl,"['10', '50mg']","['1', '2']",a phase iii studi of deimmun dileu16il2 immunocytokin administ subcutan in patient with bcell nonhodgkin lymphoma nhl
417,NCT00538096,a phase i studi to evalu safety toler in adult with lymphoma,['medi-538'],['1'],a phase i multicenter openlabel singlearm doseescalation studi to evalu the safety tolerability and antitumor activ of continu intraven infus of the bispecif tcell engag medi538 in adult with bcell nonhodgkin lymphoma not elig for curat therapi
421,NCT00927797,intervent studi on pentostatin cyclophosphamid and rituximab in indol bcell nonhodgkinlymphoma bnhl,"['cyclophosphamide', 'pentostatin', 'rituximab']",['2'],phase ii studi to evalu the safeti and efficaci of the treatment with pentostatin cyclophosphamid and rituximab follow by rituximab mainten in previous untreat and relaps patient with immunocytomamorbus waldenström bcll and other indol bcell lymphoma
428,NCT00220285,studi for evalu of efficaci and safeti of sh l 749 to indol bcell nonhodgkin lymphoma,['zevalin '],['2'],a phase ii openlabel studi of sh l 749 in relaps or refractori indol bcell nonhodgkin lymphoma
429,NCT01157988,90yibritumomab tiuxetan consolid after 6th rchop chemotherapi in patient with bulki diffus larg b cell lymphoma,['ibritumomab tiuxetan '],['2'],phase ii studi of 90yibritumomab tiuxetan treatment as a consolid after 6th rchop chemotherapi in patient with limitedstage bulki diffus larg b cell lymphoma
430,NCT01263418,ofatumumab in older patient with untreat low or intermedi risk indol bcell lymphoma,['ofatumumab'],['2'],a phase ii trial of ofatumumab in older ≥70 years patient with previous untreat low or intermedi risk indol bcell lymphoma
434,NCT02213913,lenalidomid and combin chemotherapi daepochr in treat patient with mycassoci bcell lymphoma,"['lenalidomide', 'etoposide', 'prednisone', 'vincristine sulfate', 'doxorubicin hydrochloride', 'cyclophosphamide']","['1', '2']",prospective multicent phase iii trial of lenalidomid and doseadjust epochr in mycassoci bcell lymphoma
435,NCT02436707,novel combin therapi in the treatment of relaps and refractori aggress bcell lymphoma,"['ibrutinib', 'rituximab', 'gemcitabine', 'dexamethasone', 'cisplatin', 'mesna', 'cyclophosphamide', 'etoposide', 'g-csf']",['2'],a multistag random phase ii studi of novel combin therapi in the treatment of relaps and refractori aggress bcell lymphoma
437,NCT02531841,highdos chemotherapi and asct or consolid convent chemotherapi in primari cns lymphoma,"['arm a ', 'arm b ']",['3'],highdos chemotherapi and autolog stem cell transplant or consolid convent chemotherapi in primari cns lymphoma  random phase iii trial
441,NCT02529852,a phase iii studi of lenalidomid and obinutuzumab with chop for diffus larg b cell lymphoma,"['lenalidomide', 'obinutuzumab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone']","['1', '2']",a phase iii studi of lenalidomid and obinutuzumab with chop for diffus larg b cell lymphoma
442,NCT00689169,target intensif with zbeam and autolog stem cell transplant in patient with highgrad bcell lymphoma,"['zbeam ', 'rituximab']",['2'],target intensif by a prepar regimen for patient with highgrad bcell lymphoma util standarddos yttrium90 ibritumomab tiuxetan zevalin radioimmunotherapi rit combin with highdos beam follow by autolog stem cell transplant asct
444,NCT02285062,efficaci and safeti studi of lenalidomid plus rchop chemotherapi versus placebo plus rchop chemotherapi in untreat abc type diffus larg bcell lymphoma,"['lenalidomide', 'placebo', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'prednisone', 'vincristine']",['3'],phase 3 randomized doubleblind placebo controlled multicent studi to compar the efficaci and safeti of lenalidomid cc5013 plus rchop chemotherapi r2chop versus placebo plus rchop chemotherapi in subject with previous untreat activ bcell type diffus larg bcell lymphoma
446,NCT02702141,a safeti studi of sgncd19b in patient with bcell nonhodgkin lymphoma,['sgn-cd19b'],['1'],a phase 1 openlabel doseescal studi of sgncd19b in patient with relaps or refractori aggress bcell nonhodgkin lymphoma
447,NCT01213095,rituximab mainten therapi for margin zone bcell lymphoma mzl,['rituximab'],['2'],rcvp follow by rituximab mainten therapi for patient with advanc margin zone bcell lymphoma
450,NCT01109069,safeti and toler studi of pci32765 in b cell lymphoma and chronic lymphocyt leukemia,['pci-32765'],['2'],a longterm safeti studi of bruton tyrosin kinas btk inhibitor pci32765 in b cell lymphoma and chronic lymphocyt leukemia
453,NCT01511562,combin chemotherapi with or without autolog stem cell transplant in treat patient with central nervous system bcell lymphoma,"['carmustine', 'cytarabine', 'etoposide', 'thiotepa', 'g-csf']",['2'],a random phase ii trial of myeloabl versus nonmyeloabl consolid chemotherapi for newli diagnos primari cns bcell lymphoma
458,NCT01459887,studi of recombin humanmous chimer anticd20 monoclon antibodi to treat nonhodgkin lymphoma,"['chop combined with cmab304', 'chop', 'cmab304']",['3'],an openlabeled multicenter randomized prospect phase iii studi compar cmab304 in combin with chop to chop alon with cmab304 mainten in patient with dlbcl
459,NCT01448096,studi in patient with primari breast diffus larg bcell lymphoma,['rituximab'],['2'],multicent phase ii studi of the combin of rchop rituximab plus cyclophosphamide adriamycin vincristine and prednisolone and prophylact intrathec chemotherapi with methotrex in patient with cd20 primari breast diffus larg bcell lymphoma
460,NCT02636322,smart start studi of rituximab lenalidomide and ibrutinib combin with chemotherapi for patient with high risk diffus larg bcell lymphoma,"['rituximab', 'ibrutinib', 'lenalidomide', 'etoposide', 'prednisone', 'vincristine', 'cyclophosphamide', 'doxorubicin']",['2'],a phase ii studi of rituximab lenalidomide and ibrutinib combin with chemotherapi for patient with high risk diffus larg bcell lymphoma
461,NCT00634179,a phase iii trial of vrchop in lymphoma patient,"['bortezomib', 'doxorubicin', 'cyclophosphamide', 'vincristine', 'prednisone']","['1', '2']",a phase iii trial of vrchop for patient with untreat follicular lymphoma and other low grade bcell lymphoma
462,NCT01560117,combin of oral fludarabine mitoxantron und rituximab induct therapi and rituximab mainten therapi in follicular bcell lymphoma,['rituximab'],['2'],multicent studi to evalu the combin of oral fludarabine mitoxantron und rituximab induct therapi und rituximab mainten therapi in follicular bcell lymphoma
464,NCT00983944,rituximab and combin chemotherapi with or without bleomycin sulfat in treat patient with primari mediastin larg bcell lymphoma,"['epoch regimen', 'cyclophosphamide', 'doxorubicin hydrochloride', 'etoposide', 'prednisone', 'vincristine sulfate']",['2'],a random phase ii studi of doseadjust epochr and rvacopb in primari mediastin thymic larg bcell lymphoma
465,NCT00446095,efficaci and safeti studi of fostamatinib tablet to treat bcell lymphoma,['fostamatinib'],"['1', '2']",a phase iii multicenter open label trial of the safeti and efficaci of fostamatinib in patient with relapsedrefractori bcell lymphoma
466,NCT02589145,lenalidomid combin with vorinostatgemcitabinebusulfanmelphalan with autolog stemcel transplant in diffus larg bcell lymphoma of the abc subtyp,"['lenalidomide', 'vorinostat', 'gemcitabine', 'busulfan', 'melphalan', 'rituximab', 'dexamethasone', 'caphosol', 'glutamine', 'pyridoxine', 'enoxaparin', 'palifermin']","['1', '2']",lenalidomid combin with vorinostatgemcitabinebusulfanmelphalan with autolog stemcel transplant in diffus larg bcell lymphoma of the abc subtyp
467,NCT02532192,a phase ib studi of belinostat with rdhap chemotherapi dexamethasone cytarabine cisplatinum in adult with relaps or refractori diffus larg bcell lymphoma,"['belinostat', 'rituximab', 'cisplatin', 'cytarabine', 'dexamethasone', 'ciprofloxacin', 'fluconazole']",['1'],a phase ib studi of belinostat with rdhap chemotherapi dexamethasone cytarabine cisplatinum in adult with relaps or refractori diffus larg bcell lymphoma
468,NCT02366663,beam vs 90yttrium ibritumomab tiuxetan zevalin®beam with asct for relaps dlbcl,"['carmustine', 'etoposide', 'cytarabine', 'melphalan']",['3'],spinoza  שפינוזה studi with preparatori induct of zevalin in aggress lymphoma a random phase 3 studi of beam versus 90yttrium ibritumomab tiuxetan zevalin  beam in patient requir asct for relaps dlbcl
469,NCT02141451,adam17 inhibitor rituximab after auto hct for dlbcl,"['rituximab', 'incb7839']","['1', '2']",studi of the adam17 inhibitor incb7839 combin with rituximab after autolog hematopoiet cell transplant hct for patient with diffus larg b cell nonhodgkin lymphoma dlbcl
476,NCT00169195,rituximab gemcitabin and oxaliplatin rgemox for refractoryrelaps bcell lymphoma,"['gemcitabine-oxaliplatin', 'rituximab ']",['2'],gemcitabineoxaliplatin plus rituximab rgemox in refractoryrelaps patient with cd 20 posit diffus larg bcell lymphoma non elig for highdos chemotherapi follow by autotransplant
477,NCT01354392,azd1152 in diffus larg bcell lymphoma,['azd1152'],"['1', '2']",a phase 2 trial of azd1152 in relapsedrefractori diffus larg bcell lymphoma
478,NCT00794638,a phase i clinic trial to assess the safeti of syb l0501 in combin with rituximab to patient with aggress bcell nonhodgkin lymphoma,"['syb l', 'rituximab']",['1'],a multicent phase i clinic trial to assess the safeti of two consecut day of syb l0501 in combin with rituximab to patient with aggress bcell nonhodgkin lymphoma
479,NCT01434472,highdos y90ibritumomab tiuxetan ad to reducedintens allogen stem cell transplant regimen for relaps or refractori aggress bcell lymphoma,"['cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']",['2'],a phase ii trial of highdos 90yibritumomab tiuxetan anticd20 follow by fludarabin and lowdos total bodi irradi and hlamatch allogen hematopoiet transplant for patient with relaps or refractori aggress bcell lymphoma
483,NCT00987493,rituximab bendamustin hydrochloride and lenalidomid in treat patient with aggress bcell lymphoma,"['bendamustine hydrochloride', 'lenalidomide']","['1', '2']",rituximab bendamustin and lenalidomid in patient with aggress bcell lymphoma not elig for high dose chemotherapi or anthracyclinebas therapy a phase iii trial
485,NCT02086604,brentuximab vedotin and lenalidomid for relaps or refractori diffus larg bcell lymphoma,"['brentuximab vedotin', 'lenalidomide']",['1'],a phase i trial of brentuximab vedotin in combin with lenalidomid in relaps or refractori diffus larg bcell lymphoma
486,NCT01855750,a studi of the bruton tyrosin kinas inhibitor pci32765 ibrutinib in combin with rituximab cyclophosphamide doxorubicin vincristine and prednison in patient with newli diagnos nongermin center bcell subtyp of diffus larg bcell lymphoma,"['ibrutinib', 'placebo', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone ']",['3'],a randomized doubleblind placebocontrol phase 3 studi of the bruton tyrosin kinas btk inhibitor pci32765 ibrutinib in combin with rituximab cyclophosphamide doxorubicin vincristine and prednison rchop in subject with newli diagnos nongermin center bcell subtyp of diffus larg bcell lymphoma
488,NCT00290667,rituximab and combin chemotherapi in treat older patient with previous untreat bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],2week chop chemotherapi with dosedens rituximab for the treatment of patient age 61 to 80 year with aggress cd20 posit bcell lymphomas a phaseiipharmacokinet studi chopresc
489,NCT02362997,pembrolizumab after asct for hodgkin lymphoma dlbcl and tnhl,['pembrolizumab'],['2'],a phase 2 studi of pembrolizumab mk3475 after autolog stem cell transplant in patient with relapsedrefractori classic hodgkin lymphoma and diffus larg b cell lymphoma and t cell nonhodgkin lymphoma
491,NCT00355199,comparison of hd chemotherapi follow by autotranspl and rchop in high risk patient with dlbcl,"['rituximab-hds', 'rituximab-chop']",['3'],multicentr random phase iii studi compar high dose of chemotherapi with rituximab follow by autotranspl hpc versus chop plus rituximab as first line therapi in high risk patient with dlbcl nonhodgkin lymphoma
493,NCT02391116,phase ii copanlisib in relapsedrefractori diffus larg bcell lymphoma dlbcl,['copanlisib '],['2'],an openlabel singlearm phase ii studi in patient with relaps or refractori diffus larg bcell lymphoma dlbcl to evalu efficaci and safeti of treatment with singl agent copanlisib and the impact of biomark thereupon
497,NCT00670358,lenalidomide rituximab and combin chemotherapi in treat patient with newli diagnos stage ii stage iii or stage iv diffus larg cell or follicular bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'lenalidomide', 'prednisone', 'vincristine sulfate']","['1', '2']",phase iii studi of lenalidomid revlimid rituximab cyclophosphamide doxorubicin vincristin and prednison r2chop chemoimmunotherapi in patient with newli diagnos diffus larg cell and follicular grade iiiab b cell lymphoma
498,NCT01848132,efficacysafeti studi of rchop vs bortezomibrcap for young patient with diffus larg bcell lymphoma with poor ipi,"['bortezomib', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'prednisone', 'vincristine']",['2'],multicent random phase ii studi of treatment with rchop vs bortezomibrcap for young patient with diffus larg bcell lymphoma with poor ipi
499,NCT01324596,a randomis evalu of molecular guid therapi for diffus larg bcell lymphoma with bortezomib,"['intravenous', 'bortezomib']",['3'],a randomis evalu of molecular guid therapi for diffus larg bcell lymphoma with bortezomib
501,NCT02428751,rchop versus rcdop as firstlin treatment for elder patient with diffus largebcel lymphoma,"['pegylated liposomal doxorubicin', 'doxorubicin', 'rituximab', 'cyclophophamide', 'vincristine', 'prednisone']",['3'],rituximab cyclophosphamide vincristine and prednison in combin with doxorubicin rchop versus in combin with pegylatedliposom doxorubicin rcdop as firstlin treatment for elder patient with diffus largebcel lymphoma a randomised multicentre noninferior studi
507,NCT00058422,rituximab and combin chemotherapi combin with yttrium y 90 ibritumomab tiuxetan in treat older patient with previous untreat bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],a phase ii studi of rchop and ibritumomab tiuxetan zevalin for elder patient with previous untreat diffus larg bcell lymphoma
512,NCT02031419,novel combin of cc122 cc223 cc292 and rituximab in diffus larg bcell lymphoma and follicular lymphoma,"['cc-122', 'cc-223', 'rituximab', 'cc-292']",['1'],a phase 1b multicenter openlabel studi of novel combin of cc122 cc223 cc292 and rituximab in diffus larg bcell lymphoma and follicular lymphoma
513,NCT01359592,s1001 petdirect therapi in treat patient with limitedstag diffus larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],a phase ii trial of petdirect therapi for limit stage diffus larg bcell lymphoma dlbcl
516,NCT01144403,a studi of mabthera rituximab addit to regular prescrib chemotherapi in patient with untreat mantl cell lymphoma,"['cyclophosphamide', 'fludarabine', 'mitoxantrone', 'rituximab']",['2'],a phase ii multicent openlabel studi of mabtherarituximab addit to regular prescrib chemotherapi in patient with untreat mantl cell lymphoma
518,NCT02343536,a phase 1 openlabel trial of oral azacitidin cc486 plus rchop in subject with larg bcell lymphoma or follicular lymphoma or transform lymphoma,"['oral azacitidine', 'rituximab', 'cyclophosphamide', 'vincristine', 'prednisone']",['1'],a phase 1 openlabel multicent trial of oral azacitidin cc486 plus rchop in subject with high risk ipi 3 or more previous untreat diffus larg bcell lymphoma or grade 3b follicular lymphoma
522,NCT01334502,everolimus rituximab and combin chemotherapi in treat patient with newli diagnos untreat diffus larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'everolimus', 'prednisone', 'vincristine sulfate']",['1'],a phase i and feasibl studi of everolimus rad001 plus rchop for new untreat diffus larg bcell lymphoma dlbcl
523,NCT01278615,selumetinib in treat patient with relaps or refractori diffus larg bcell lymphoma,['selumetinib'],['2'],a singlearm phase ii clinic trial with the novel mek inhibitor azd6244 for the treatment of mct1 relat relaps or refractori diffus larg bcell lymphoma
524,NCT00880581,a phase 2 intratumor inject pf3512676 plus local radiat in lowgrad bcell lymphoma,['pf-3512676'],['2'],a phase 2 studi of intratumor inject pf3512676 in combin with local radiat in lowgrad bcell lymphoma
525,NCT01321541,comparison of pixantron  rituximab with gemcitabin  rituximab in patient with aggress bcell nonhodgkin lymphoma or follicular grade 3 lymphoma who have relaps after therapi and are not elig for stem cell transplant,"['pixantrone', 'rituximab', 'gemcitabine', 'rituximab']",['3'],a random multicent studi compar pixantron  rituximab with gemcitabin  rituximab in patient with aggress bcell nonhodgkin lymphoma who have relaps after therapi with chopr or an equival regimen and are inelig for stem cell transplant
526,NCT01649856,a studi of subcutan versus intraven mabtherarituxan rituximab in combin with chop chemotherapi in patient with previous untreat cd20posit diffus larg bcell lymphoma,"['chop', 'rituximab ']",['3'],a comparative randomized parallelgroup multicenter phase iiib studi to investig the efficaci of subcutan sc rituximab versus intraven iv rituximab both in combin with chop rchop in previous untreat patient with cd20posit diffus larg bcell lymphoma dlbcl
528,NCT02257567,a studi of polatuzumab vedotin dcds4501a in combin with rituximab or obinutuzumab plus bendamustin in particip with relaps or refractori follicular or diffus larg bcell lymphoma,"['bendamustine', 'obinutuzumab', 'polatuzumab vedotin ', 'rituximab', 'polatuzumab vedotin ']","['1', '2']",a phase ibii studi evalu the safety toler and antitumor activ of polatuzumab vedotin dcds4501a in combin with rituximab r or obinutuzumab g plus bendamustin b in relaps or refractori follicular or diffus larg bcell lymphoma
533,NCT00851552,bortezomib doxorubicin hydrochlorid liposome and rituximab in treat patient with diffus larg bcell lymphoma that has relaps or not respond to treatment,"['bortezomib', 'pegylated liposomal doxorubicin hydrochloride']",['2'],a phase ii studi of vdr velcade™ doxil® and rituxan™ in relapsedrefractori diffus larg bcell lymphoma
534,NCT01926665,carfilzomib consolid therapi after autolog stem cell transplant asct for mantl cell lymphoma mcl tcell lymphoma tcl and diffus larg bcell lymphoma dlbcl,"['carfilzomib', 'dexamethasone']",['1'],carfilzomib consolid therapi after autolog stem cell transplant asct for patient with mantl cell mcl tcell tcl and diffus bcell lymphoma dlbcl
535,NCT01351935,escal dose studi in subject with relaps or refractori b cell nonhodgkin lymphoma chronic lymphocyt leukemia and waldenstrom macroglobulinemia,['avl-292'],['1'],phase 1b escal dose studi of avl292 a bruton tyrosin kinas btk inhibitor as monotherapi in subject with relaps andor refractori b cell nonhodgkin lymphoma chronic lymphocyt leukemia and waldenstrom macroglobulinemia
537,NCT02038933,studi of nivolumab in patient with relaps or refractori diffus larg bcell lymphoma dlbcl that have either fail or are not elig for autolog stem cell transplant checkmat 139,['nivolumab'],['2'],a singlearm openlabel phase 2 studi of nivolumab bms936558 in subject with relaps or refractori diffus larg bcell lymphoma dlbcl after failur of autolog stem cell transplant asct or after failur of at least two prior multiag chemotherapi regimen in subject who are not candid for asct
538,NCT00156013,clofarabin for relaps or refractori tcell or bcell nonhodgkin lymphoma nhl,['clofarabine'],"['1', '2']",a phase iii openlabel studi of clofarabin in patient with relaps or refractori diffus larg cell bcell nhl
539,NCT01014208,ofatumumab versus rituximab salvag chemoimmunotherapi follow by autolog stem cell transplant in relaps or refractori diffus larg b cell lymphoma,"['ofatumumab', 'dhap', 'rituximab', 'dhap']",['3'],ofatumumab versus rituximab salvag chemoimmunotherapi follow by autolog stem cell transplant asct in relaps or refractori diffus larg b cell lymphoma dlbcl
540,NCT00136591,a phase 2 studi of velcade™ in subject with relaps or refractori follicular bcell lymphoma,['bortezomib'],['2'],a phase 2 studi of velcade™ in subject with relaps or refractori follicular bcell lymphoma
541,NCT00644124,aflibercept and standard chemotherapi rchop in first line of non hodgkin bcell lymphoma,['aflibercept'],['1'],a phase i openlabel doseescal studi of intraven aflibercept ave0005 vegf trap in combin with rchop administ everi 2 week or everi 3 week in patient with non hodgkin bcell lymphoma
543,NCT00445341,flavopiridol to treat relaps mantl cell lymphoma or diffus larg bcell lymphoma,['flavopiridol'],"['1', '2']",a phase iii studi of flavopiridol in relaps or refractori mantl cell lymphoma mcl and diffus larg bcell lymphoma dlbcl
544,NCT01555541,studi of intens consolid and stem cell mobil therapi follow by autolog stem cell transplant in highrisk patient with relapsedrefractori diffus larg bcell lymphoma,"['ofatumumab', 'etoposide', 'cytarabine']",['2'],a phase ii studi of intens consolid and stem cell mobil therapi with ofatumumab etoposide and highdos arac ova follow by autolog stem cell transplant in highrisk patient with relapsedrefractori diffus larg bcell lymphoma
545,NCT00135499,racvbp versus rchop in patient age 6065 with diffus larg bcell lymphoma,"['rituximab', 'doxorubicin', 'cyclophosphamide', 'vindesine', 'bleomycin', 'prednisone', 'vincristine']",['3'],random studi of acvbp plus rituximab versus chop plus rituximab in non previous treat patient age from 60 to 65 year with diffus larg bcell lymphoma
546,NCT00140660,acvbp versus acvbp plus rituximab in low risk local diffus larg bcell lymphoma,['rituximab'],['3'],random studi of acvbp versus acvbp plus rituximab in previous untreat patient age from 18 to 65 year with lowrisk local diffus larg bcell lymphoma ageadjust ipi  0
547,NCT00971763,gemcitabin hydrochloride cyclophosphamide vincristin sulfate prednisolone and rituximab in treat patient with newli diagnos diffus larg bcell lymphoma,"['cyclophosphamide', 'gemcitabine hydrochloride', 'prednisolone', 'vincristine sulfate']",['2'],a phase ii multicentr trial of gemcitabine cvp and rituximab rgcvp for the treatment of patient with newli diagnos diffus larg bcell lymphoma consid unsuit for rchop chemotherapi
549,NCT00829205,semethylselenolcysteine rituximab ifosfamide carboplatin and etoposid in treat patient with diffus larg bcell lymphoma that has relaps or not respond to treatment,"['carboplatin', 'etoposide', 'ifosfamide']","['1', '2']",a phase iii studi of methylselenocystein msc in combin with immunochemotherapi rice in patient with relapsedrefractori diffus larg bcell lymphoma dlbcl
550,NCT00144807,acvbp plus rituximab in patient age from 18 to 59 year with highrisk diffus larg bcell lymphoma,"['rituximab', 'doxorubicin', 'cyclophosphamide']",['2'],studi of acvbp plus rituximab in previous untreat patient age from 18 to 59 year with high risk diffus larg bcell lymphoma ageadjust ipi  23
552,NCT00066508,bortezomib in treat patient with diffus larg bcell lymphoma that is refractori to chemotherapi,['bortezomib'],['2'],a phase ii studi of ps341 velcade in chemotherapyrefractori diffus larg bcell lymphoma dlbcl
553,NCT00137995,rice versus rdhap in patient age 1865 with relaps diffus larg bcell lymphoma,"['rituximab', 'etoposide', 'carboplatine', 'ifosfamide', 'mesna', 'cisplatine', 'cytosine arabinoside', 'dexamethasone', 'bcnu', 'cytarabine', 'melphalan']",['3'],random studi of ice plus rituximab versus dhap plus rituximab in previous treat patient with diffus larg bcell lymphoma follow by random mainten with rituximab
554,NCT00301821,monoclon antibodi therapi and combin chemotherapi in treat patient with stage ii stage iii or stage iv diffus larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],a phase ii studi of epratuzumab rituximab erchop for patient with previous untreat diffus larg bcell lymphoma
556,NCT00140595,acvbp plus rituximab versus chop plus rituximab in patient with diffus larg bcell lymphoma and ageadjust ipi of 1,"['rituximab', 'doxorubicin', 'cyclophosphamide']",['3'],random studi of acvbp plus rituximab versus chop plus rituximab in patient age from 18 to 59 year with diffus larg bcell lymphoma and a ageadjust ipi of 1
557,NCT00169130,acvbp follow by asct in patient with bcl2 posit diffus larg bcell lymphoma,"['doxorubicin', 'cyclophosphamide']","['2', '3']",prospect studi of acvbp follow by autolog stem cell transplant in case of bcl2 overexpress in non previous treat patient age 60 year or less with lowintermedi risk diffus larg bcell lymphoma
561,NCT00308087,comparison studi of rituximab plus sargramostim to rituximab alon for relaps follicular bcell lymphoma a form of nonhodgkin lymphoma,"['sargramostim ', 'rituximab']",['2'],randomized open label phase ii trial compar rituximab plus sargramostim to rituximab monotherapi for the treatment of relaps follicular bcell lymphoma
562,NCT00268853,a trial in patient with diffus largebcel lymphoma compar pixantron against doxorubicin,"['cpop-r', 'chop-r']",['2'],cyclophosphamide doxorubicin vincristine prednison plus rituximab chopr and cyclophosphamide pixantrone vincristine prednison plus rituximab cpopr in patient with diffus largebcel lymphoma a phase ii randomized multicenter compar trial
563,NCT00144755,rchop14 versus rchop21 and darbepoetin alpha in patient age 6080 year with diffus larg bcell lymphoma,['darbepoetin alfa'],['3'],intensifi chop plus rituximab rchop 14 versus chop plus rituximab rchop 21 and frontlineprophylact darbepoetin alfa treatment versus usual symptomat treatment of anemia in patient age 60 to 80 year with diffus larg bcell lymphoma
564,NCT00193505,ifosfamidecarboplatinetoposiderituxan follow by zevalin in relapsedrefractori intermedi grade bcell lymphoma,"['ifosfamide', 'carboplatin', 'etoposide', 'rituximab', '90y zevalin']",['2'],phase ii trial of ifosfamidecarboplatinetoposiderituxan follow by zevalin in the treatment of patient with relapsedrefractori intermedi grade bcell lymphoma
567,NCT00435916,studi of sgn40 in patient with relaps diffus larg bcell lymphoma,['sgn-40'],['2'],a phase ii studi of sgn40 antihucd40 mab in patient with relaps diffus larg bcell lymphoma dlbcl
571,NCT00324831,gmcsf with or without vaccin therapi after combin chemotherapi and rituximab as firstlin therapi in treat patient with stage ii stage iii or stage iv diffus larg bcell lymphoma,"['autologous immunoglobulin idiotype', 'cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'rituximab', 'sargramostim', 'vincristine']",['3'],phase iii doubleblind randomized placebocontrol trial of favid® idklh and gmcsf follow choprituximab as firstlin therapi in subject with highintermedi and highrisk diffus larg bcell lymphoma
572,NCT01239394,ofatumumab for initi system treatment of indol bcell lymphoma,['ofatumumab'],['2'],phase ii trial ofatumumab for initi system treatment of indol bcell lymphoma
574,NCT00457782,a phase i safety pk and pd studi of kw2478 in patient with multipl myeloma chronic lymphocyt leukaemia or bcell nonhodgkin lymphoma,['kw-2478'],['1'],a phase i openlabel doseescalation multicentr studi of kw2478 administ as a singl agent intraven in a consecut dose schedul in patient with relapsedrefractori multipl myeloma chronic lymphocyt leukaemia or bcell nonhodgkin lymphoma
575,NCT00070083,oblimersen rituximab cyclophosphamide doxorubicin vincristine and prednison in treat patient with stage ii stage iii or stage iv diffus larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['1'],a phase i studi of g3139 antisens oligonucleotid oblimersen in combin with chop and rituximab in untreat advanc stage diffus larg b cell lymphoma
576,NCT02073097,carfilzomib rituximab and combin chemotherapi in treat patient with diffus larg bcell lymphoma,"['carfilzomib', 'cyclophosphamide', 'doxorubicin hydrochloride', 'vincristine sulfate', 'prednisone']","['1', '2']",a phase iii studi of carfilzomib in combin with rchop crchop for patient with diffus larg bcell lymphoma
577,NCT00588094,dose augment rituximab and ice for pts with primari refractori and poor risk relaps aggress bcell nhl,"['rituximab', 'ifosfamide', 'carboplatin', 'vp']",['2'],a phase ii studi of dose augment rituximab and ice for patient with primari refractori and poor risk relaps aggress bcell nonhodgkin lymphoma undergo secondlin therapi prior to stem cell transplant
578,NCT01980628,studi of the bruton tyrosin kinas inhibitor in subject with relapsedrefractori margin zone lymphoma,['ibrutinib'],['2'],a multicenter openlabel phase 2 studi of the bruton tyrosin kinas btk inhibitor ibrutinib in subject with relapsedrefractori margin zone lymphoma
579,NCT02281279,rituximab romidepsin and lenalidomid in treat patient with recurr or refractori bcell nonhodgkin lymphoma,"['lenalidomide', 'romidepsin']","['1', '2']",a phase iii trial of romidepsin rituximab and lenalidomid r3 in relapsedrefractori b cell lymphoma includ transform follicular lymphoma
581,NCT01994850,a phase iii studi of brentuximab vedotin in combin with multiag chemotherapi as frontlin treatment in patient with cd30 posit primari mediastin larg bcell diffus larg bcell and grey zone lymphoma,['brentuximab vedotin'],"['1', '2']",a phase iii studi of brentuximab vedotin in combin with multiag chemotherapi as frontlin treatment in patient with cd30 posit primari mediastin larg bcell diffus larg bcell and grey zone lymphoma
582,NCT00764517,vorinostat cladribine and rituximab in treat patient with mantl cell lymphoma relaps chronic lymphocyt leukemia or relaps b cell nonhodgkin lymphoma,"['cladribine', 'vorinostat']",['2'],phase ii studi of vorinostat saha cladribine and rituximab scr in mantl cell lymphoma chronic lymphocyt leukemia and relaps b cell nonhodgkin lymphoma
583,NCT00796731,sar3419 administ week in patient with relapsedrefractori cd19posit bcell nonhodgkin lymphoma,['sar3419'],['1'],a doseescalation safeti and pharmacokinet studi of sar3419 administ as a singl agent by intraven infus onc week in patient with relapsedrefractori cd19posit bcell nonhodgkin lymphoma nhl
584,NCT01812005,alisertib with and without rituximab in treat patient with relaps or refractori bcell nonhodgkin lymphoma,['alisertib'],['2'],a phase ii studi of mln8237 alon and in combin with rituximab in patient with relaps or refractori bcell nonhodgkin lymphoma
585,NCT01193842,vorinostat and combin chemotherapi with rituximab in treat patient with hivrel diffus larg bcell nonhodgkin lymphoma or other aggress bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'etoposide', 'prednisone', 'vincristine sulfate', 'vorinostat']","['1', '2']",a sequenti phase irandom phase ii trial of vorinostat and riskadapt chemotherapi with rituximab in hivrel bcell nonhodgkin lymphoma
586,NCT00622388,ofatumumab in patient with relapsedprogress diffus larg bcell lymphoma dlbcl inelig for or relapseprogress after transplant,['ofatumumab'],['2'],an openlabel singlearm multicent phase 2 trial with ofatumumab in patient with relapsedprogress diffus larg bcell lymphoma dlbcl inelig for transplant or relapseprogress after autolog transplant
587,NCT00945724,safeti and feasibl studi of combin of state of art chemoimmunotherapy intens central nervous system prophylaxi and scrotal irradi to treat primari diffus larg bcell lymphoma of testi,"['rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisolone', 'liposomal cytarabine', 'methotrexate']",['2'],a phase ii studi of rchop with intens cns prophylaxi and scrotal irradi in patient with primari testicular diffus larg bcell lymphoma
588,NCT00783367,combin therapi use lenalidomid revlimid low dose dexamethason and rituximab for treatment of rituximabresistant nonaggress bcell lymphoma,"['lenalidomide-low dose dexamethasone', 'rituximab', 'lenalidomide', 'rituximab']",['2'],phase 2 trial of lenalidomid revlimiddexamethason  rituximab in recurr small bcell nonhodgkin lymphoma nhl resist to rituximab
589,NCT02220842,a safeti and pharmacolog studi of atezolizumab mpdl3280a administ with obinutuzumab or tazemetostat in particip with relapsedrefractori follicular lymphoma and diffus larg bcell lymphoma,"['atezolizumab', 'obinutuzumab', 'tazemetostat']",['1'],a phase ib studi of the safeti and pharmacolog of atezolizumab administ with obinutuzumab in patient with relapsedrefractori follicular lymphoma or atezolizumab administ with obinutuzumab or tazemetostat in patient with relapsedrefractori diffus larg bcell lymphoma
590,NCT00901615,lenalidomid and rchop in bcell lymphoma,"['lenalidomide', 'r']","['1', '2']",a phase ib studi of escal dose of revlimid in associ with rchop r2chop in the treatment of bcell lymphoma
593,NCT01889069,a studi to evalu safety efficaci and pharmacokinet of rituximab mabtherarituxan in particip with diffus larg b cell lymphoma dlbcl or follicular lymphoma fl,"['rituximab', 'cyclophosphamide', 'vincristine', 'doxorubicin', 'prednisone', 'bendamustine']",['3'],a singl arm multicentre phase iiib studi to evalu safety efficaci and pharmacokinet pk of subcutan sc rituximab administ dure induct phase or mainten in previous untreat patient with cd20 diffus larg b cell lymphoma dlbcl or follicular lymphoma fl
594,NCT01063439,bueam condit for autolog stem cell transplant asct to treat diffus larg b cell lymphoma dlcbl,"['busulfan', 'etoposide', 'cytarabine', 'melphalan']",['2'],busulfan etoposide cytarabin and melphalan bueam as a condit for autolog stem cell transplant in patient with diffus larg b cell lymphoma dlcbl previous treat with rituximab base regimen
595,NCT00290472,cci779 in treat patient with recurr or refractori bcell nonhodgkin lymphoma or chronic lymphocyt leukemia,['temsirolimus'],['2'],a phase ii studi of cci779 in bcell lymphoma and cll
596,NCT01539174,rituximab and combin chemotherapi in treat patient with previous untreat high or highintermediaterisk diffus larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'vincristine sulfate', 'prednisone']",['2'],a phase ii studi of rituximab intens dose with chop21 ridchop in patient with previous untreat high or highintermedi risk ipi 35 diffus larg bcell lymphoma dlbcl
597,NCT02729896,a studi evalu safeti and efficaci of obinutuzumab polatuzumab vedotin pola and atezolizumab atezo in particip with relaps or refractori follicular lymphoma fl and rituximab atezo and pola in particip with relaps or refractori diffus larg bcell lymphoma dlbcl,"['atezolizumab ', 'obinutuzumab', 'polatuzumab vedotin', 'rituximab']","['1', '2']",a phase ibii studi evalu the safeti and efficaci of obinutuzumab in combin with atezolizumab plus polatuzumab vedotin in patient with relaps or refractori follicular lymphoma and rituximab in combin with atezolizumab plus polatuzumab vedotin in patient with relaps or refractori diffus larg bcell lymphoma
599,NCT00288067,fenretinid and rituximab in treat patient with bcell nonhodgkin lymphoma,"['fenretinide', 'rituximab']","['1', '2']",a phase iii trial of fenretinid 4hpr  rituximab in patient with bcell lymphoma
600,NCT02706405,jcar014 and durvalumab in treat patient with relaps or refractori bcell nonhodgkin lymphoma,"['cyclophosphamide', 'fludarabine phosphate']",['1'],a phase 1b studi of jcar014 autolog t cell engin to express a cd19specif chimer antigen receptor in combin with durvalumab medi4736 for relapsedrefractori bcell nonhodgkin lymphoma
601,NCT00312845,studi of velcad and rituximab in patient with relaps or refractori bcell nonhodgkin lymphoma,"['bortezomib', 'rituximab', 'rituximab']",['3'],a randomized openlabel multicent studi of velcad with rituximab or rituximab alon in subject with relaps or refractory rituximab naiv or sensit follicular bcell nonhodgkin lymphoma
602,NCT01178645,studi of busulfan etoposide cytarabine and melphalan bueam condit for autolog stem cell transplant asct to treat b cell lymphoma except for diffus larg b cell lymphoma,"['busulfan', 'etoposide', 'cytarabine,', 'melphalan']",['2'],busulfan etoposide cytarabine and melphalan bueam as a condit for autolog stem cell transplant in patient with b cell lymphoma except for diffus larg b cell lymphoma
604,NCT00972478,vorinostat rituximab and combin chemotherapi in treat patient with newli diagnos stage ii stage iii or stage iv diffus larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate', 'vorinostat']","['1', '2']",a phase iii trial of vorinostat saha nsc701852 in combin with rituximabchop in patient with newli diagnos advanc stage diffus larg bcell lymphoma dlbcl
606,NCT00042666,a studi of oral ly317615 in relaps or refractori diffus larg bcell lymphomas,['ly317615'],['2'],a phase 2 evalu of oral ly317615 in patient with relaps or refractori diffus larg bcell lymphoma
607,NCT00392496,sunitinib in treat patient with relaps or refractori diffus or mediastin larg bcell lymphoma,['sunitinib malate'],['2'],a phase ii studi of sunitinib su11248 nsc 736511 ind 74019 an oral multitarget tyrosin kinas inhibitor in patient with relaps or refractori diffus larg bcell lymphoma
608,NCT00712582,therapi for patient with untreat ageadjust intern prognost index lowintermedi risk highintermedi risk or high risk diffus larg b cell lymphoma,"['etoposide', 'carboplatin', 'ifosfamide', 'rituximab', 'ifosfamide', 'etoposide', 'carboplatin', 'rituximab', 'ifosfamide', 'etoposide', 'carboplatin', 'stem cell collection', 'mitoxantrone', 'cyclophosphamide', 'etoposide', 'carmustine']",['2'],riskadapt therapi for patient with untreat ageadjust intern prognost index lowintermedi risk highintermedi risk or high risk diffus larg b cell lymphoma
609,NCT00667615,trial of vorinostat in combin with cyclophosphamide etoposide prednison and rituximab for elder patient with relaps diffus larg bcell lymphoma dlbcl,"['rituximab', 'cyclophosphamide', 'etoposide', 'prednisone', 'vorinostat', 'qol questionnaire', 'peg']","['1', '2']",a multicent phase iii trial of vorinostat in combin with cyclophosphamide etoposide prednison and rituximab for elder patient with relaps diffus larg bcell lymphoma dlbcl
615,NCT00621452,genet engin lymphocytes cyclophosphamide and aldesleukin in treat patient with relaps or refractori mantl cell lymphoma or indol bcell nonhodgkin lymphoma,['cyclophosphamide'],['1'],a pilot studi to evalu the safeti and feasibl of cellular immunotherapi use genet modifi autolog cd20specif t cell for patient with relaps or refractori mantl cell and indol b cell lymphoma
616,NCT00532259,ct011 mab in dlbcl patient follow asct,['ct-011'],['2'],phase ii safeti and efficaci studi of the monoclon antibodi ct011 in patient with diffus larg bcell lymphoma follow autolog stem cell transplant
619,NCT01284192,studi of an investig drug asp3026 in patient with advanc malign solid tumor and bcell lymphoma,['asp3026'],['1'],a phase 1 multicenter openlabel dose escal studi of asp3026 in subject with advanc malign
622,NCT02611323,a studi of obinutuzumab rituximab polatuzumab vedotin and venetoclax in relaps or refractori follicular lymphoma fl or diffus larg bcell lymphoma dlbcl,"['obinutuzumab', 'rituximab', 'polatuzumab vedotin', 'venetoclax']",['1'],a phase ibii studi evalu the safeti and efficaci of obinutuzumab in combin with polatuzumab vedotin and venetoclax in patient with relaps or refractori follicular lymphoma and rituximab in combin with polatuzumab vedotin and venetoclax in patient with relaps or refractori diffus larg bcell lymphoma
623,NCT02413489,an efficaci and safeti proof of concept studi of daratumumab in relapsedrefractori mantl cell lymphoma diffus larg bcell lymphoma and follicular lymphoma,['daratumumab'],['2'],an open label phase 2 studi to evalu efficaci and safeti of daratumumab in relaps or refractori mantl cell lymphoma diffus larg bcell lymphoma and follicular lymphoma
624,NCT00703664,bortezomib and vorinostat in treat patient with recurr mantl cell lymphoma or recurr andor refractori diffus larg bcell lymphoma,"['bortezomib', 'vorinostat']",['2'],phase ii trial of bortezomib and vorinostat in mantl cell and diffus larg bcell lymphoma
626,NCT02624986,a studi of idasanutlin in combin with obinutuzumab in relapsedrefractori rr follicular lymphoma fl and in combin with rituximab in rr diffus larg bcell lymphoma dlbcl particip,"['idasanutlin', 'obinutuzumab', 'rituximab']","['1', '2']",a phase ibii studi evalu the safeti and efficaci of obinutuzumab in combin with idasanutlin in patient with relaps or refractori follicular lymphoma and obinutuzumab or rituximab in combin with idasanutlin in patient with relaps or refractori diffus larg bcell lymphoma
627,NCT00466531,treatment of relaps or chemotherapi refractori chronic lymphocyt leukemia or indol b cell lymphoma use autolog t cell genet target to the b cell specif antigen cd19,['cyclophosphamide'],"['1', '2']",a phase iiia trial for the treatment of relaps or chemotherapi refractori chronic lymphocyt leukemia or indol b cell lymphoma use autolog t cell genet target to the b cell specif antigen cd19
628,NCT02086175,a phase 2 clinic trial of rituxan and bglucan pgg in relaps indol nonhodgkin lymphoma,"['imprime pgg', 'rituximab']",['2'],a phase 2 clinic trial of rituxan and bglucan pgg in relaps indol nonhodgkin lymphoma
629,NCT00880867,intratumor polyiclc plus low dose local radiat in low grade recurr b and t cell lymphoma,['poly-iclc'],['1'],a phase i studi of intratumor polyiclc plus low dose local radiat in low grade recurr b and t cell lymphoma
630,NCT00294632,lenalidomid and rituximab in the treatment of relaps mantl cell lymphoma mcl and diffus larg bcell lymphoma,"['lenalidomide', 'rituximab']","['1', '2']",lenalidomid and rituximab treatment of relaps mantl cell lymphoma and diffus larg bcell nonhodgkin lymphoma transform larg cell lymphoma andor grade 3 follicular lymphoma follicular cleav larg cell lymphoma or follicular noncleav larg cell lymphoma rvlympi0056
632,NCT00210366,salvag therapi with idarubicin in relaps cns lymphoma,['idarubicin'],['2'],salvag therapi with idarubicin in immunocompet patient with relaps or refractori primari central nervous system lymphoma
633,NCT00210314,phase ii trial of combin modal treatment in primari central nervous system lymphoma,"['high dose methotrexate', 'high dose cytarabine']",['2'],random phase ii trial on primari chemotherapi with highdos methotrexate alon or associ with highdos cytarabine follow by response and agetailor radiotherapi for immunocompet patient with newli diagnos primari central nervous system lymphoma
634,NCT00907348,prospect multicent dose find phase ii pilot trial to evalu efficaci and safeti of lrchop21 for elder patient with untreat diffus larg b cell lymphoma,['lr-chop21'],['2'],prospect multicent dose find phase ii pilot trial to evalu efficaci and safeti of treatment with lenalidomid plus rchop21 lrchop21 for elder patient with untreat diffus larg b cell lymphoma dlbcl
635,NCT00329030,rituxan vs bexxar when combin with carmustine etoposide cytarabin and melphalan beam with autolog hematopoiet stem cell transplant bmt ctn 0401,"['autologous transplantation using rituxan', 'autologous transplantation using bexxar']",['3'],phase iii rituxanbeam vs bexxarbeam with autolog hematopoiet stem cell transplant asct for persist or relaps chemotherapi sensit diffus larg bcell nonhodgkin lymphoma bmt ctn 0401
636,NCT01118845,studi of syb l0501 in combin with rituximab to treat relapsedrefractori diffus larg bcell lymphoma,"['syb l', 'rituximab']",['2'],a multinational multicenter openlabel phase ii studi of syb l0501 in combin with rituximab in patient with relapsedrefractori diffus larg bcell lymphoma
637,NCT01300793,studi of standarddos rituximab ifosfamide carboplatin and etoposid,['velcade '],['1'],rice plus bortezomib velcade in a doseescal fashion for patient with relaps or primari refractori aggress bcell nhl
639,NCT02082977,a studi to investig the safety pharmacokinetics pharmacodynam and clinic activ of gsk2816126 in subject with relapsedrefractori diffus larg b cell lymphoma transform follicular lymphoma other nonhodgkin lymphomas solid tumor and multipl myeloma,['gsk2816126'],['1'],a phase i openlabel dose escal studi to investig the safety pharmacokinetics pharmacodynam and clinic activ of gsk2816126 in subject with relapsedrefractori diffus larg b cell lymphoma transform follicular lymphoma other nonhodgkin lymphomas solid tumor and multipl myeloma
640,NCT02623920,brentuximab vedotin bendamustine and rituximab in patient with relaps or refractori bcell nonhodgkin lymphoma,"['brentuximab', 'bendamustine', 'rituximab']",['2'],phase ii studi of brentuximab vedotin in combin with bendamustin and rituximab in patient with cd30 positive relaps or refractori b cell nonhodgkin lymphoma nhl
641,NCT02405676,bnhl2015 for children or adolesc in china,"['prednisone,vincristine', 'cyclophosphamide', 'cyclophosphamide', 'vincristine', 'cytarabine', 'doxorubincin', 'prednisone', 'ifosphamide', 'etoposide', 'methotrexate', 'vincristine', 'prednisone', 'cyclophosphamide', 'vindelsine', 'cytarabine', 'doxorubincin', 'prednisone', 'ifosphamide', 'etoposide', 'methotrexate', 'vindelsine', 'prednisone', 'rituximab']","['2', '3']",treatment regimen or children or adolesc with matur bcell nhl or bal in china
643,NCT00968760,cd19specif t cell infus in patient with blineag lymphoid malign,"['il-2', 'carmustine', 'etoposide', 'cytarabine', 'melphalan']",['1'],cd19specif t cell infus in patient with blineag lymphoid malign
646,NCT01078922,patient with relaps or refractori diffus larg b cell non hodgkin lymphoma,['ofatumumab'],['2'],a phase ii openlabel studi of singl agent ofatumumab in patient with relaps andor refractori diffus larg b cell non hodgkin lymphoma
648,NCT00225212,rituximab after autolog stem cell transplant for relaps bcell nonhodgkin lymphoma,['rituximab 375 mg'],['2'],clinic trial of c2b8 monoclon antibodi follow high dose therapi and autograft in bcell nonhodgkin lymphoma
649,NCT00482053,phase 2 poor risk dlbcl of tli and atg follow by match allogen ht as consolid to autolog hct,"['rituximab', 'carmustine', 'etoposide', 'filgrastim', 'anti-thymocyte globulin ', 'cyclosporine', 'mycophenolate mofetil ', 'cyclophosphamide', 'acetaminophen', 'diphenhydramine', 'hydrocortisone', 'methylprednisolone']",['2'],a phase 2 studi in poor risk diffus larg bcell lymphoma of total lymphoid irradi  antithymocyt globulin follow by match allogen hematopoiet transplant as consolid to autolog hematopoiet cell transplant
654,NCT01122472,studi of lenalidomid mainten versus placebo in respond elder patient with dlbcl and treat with rchop,"['lenalidomide', 'placebo']",['3'],doubl blind random phase iii studi of lenalidomid mainten versus placebo in respond elder patient with dlbcl and treat with rchop in first line
655,NCT01030900,phase ii trial of alemtuzumab campath and doseadjust epochrituximab daepochr in relaps or refractori diffus larg bcell and hodgkin lymphoma,['epoch'],['2'],phase ii trial of alemtuzumab campath and doseadjust epochrituximab daepochr in relaps or refractori diffus larg bcell and hodgkin lymphoma
656,NCT02168907,cpi613 bendamustin hydrochloride and rituximab in treat patient with relaps or refractori bcell nonhodgkin lymphoma,['bendamustine hydrochloride'],['1'],phase i doseescal studi of cpi613 in combin with bendamustin and rituximab in patient with relaps or refractori bcell nonhodgkin lymphoma
659,NCT02367040,copanlisib and rituximab in relaps indol bcell nonhodgkin lymphoma inhl,"['copanlisib ', 'placebo', 'rituximab']",['3'],a phase iii randomized doubleblind placebocontrol studi evalu the efficaci and safeti of copanlisib in combin with rituximab in patient with relaps indol bcell nonhodgkin lymphoma inhl  chronos3
660,NCT01680991,a studi of obinutuzumab in chines particip with cd20 malign diseas,['obinutuzumab'],['1'],a multicenter open label singl arm multipl dose studi to assess the pharmacokinet of ro5072759 in chines patient with cd20 malign diseas
662,NCT01955499,lenalidomid and ibrutinib in treat patient with relaps or refractori bcell nonhodgkin lymphoma,"['ibrutinib', 'lenalidomide']",['1'],a phase i studi of ibrutinib pci32765 in combin with lenalidomid in relaps and refractori bcell nonhodgkin lymphoma
668,NCT01055496,studi evalu chemotherapi in combin with inotuzumab ozogamicin in subject with nonhodgkin lymphoma,"['inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone', 'inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone']",['1'],an openlabel phase 1 studi of rcvp or rgdp in combin with inotuzumab ozogamicin in subject with cd22posit nonhodgkin lymphoma
669,NCT01045928,lenalidomid and rituximab as mainten therapi in treat patient with bcell nonhodgkin lymphoma,['lenalidomide'],['1'],phase iii trial of mainten therapi with lenalidomid and rituximab follow highdos chemotherapi and autolog stem cell transplant for bcell nonhodgkin lymphoma
674,NCT00336843,zevalin plus bucy highdos therapi in bcell nonhodgkin lymphoma,['zevalin-bucye'],['2'],combin 90yibritumomab tiuxetan with highdos chemotherapi of bucy and autolog stem cell transplant in patient with bcell nonhodgkin lymphoma  an openlabel phase ii studi
676,NCT00061425,treatment of nonhodgkin lymphoma with 90yhll2 igg,['radiolabeled epratuzumab'],"['1', '2']",phase iii radioimmunotherapi of nonhodgkin lymphoma with radiolabel human immunoll2 treatment with 90yhll2 igg
677,NCT00542919,a studi for patient with nonhodgkin lymphoma,['enzastaurin'],['2'],a multicenter openlabel noncompar studi of enzastaurin in patient with nonhodgkin lymphoma
678,NCT00210379,phase ii studi of combin modal treatment in primari testicular nonhodgkin lymphoma,"['rituximab', 'chop', 'intrathecal methotrexate']",['2'],a phase ii studi of chop  rituximab with intrathec methotrex follow by radiotherapi in patient with primari testicular nonhodgkin lymphoma
680,NCT02106091,safeti studi to assess afm11 in patient with relaps andor refractori cd19 posit bcell nhl,['afm11'],['1'],a pharmacodynamicallyguided doseescalation phase i studi to assess the safeti of afm11 recombin antibodi construct against human cd19 and cd3 in patient with relaps andor refractori cd19 posit bcell nhl
684,NCT01647971,studi of the efficaci and safeti of ublituximab in patient with relaps or refractori bcell nonhodgkin lymphoma,['ublituximab'],"['1', '2']",an open label phase iii studi of the efficaci and safeti of ublituximab in patient with bcell nonhodgkin lymphoma who have relaps or are refractori after cd20 direct antibodi therapi
688,NCT00081861,avastin plus rituximab for patient with bcell nonhodgkin lymphoma,"['avastin', 'rituximab']",['2'],a phase ii studi of avastin plus rituximab for patient with relaps and chemotherapy or rituxanrefractori aggress bcell nonhodgkin lymphoma
693,NCT02401048,a multicent studi of ibrutinib in combin with medi4736 in subject with relaps or refractori lymphoma,"['ibrutinib', 'medi4736']","['1', '2']",a multicent openlabel studi of the bruton tyrosin kinas btk inhibitor ibrutinib in combin with medi4736 in subject with relaps or refractori lymphoma
694,NCT00397800,rituximab fludarabine cyclophosphamide and yttrium y 90 ibritumomab tiuxetan in treat patient with relaps bcell nonhodgkin lymphoma,"['cyclophosphamide', 'fludarabine phosphate']","['1', '2']",safeti and efficaci of sequenti treatment with a combin of rituximab fludarabin and cyclophosphamid follow by zevalin rituximab and yibritumomab tiuxetan  a phase iii studi for treatment of patient with relaps indol and transform cd20posit bcell nonhodgkinslymphoma inelig for highdos chemoradiotherapi support by autolog peripher blood stemcel
698,NCT02703272,a safeti and efficaci studi of ibrutinib in pediatr and young adult particip with relaps or refractori matur bcell nonhodgkin lymphoma,"['ibrutinib', 'rituximab', 'ifosfamide', 'carboplatin', 'etoposide', 'vincristine', 'idarubicin', 'dexamethasone']",['3'],a randomized openlabel safeti and efficaci studi of ibrutinib in pediatr and young adult patient with relaps or refractori matur bcell nonhodgkin lymphoma
700,NCT00210340,a phase i studi of intrathec rituximab in patient with lymphomat mening,['intrathecal rituximab'],['1'],a phase i studi of intrathec rituximab in patient with lymphomat mening
704,NCT01491841,iit cti bendamustine rituximab pixantron in relapsedrefractori b cell nonhodgkin lymphoma,"['bendamustine', 'rituximab', 'pixantrone']","['1', '2']",phase iii studi of the combin of bendamustine rituximab and pixantron in patient with relapsedrefractori b cell nonhodgkin lymphoma
705,NCT02453087,a studi of escal dose of dcds0780a in particip with relaps or refractori bcell nonhodgkin lymphoma,"['dcds0780a', 'rituximab', 'obinutuzumab']",['1'],an openlabel multicenter phase 11b dose escal studi evalu the pharmacokinetics safety tolerability and preliminari efficaci of dcds0780a alon or in combin with rituximab or obinutuzumab in patient with relapsedrefractori bcell nonhodgkin lymphoma
706,NCT00863369,bortezomib and gemcitabin in treat patient with relaps bcell nonhodgkin lymphoma,"['bortezomib', 'gemcitabine hydrochloride']","['1', '2']",a phase iii studi of velcad in combin with gemcitabin in relaps bcell nonhodgkin lymphoma
707,NCT02109224,ibrutinib in treat relaps or refractori bcell nonhodgkin lymphoma in patient with hiv infect,['ibrutinib'],['1'],phase i and pharmacokinet studi of ibrutinib in hivinfect patient with relaps or refractori bcell nonhodgkin lymphoma or multipl myeloma
709,NCT01760226,dose adjust epochr to treat matur b cell malign,"['da-epoch', 'methotrexate', 'etoposide', 'doxorubicin', 'vincristine', 'rituximab', 'cyclophosphamide', 'prednisone', 'g-csf']",['1'],use of dose adjust epochr in the treatment of childhood matur b cell malign
710,NCT02568683,safeti and efficaci of entospletinib ento gs9973 combin with vincristin vcr in adult particip with relaps or refractori bcell nonhodgkin lymphoma nhl,"['ento', 'vcr']","['1', '2']",a phase 1b2 openlabel dose escal and expans studi evalu the safeti and efficaci of entospletinib ento gs9973 combin with vincristin vcr in adult subject with relaps or refractori bcell nonhodgkin lymphoma nhl
711,NCT00809341,rice and highdos cyclophosphamid with petct for diffus larg bcell nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone', 'ifosfamide', 'carboplatin', 'etoposide', 'high-dose cyclophosphamide']",['2'],treatment intensif with rice and highdos cyclophosphamid for diffus larg bcell nonhodgkin lymphoma base on earli 18f fdgpet scan
712,NCT00290498,studi of rituximabhcvad altern with rituximabmethotrexatecytarabin versus standard rituximabchop everi 21 day for patient with newli diagnos high risk aggress bcell nonhodgkin lymphoma in patient 60 year old or younger,"['rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'dexamethasone', 'methotrexate', 'cytarabine', 'prednisone']",['2'],a phase ii random studi of rituximabhcvad altern with rituximabmethotrexatecytarabin versus standard rituximabchop everi 21 day for patient with newli diagnos high risk aggress bcell nonhodgkin lymphoma in patient 60 year old or younger
713,NCT00607854,safeti of ibritumomab tiuxetan zevalin® in combin with a fludarabinebas reduc intens condit ric regimen zevallo 2007,['ibritumomab tiuxetan '],['2'],safeti and efficaci of ibritumomab tiuxetan zevalin® in associ with a fludarabin base reduc condit regimen and allogen stem cell support in chemosensit relaps cd20 posit aggress nonhodgkin lymphoma patients
714,NCT01805375,a phase i trial of dib4 in patient with advanc cd19 posit indol bcell malign,['di-b4'],['1'],a cancer research uk phase i trial of the anticd19 dib4 monoclon antibodi given intravenously week for four weeks in patient with advanc cd19 posit indol bcell malign
716,NCT01992653,a studi of polatuzumab vedotin in combin with rituximab or obinutuzumab cyclophosphamide doxorubicin and prednison in particip with bcell nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin', 'obinutuzumab', 'polatuzumab vedotin', 'prednisolone', 'prednisone', 'rituximab']","['1', '2']",a phase ibii studi evalu the safety toler and antitumor activ of polatuzumab vedotin dcds4501a in combin with rituximab or obinutuzumab cyclophosphamide doxorubicin and prednison in patient with bcell nonhodgkin lymphoma
717,NCT01691807,drugdrug interact studi of ofatumumab with bendamustin in subject with indol bcell nonhodgkin lymphoma,"['ofatumumab', 'bendamustine']",['1'],an openlabel phase i drugdrug interact studi of ofatumumab with bendamustin for the treatment of subject with indol bcell nonhodgkin lymphoma
718,NCT01549886,phase 2 studi of zevalin versus zevalin and motexafin gadolinium in patient with rituximabrefractori lowgrad or follicular bcell nonhodgkin lymphoma,"['zevalin regimen', 'moxtezafin gadolinium']",['2'],a randomized openlabel multicenter phase 2 studi of zevalin 90y ibritumomab tiuxetan versus zevalin and motexafin gadolinium in patient with rituximab refractori lowgrad or follicular bcell nonhodgkin lymphoma
719,NCT01294579,ofatumumab and bendamustin follow by mainten ofatumumab for rituximab relaps indol bcell nonhodgkin lymphoma bnhl,['bendamustine'],['2'],a phase ii openlabel studi of ofatumumab and bendamustin follow by mainten ofatumumab for indol bcell nonhodgkin lymphoma bnhl which has relaps after rituximab or a rituximab contain therapi
723,NCT01840566,high dose therapi and autolog stem cell transplant follow by infus of chimer antigen receptor car modifi tcell direct against cd19 bcell for relaps and refractori aggress b cell nonhodgkin lymphoma,"['carmustine', 'etoposide', 'cytarabine', 'melphalan']",['1'],a phase i trial of high dose therapi and autolog stem cell transplant follow by infus of chimer antigen receptor car modifi tcell direct against cd19 bcell for relaps and refractori aggress b cell nonhodgkin lymphoma
725,NCT00073957,y 90 ibritumomab tiuxetan rituximab relaps or refractori diffus larg bcell nonhodgkin lymphoma,"['cytarabine', 'liposomal cytarabine']",['2'],zevalin and rituxan for the treatment of relaps or refractori diffus larg bcell nonhodgkin lymphoma
727,NCT01108341,studi to evalu the efficaci and safeti of treatment with bendamustin in combin with ofatumumab in previous untreat patient with indol bcell nonhodgkin lymphoma nhl,"['bendamustine hydrochloride', 'ofatumumab']",['2'],an openlabel studi to evalu the efficaci and safeti of treatment with bendamustin in combin with ofatumumab in previous untreat patient with indol bcell nonhodgkin lymphoma nhl
728,NCT00389818,combin chemotherapi and rituximab in treat patient with newli diagnos aidsrel bcell nonhodgkin lymphoma,"['cyclophosphamide', 'pegylated liposomal doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],a phase ii trial of doxil rituximab cyclophosphamide vincristine and prednison drcop in patient with newli diagnos aidsassoci bcell nonhodgkin lymphoma
729,NCT00303953,pxd101 in treat patient with relaps or refractori aggress bcell nonhodgkin lymphoma,['belinostat'],['2'],phase ii studi of pxd101 nsc726630 in relaps and refractori aggress bcell lymphoma
730,NCT00549185,multidoseescal safeti and pharmacokinet studi of sar3419 as singl agent in relapsedrefractori bcell non hodgkin lymphoma,['sar3419'],['1'],an openlabel multidoseescalation safeti and pharmacokinet studi of sar3419 administ as a singl agent by intraven infus everi 3 week in patient with relapsedrefractori bcell nonhodgkin lymphoma nhl
732,NCT00911183,rituximab cyclophosphamide vincristin sulfate and prednison with or without liposomeencapsul doxorubicin citrat in treat older patient with stage ii stage iii or stage iv diffus larg bcell nonhodgkin lymphoma,"['cyclophosphamide', 'liposome-encapsulated doxorubicin citrate', 'prednisone', 'vincristine sulfate']",['2'],diffus larg b cell nonhodgkin lymphoma in the vulnerablefrail elderly a multicentr random phase ii trial with emphasi on geriatr assess and qualiti of life
733,NCT00193479,combin chemotherapi and rituximab with pegfilgrastim follow by rituximab in larg bcell nonhodgkin lymphoma,"['cyclophosphamide', 'mitoxantrone', 'vincristine', 'prednisone', 'rituximab']",['2'],a phase ii trial of brief durat combin chemotherapi and rituximab with prophylact pegfilgrastim follow by mainten rituximab in elderlypoor perform status patient with larg bcell nonhodgkin lymphoma
734,NCT00556699,a studi of sgn40 in combin with rituximab in patient with cd20positive follicular and margin zone bcell nonhodgkin lymphoma,"['rituximab', 'sgn-40']",['1'],an openlabel phase ib studi of the safety pharmacokinetics and activ of the anticd40 monoclon antibodi sgn40 administ in combin with rituximab in patient with cd20positive follicular and margin zone bcell nonhodgkin lymphoma who have relaps follow previous rituximab therapi
739,NCT02180711,studi of acalabrutinib alon or in combin with rituximab in indol bcell nonhodgkin lymphoma,"['acalabrutinib', 'rituximab ']","['1', '2']",an openlabel phase 1b2 studi of acalabrutinib alon or in combin with rituximab in subject with indol b cell nonhodgkin lymphoma
740,NCT00741871,a phase 1 studi of sb1518 for the treatment of advanc lymphoid malign,['sb1518'],['1'],a phase 1 studi of sb1518 for the treatment of advanc lymphoid malign
741,NCT01665768,mainten rituximab with mtor inhibit after highdos consolid therapi in lymphoma,"['everolimus', 'rituximab']",['2'],a trial of mainten rituximab with mtor inhibit after highdos consolid therapi in cd20 bcell lymphomas gray zone lymphoma and hodgkin lymphoma
742,NCT00001512,activ specif immunotherapi for follicular lymphoma with tumorderiv immunoglobulin idiotyp antigen vaccin,"['id-klh vaccine', 'gm-csf']",['1'],activ specif immunotherapi for follicular lymphoma with tumorderiv immunoglobulin idiotyp antigen vaccin
743,NCT01120834,studi of 5azacitidin in combin with vorinostat in patient with relaps or refractori diffus larg b cell lymphoma dlbcl,"['azacytidine', 'vorinostat']","['1', '2']",phase iii studi of 5azacitidin in combin with vorinostat in patient with relaps or refractori dlbcl
744,NCT00577278,yttrium y 90 ibritumomab tiuxetan rituximab indium in111 ibritumomab tiuxetan fludarabine melphalan and donor stem cell transplant in treat patient with bcell nonhodgkin lymphoma,"['fludarabine phosphate', 'melphalan', 'sirolimus', 'tacrolimus']",['2'],a phase ii studi of allogen hematopoiet stem cell transplant for bcell nonhodgkin lymphoma use zevalin fludarabin and melphalan
745,NCT00612183,clinic studi on syb l0501 in patient with indol bcell nonhodgkin lymphoma or mantl cell lymphoma,['bendamustine hydrochloride'],['2'],phase ii clinic studi on syb l0501 in patient with indol bcell nonhodgkin lymphoma or mantl cell lymphoma multicenter openlabel study
746,NCT01955668,azd6738 first time in patient multipl ascend dose studi,['administration of azd6738'],['1'],a twopart phase i openlabel multicentr studi to assess the safety tolerability pharmacokinetics pharmacodynam and preliminari antitumour activ of multipl ascend dose of azd6738 in patient with relapsedrefractori b cell malign with expans to patient with prospect identifi 11qdelet or atmdeficient relapsedrefractori chronic lymphocyt leukaemia cll
747,NCT00101010,rituximab and combin chemotherapi in treat older patient with diffus larg bcell lymphoma,"['cyclophosphamide', 'pegylated liposomal doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],a phase ii studi of rituximabchop with pegyl liposom doxorubicin in patient older than 60 year of age with untreat aggress bcell nonhodgkin lymphoma
749,NCT01077518,ofatumumab and bendamustin combin therapi compar with bendamustin monotherapi in indol bcell nonhodgkin lymphoma nhl unrespons to rituximab or a rituximabcontain regimen,"['ofatumumab', 'bendamustine infusions ', 'bendamustine infusion ']",['3'],a randomized open label studi of ofatumumab and bendamustin combin therapi compar with bendamustin monotherapi in indol bcell nonhodgkin lymphoma unrespons to rituximab or a rituximabcontain regimen dure or within six month of treatment
750,NCT00278408,rituximab and combin chemotherapi with or without radiat therapi in treat patient with bcell nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['3'],random studi compar an immunochemotherapi with 6 cycl of the monoclon anticd20 antibodi rituximab in combin with 6 cycl of chemotherapi with chop  cyclophosphamide doxorubicin vincristine and prednisone at 21day interv or 14day intervals both with or without consolid radiotherapi or larg tumour mass ≥75 cm andor extranod involv in patient with aggress cd20 bcell lymphoma age 18 to 60 year with ageadjust ipi1 all or ipi0 with a larg tumour mass ≥75 cm unfold 2114 study
751,NCT00062296,epirubicin and rituximab in treat patient with relaps or refractori bcell nonhodgkin lymphoma or chronic lymphocyt leukemia,['epirubicin hydrochloride'],['2'],phase ii studi of epirubicin and rituximab in relaps and refractori bcell nonhodgkin lymphoma and cll
752,NCT00974792,combin chemotherapi and rituximab in treat patient with diffus larg bcell nonhodgkin lymphoma,"['cyclophosphamide', 'cytarabine', 'doxorubicin hydrochloride', 'etoposide phosphate', 'ifosfamide', 'leucovorin calcium', 'methotrexate', 'vincristine sulfate']",['2'],a phase ii singl arm studi of the use of codoxmivac with rituximab rcodoxmivac in the treatment of patient with diffus larg bcell lymphoma intern prognost index high or highintermedi risk
753,NCT00001572,vaccin of follicular lymphoma with tumorderiv immunoglobulin idiotyp,"['id-klh vaccine', 'qs-21 ']",['1'],vaccin of follicular lymphoma with tumorderiv immunoglobulin idiotyp
755,NCT00695409,yttrium90 ibritumomab tiuxetan plus highdos beam follow by asct for relaps bcell nonhodgkin lymphoma,"['carmustine', 'cytarabine', 'etoposide', 'melphalan']",['2'],a phase ii studi of yttrium90label anticd20 monoclon antibodi in combin with highdos beam follow by autolog stem cell transplant for poor riskrelaps bcell lymphoma
757,NCT00765245,lenalidomid with or without rituximab after standard chemotherapi in treat patient with diffus larg bcell nonhodgkin lymphoma,"['lenalidomide', 'rituximab']",['2'],a phase ii random studi of lenalidomid or lenalidomid and rituximab as mainten therapi follow standard chemotherapi for patient with highhighintermedi risk diffus larg bcell lymphoma
761,NCT02017613,safeti and efficaci studi of a dual pi3k deltagamma inhibitor in hematolog malign,['rp6530'],['1'],a phase i dose escal studi to evalu safeti and efficaci of rp6530 a dual pi3k deltagamma inhibitor in patient with relaps or refractori hematolog malign
762,NCT00498043,a studi of two associ of rituximab and chemotherapy with a petdriven strategy in lymphoma,"['r-chop14 induction regimen', 'r-acvbp14 induction regimen']",['2'],random phase ii studi of two associ of rituximab and chemotherapy with a pet driven strategy in patient from 18 to 59 with dlbcl cd20 lymphoma and 2 or 3 advers prognost factor of the ageadjust ipi
763,NCT00079443,fr901228 alon or combin with rituximab and fludarabin in treat patient with relaps or refractori lowgrad bcell nonhodgkin lymphoma,"['romidepsin', 'fludarabine phosphate']",['2'],a phase ii studi of singl agent depsipeptid nsc 630176 follow by a phase i studi of rituximabfludarabin combin with an escal dose of depsipeptid in relaps or refractori low grade b cell lymphoma
764,NCT02572453,onalespib in treat patient with relaps or refractori anaplast larg cell lymphoma mantl cell lymphoma or diffus larg bcell lymphoma,['onalespib'],['2'],phase 2 studi of at13387 onalespib in alk alcl mcl and bcl6 dlbcl
765,NCT00875056,studi of vorinostat mk0683 with follicular lymphoma fl other indol bcell nonhodgkin lymphoma bnhl or mantl cell lymphoma mcl patient mk0683103,['vorinostat'],['2'],a phase ii studi of mk0683 in patient with relaps  refractori follicular lymphoma fl other indol bcell nonhodgkin lymphoma bnhl or mantl cell lymphoma mcl
766,NCT01980654,studi of the bruton tyrosin kinas inhibitor in combin with rituximab in previous untreat subject with follicular lymphoma,"['ibrutinib', 'rituximab']",['2'],a multicenter openlabel phase 2 studi of the bruton tyrosin kinas btk inhibitor ibrutinib in combin with rituximab in previous untreat subject with follicular lymphoma
767,NCT01282424,efficaci and safeti studi of idelalisib in subject with indol bcell nonhodgkin lymphoma,['idelalisib'],['2'],a phase 2 studi to assess the efficaci and safeti of idelalisib in subject with indol bcell nonhodgkin lymphoma refractori to rituximab and alkyl agent
769,NCT02254772,a phase iii studi of intratumor inject of sd101,['sd-101'],"['1', '2']",a phase iii studi of intratumor inject of sd101 an immunostimulatori cpg and intratumor inject of ipilimumab an antictla4 monoclon antibody in combin with local radiat in lowgrad bcell lymphoma
771,NCT02332980,pembrolizumab alon or with idelalisib or ibrutinib in treat patient with relaps or refractori chronic lymphocyt leukemia or other lowgrad bcell nonhodgkin lymphoma,"['ibrutinib', 'idelalisib']",['2'],a phase ii studi of antipd1 antibodi mk3475 in relapsedrefractori chronic lymphocyt leukemia cll and other low grade b cell nonhodgkin lymphoma nhl
772,NCT02242045,safety tolerability and pharmacokinet of idelalisib in japanes adult with relaps or refractori indol bcell nonhodgkin lymphoma or chronic lymphocyt leukemia,['idelalisib'],['1'],a phase 1b studi to investig the safety tolerability and pharmacokinet of idelalisib in japanes subject with relaps or refractori indol bcell nonhodgkin lymphoma or chronic lymphocyt leukemia
773,NCT01030536,safeti studi of cat8015 to treat advanc bcell nonhodgkin lymphoma and chronic lymphocyt leukemia nhl or cll,"['cat-8015 20 mcg', 'cat-8015 30 mcg', 'cat-8015 40 mcg', 'cat-8015 50 mcg', 'cat-8015 60 mcg']","['1', '2']",a phase 12 studi of cat8015 in adult relaps or refractori bcell nonhodgkin lymphoma and chronic lymphocyt leukemia
774,NCT00413959,velcaderituximabcyclophosphamid and decadron,"['velcade', 'rituximab', 'cyclophosphamide', 'decadron']",['2'],phase ii studi investig the efficaci of velcade® rituximab cyclophosphamid and decadron vrcd regimen in frontlin therapi of patient with lowgrad nonhodgkin lymphoma
777,NCT02659943,t cell express a fullyhuman anticd19 chimer antigen receptor for treat bcell malign,"['cyclophosphamide', 'fludarabine']",['1'],t cell express a fullyhuman anticd19 chimer antigen receptor for treat bcell malign
778,NCT00968656,assess of cellular prolifer in tumor by positron emiss tomographi pet use 18fiso1,['f-18'],['1'],assess of cellular prolifer in tumor by positron emiss tomographi pet use 18fiso1
779,NCT00087425,bryostatin 1 and rituximab in treat patient with bcell nonhodgkin lymphoma or chronic lymphocyt leukemia,['bryostatin 1'],['2'],a phase ii trial of bryostatin1 in combin with rituximab in rituximabrefractori indol bcell non hodgkin lymphoma and chronic lymphocyt leukemia
780,NCT00543582,mgcd0103 administ in combin with azacitidin vidaza® to subject with relaps or refractori hodgkin or nonhodgkin lymphoma,"['mgcd0103', 'azacitidine']",['2'],a phase 2 openlabel trial to evalu the efficaci and safeti of mgcd0103 administ in combin with azacitidin vidaza® to subject with relaps or refractori hodgkin or nonhodgkin lymphoma and to evalu the pharmacokinet of differ formul of mgcd0103
781,NCT00210327,velcad in malt lymphoma pretreat with prior system therapi,['bortezomib '],['2'],phase ii studi of velcad in patient with extranod margin zone bcell lymphoma of malttyp pretreat with prior system therapi regimen x05142
782,NCT01209130,a studi of the safeti and pharmacokinet of escal dose of dcdt2980s in patient with relaps or refractori bcell nonhodgkin lymphoma and chronic lymphocyt leukemia and dcdt2980s in combin with rituximab in patient with relaps or refractori bcell non hodgkin lymphoma,"['dcdt2980s', 'rituximab']",['1'],an openlabel multicenter phase i trial of the safeti and pharmacokinet of escal dose of dcdt2980s in patient with relaps or refractori bcell nonhodgkin lymphoma and chronic lymphocyt leukemia and dcdt2980s in combin with rituximab in patient with relaps or refractori bcell non hodgkin lymphoma
783,NCT01290549,a studi of escal dose of polatuzumab vedotin in particip with relaps or refractori bcell nonhodgkin lymphoma and chronic lymphocyt leukemia and polatuzumab vedotin in combin with rituximab in particip with relaps or refractori bcell nonhodgkin lymphoma,"['polatuzumab vedotin', 'rituximab']",['1'],an openlabel multicenter phase i trial of the safeti and pharmacokinet of escal dose of dcds4501a in patient with relaps or refractori bcell nonhodgkin lymphoma and chronic lymphocyt leukemia and dcds4501a in combin with rituximab in patient with relaps or refractori bcell nonhodgkin lymphoma
784,NCT00210392,velcad in malt lymphoma pretreat with more than one prior system therapi,['bortezomib '],['2'],phase ii studi of velcad in patient with extranod margin zone bcell lymphoma of malttyp pretreat with more than one prior system therapi regimen x05142
785,NCT01851551,phase 12 studi of vsli plus rituximab in patient with relaps andor refractori nhl,"['vincristine sulfate liposome injection', 'rituximab']","['1', '2']",a phase iii studi of rituximab plus vincristin sulfat liposom inject in the treatment of relaps or refractori aggress non hodgkin lymphoma
786,NCT00210353,random trial of chlorambucil versus chlorambucil plus rituximab versus rituximab in malt lymphoma,"['chlorambucil ', 'rituximab+chlorambucil', 'rituximab']",['3'],multicent random trial of chlorambucil versus chlorambucil plus rituximab versus rituximab in extranod margin zone bcell lymphoma of mucosa associ lymphoid tissu malt lymphoma
787,NCT00412321,a safeti and efficaci studi of cnto 328 in patient with bcell nonhodgkin lymphoma multipl myeloma or castleman diseas,['cnto 328'],['1'],a phase 1 studi of multipl intraven administr of a chimer antibodi against interleukin6 cnto 328 in subject with bcell nonhodgkin lymphoma multipl myeloma or castleman diseas
788,NCT02257242,vincristin sulfat liposom inject marqibo® bendamustin and rituximab—phas i trial in indol bcell lymphoma,"['rituximab', 'bendamustine', 'vincristine sulfate liposome injection']",['1'],bruog 326 a phase i doseescal studi of vincristin sulfat liposom inject marqibo® in combin with bendamustin and rituximab brim in indol nonhodgkin lymphoma
789,NCT00082784,bortezomib and flavopiridol in treat patient with recurr or refractori indol bcell neoplasm,"['bortezomib', 'alvocidib hydrochloride']",['1'],phase i trial of bortezomib ps341 nsc 681239 and alvocidib flavopiridol nsc 649890 in patient with recurr or refractori indol bcell neoplasm
792,NCT01088048,studi to investig idelalisib in combin with chemotherapeut agents immunomodulatori agent and anticd20 monoclon antibodi mab in subject with relaps or refractori indol bcell nonhodgkin lymphoma mantl cell lymphoma or chronic lymphocyt leukemia,"['idelalisib', 'rituximab', 'bendamustine', 'ofatumumab', 'fludarabine', 'everolimus', 'bortezomib', 'chlorambucil', 'lenalidomide']",['1'],a phase i studi to investig the safeti and clinic activ of idelalisib in combin with chemotherapeut agents immunomodulatori agent and anticd20 mab in subject with relaps or refractori indol bcell nonhodgkin lymphoma mantl cell lymphoma or chronic lymphocyt leukemia
793,NCT01479842,rituxanbendamustinepci32765 in relaps dlbcl mcl or indol nonhodgkin lymphoma,"['btk inhibitor pci', 'bendamustine hydrochloride']",['1'],a phase i doseescal trial of rituxan and bendamustin in combin with bruton tyrosin kinas inhibitor pci32765 in patient with relaps diffus larg bcell lymphoma mantl cell lymphoma or indol nonhodgkin lymphoma
795,NCT00523939,depocyt for activ lymphomat or leukem mening,['cytarabine liposome injection'],['2'],phase ii studi of intrathec therapi with depocyt for activ lymphomat or leukem mening
798,NCT01791595,a phase i trial of azd3965 in patient with advanc cancer,['azd3965'],['1'],a cancer research unit kingdom phase i trial of azd3965 a monocarboxyl transport 1 inhibitor mct1 in patient with advanc cancer
802,NCT00337259,gemcitabin for margin zone lymphoma,['gemcitabine'],['2'],phase ii studi of gemcitabin in patient with advanc stage margin zone bcell lymphoma
804,NCT01786135,a safeti studi of sgncd19a for bcell lymphoma,['sgn-cd19a'],['1'],a phase 1 openlabel doseescal studi of sgncd19a in patient with relaps or refractori blineag nonhodgkin lymphoma
805,NCT01562977,studi to evalu efficaci and toler of rgemox in dlbcl and mcl,"['rituximab', 'gemcitabine', 'oxaliplatin', 'dexametasone']",['2'],prospective openlabel multicentric ph ii studi of rgemox and dexametason in patient with agress lymphoma refractori or relaps to previous treatment and non elig for highdos chemotherapi follow by autolog stem cell transplant
812,NCT00119392,yttrium y 90 ibritumomab tiuxetan fludarabine radiat therapy and donor stem cell transplant in treat patient with relaps or refractori nonhodgkin lymphoma,"['cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']",['2'],a phase ii trial evalu the safeti and efficaci of nonmyeloabl 90yibritumomab tiuxetan anticd20 antibodi with fludarabine lowdos total bodi irradi tbi and hla match allogen transplant for relaps bcell lymphoma
813,NCT01352312,combin of pentostatin bendamustin and ofatumumab for treatment of chronic lymphocyt leukemia and lymphoma,"['bendamustine', 'pentostatin', 'ofatumumab']",['1'],phase i trial with cohort expans of pentostatin bendamustin and ofatumumab pbo for the treatment of chronic lymphocyt leukemia and nonhodgkin lymphoma
818,NCT01808599,phase ii studi of chlorambucil and subcutan rituximab in patient with extranod malt lymphoma,"['chlorambucil', 'rituximab i', 'rituximab s']",['2'],a phase ii studi of chlorambucil in combin with subcutan rituximab follow by mainten therapi with subcutan rituximab in patient with extranod margin zone bcell lymphoma of mucosa associ lymphoid tissu malt lymphoma
819,NCT01119794,ofatumumab and bortezomib for patient with lowgrad bcell nonhodgkin lymphoma that relaps after rituximab,"['ofatumumab', 'bortezomib']",['2'],ofatumumab in combin with bortesomib in patient with relaps or refractori lowgrad nonhodgkin lymphoma
821,NCT00051025,phase ii studi of ontak in previous treat patient with lowgrad nonhodgkin lymphoma nhl,['ontak'],['2'],a randomized multicenter phase ii evalu of ontak denileukin diftitox in patient with previous treated indolent bcell nonhodgkin lymphoma
822,NCT02650999,phase iii studi of pembrolizumab in patient fail to respond to or relaps after anticd19 chimer antigen receptor modifi t cell therapi for relaps or refractori cd19 lymphoma,['pembrolizumab'],"['1', '2']",phase iii studi of pembrolizumab in patient fail to respond to or relaps after anticd19 chimer antigen receptor modifi t cell therapi for relaps or refractori cd19 lymphoma
823,NCT00823719,phase ii studi of ofatumumab plus ifosfamide carboplatin etoposid ice or dexamethasone cytarabine cisplatin dhap chemotherapi regimen in relapsed refractori diffus larg b cell lymphoma dlbcl,"['ofatumumab', 'ice', 'ofatumumab', 'dhap']",['2'],a singl arm safeti and efficaci studi of ofatumumab in combin with ice or dhap chemotherapi in relaps or refractori aggress lymphoma prior to autolog stem cell transplant
825,NCT02499003,goal ga101 plus pixantron for relaps aggress lymphoma,"['obinutuzumab', 'pixantrone']",['2'],the goal trial rescu treatment with the monoclon anti cd20antibodi obinutuzumab ga101 in combin with pixantron for the treatment of patient with relaps aggress bcell lymphoma
826,NCT02226965,pnt2258 for treatment of patient with rr dlbcl wolverine,['pnt2258'],['2'],a phase ii studi of pnt2258 in patient with relaps or refractori diffus larg bcell lymphoma
828,NCT02652910,memoryenrich cart cell immunotherapi for b cell lymphoma,['cd19'],"['1', '2']",a twoarm singlecenter openlabel pilot studi of il2 program or il7il15 program anticd19tcrzcd28 tcell in patient with cd19posit lymphoma that is resist or refractori to chemotherapi
830,NCT00110071,iodin i 131 tositumomab and fludarabin phosphat in treat older patient who are undergo an autolog or syngen stem cell transplant for relaps or refractori nonhodgkin lymphoma,['fludarabine phosphate'],['1'],a clinic trial evalu i131tositumomab anticd20 with escal dose of fludarabin follow by autolog or syngen stem cell transplant for relaps or refractori bcell nonhodgkin lymphoma in patient 60 year of age and older
832,NCT01431209,ruxolitinib phosphat in treat patient with relaps or refractori diffus larg bcell or peripher tcell nonhodgkin lymphoma after donor stem cell transplant,['ruxolitinib phosphate'],['2'],a phase 2 multicenter investig initi studi of oral ruxolitinib phosphat for the treatment of relaps or refractori diffus larg bcell and peripher tcell nonhodgkin lymphoma
835,NCT02417285,a phase 1b openlabel studi to evalu the safeti and efficaci of cc122 with obinutuzumab ga101 in relapsedrefractori dlbcl and inhl,"['obinutuzumab', 'cc-122']",['1'],a phase 1b openlabel studi to evalu the safeti and efficaci of cc122 in combin with obinutuzumab ga101 in subject with relapsedrefractori diffus larg bcell lymphoma and indol nonhodgkin lymphoma
838,NCT00121199,combin chemo rituximab and bevacizumab in older patient with stage iiiv diffus larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'vincristine sulfate', 'prednisone']",['2'],phase ii trial of standard dose cyclophosphamide doxorubicin vincristine prednison chop and rituximab plus bevacizumab for advanc stage diffus larg bcell nhl
839,NCT01165112,bendamustin hydrochloride rituximab etoposide and carboplatin in treat patient with relaps or refractori diffus larg bcell lymphoma or hodgkin lymphoma,"['bendamustine hydrochloride', 'carboplatin', 'etoposide']","['1', '2']",a phase iii trial of bendamustinetreanda® rituximab etoposide and carboplatin for patient with relaps or refractori lymphoid malign and select untreat lymphoma trec
840,NCT00854568,comparison studi of doxorubicin versus epirubicininduc cardiotox in patient with dlbcl,"['ceop regimen', 'chop regimen']",['3'],a random phase iii studi compar chop versus ceopinduc cardiotox in patient with aggress bcell lymphoma
844,NCT01567709,alisertib in combin with vorinostat in treat patient with relaps or recurr hodgkin lymphoma bcell nonhodgkin lymphoma or peripher tcell lymphoma,"['alisertib', 'vorinostat']",['1'],phase i studi of the aurora kinas a inhibitor mln8237 in combin with the histon deacetylas inhibitor vorinostat in lymphoid malign
851,NCT01695941,alisertib bortezomib and rituximab in treat patient with relaps or refractori mantl cell lymphoma or bcell low grade nonhodgkin lymphoma,"['alisertib', 'bortezomib']",['1'],a phase i studi of mln8237 in combin with bortezomib and rituximab in relaps and refractori mantl cell and low grade nonhodgkin lymphoma
853,NCT02374424,phase ii studi with ga101dhap as induct therapi in relapsedrefractori dlbcl patient,['ga101_dhap'],['2'],phase ii studi with ga101dhap as induct therapi in relapsedrefractori diffus larg bcell lymphoma dlbcl patient befor highdos chemotherapi beam with autolog stem cell transplant asct
856,NCT01141712,autolog transplant in hiv patient bmt ctn 0803,"['bcnu', 'etoposide', 'cytarabine', 'melphalan']",['2'],high dose chemotherapi with autolog stem cell rescu for aggress b cell lymphoma and hodgkin lymphoma in hivinfect patient bmt ctn 0803
858,NCT01686321,rituximab and bendamustin in veri elder patient or elder medic non fit patient with aggress bcell lymphoma,"['bendamustine', 'subcutaneous rituximab']",['2'],subcutan rituximab and intraven bendamustin in veri elder patient or elder medic non fit patient slow go with aggress cd20posit bcell
859,NCT02624492,to determin the dose of bi 836826gemox and the efficaci of bi 836826gemox versus rgemox in patient with relapsedrefractori dlbcl,"['bi 836826', 'gemox', 'rituximab']",['2'],an open label multicent phase ibii trial to determin the dose of bi 836826 in combin with gemcitabin and oxaliplatin gemox and the efficaci of bi 836826gemox versus rituximab r gemox rgemox in patient with relapsed refractori diffus larg bcell lymphoma dlbcl who are not elig for or have relapsedprogress after autologousallogen stem cell transplant
860,NCT00655837,trial to defin the safeti and toler of sgn40 rituximab and gemcitabin in patient with dlbcl,"['sgn-40', 'rituximab', 'gemcitabine']",['1'],a phase ib studi of sgn40 in combin with rituximab and gemcitabin for the treatment of patient with relaps or refractori diffus larg bcell lymphoma dlbcl
862,NCT01397591,ofatumumab and bortezomib in subject with relaps cd20diffus larg b cell follicular or mantl cell lymphoma,['bortezomib'],['2'],phase ii trial of ofatumumab and bortezomib in subject with relaps cluster of differenti antigen 20 cd20 diffus larg b cell lymphoma follicular lymphoma or mantl cell lymphoma
864,NCT00529503,a random phase iib placebocontrol studi of rice chemotherapi with and without sgn40 for patient with dlbcl,"['sgn-40', 'placebo', 'rituximab', 'etoposide', 'carboplatin', 'ifosfamide']",['2'],a random phase iib placebocontrol studi of rice chemotherapi with and without sgn40 anticd40 human monoclon antibody for secondlin treatment of patient with diffus larg bcell lymphoma dlbcl
865,NCT00568815,rituximab combin with eshap in patient with relaps or refractori diffus larg b cell lymphoma dlbcl,['rituximab combined with eshap'],['2'],phase ii studi of rituximab combin with eshap in patient with relaps or refractori dlbcl
867,NCT00591630,zevalinbeamrituximab vs beamrituximab with or without rituximab in autolog stem cell transplant,"['zevalin', 'carmustine', 'etoposide', 'cytarabine', 'melphalan', 'rituximab']",['2'],zevalinbeamrituximab vs beamrituximab with or without rituximab mainten in autolog stem cell transplant for diffus larg bcell lymphoma
868,NCT01138579,studi of the trifunct antibodi fbta05 and donor lymphocyt infus in bcell lymphoma after allogen stem cell transplant,['fbta05'],"['1', '2']",phase iii doseescal studi of the investig trifunct bispecif anticd20 x anticd3 antibodi fbta05 in combin with donor lymphocyt infus dli in patient with cd20 posit chronic lymphocyt leukemia cll low and high grade nonhodgkin´ lymphoma nhl after allogen stem cell transplant
869,NCT00242996,rituximab cyclophosphamide and gcsf follow by combin chemotherapi in treat patient who are undergo autolog stem cell transplant follow by rituximab and gmcsf for refractori diffus larg bcell lymphoma,"['carmustine', 'cyclophosphamide', 'etoposide']",['2'],phase ii trial of rituximab and autolog stem cell transplant for refractori b cell larg cell lymphoma
870,NCT00436280,chemotherapi for patient with lymphoma,"['enzastaurin', 'gemcitabine', 'rituximab', 'oxaliplatin']",['2'],an openlabel singl arm phase 2 studi of rituximab gemcitabin and oxaliplatin plus enzastaurin as treatment for patient with relaps diffus larg bcell lymphoma
871,NCT00093769,bortezomib and rituximab in treat patient with nonhodgkin lymphoma,"['bortezomib', 'rituximab']",['2'],a phase ii studi of velcad with rituximab in subject with relaps or refractori indol bcell lymphoma
872,NCT00001337,doseadjust epoch chemotherapi and rituximab cd20 in previous untreat aggress nonhodgkin lymphoma,['epoch'],['2'],doseadjust epoch chemotherapi and rituximab cd20 in adult and children with previous untreat patient with aggress nonhodgkin lymphoma
873,NCT00690560,combin chemotherapy rituximab and yttrium y 90 ibritumomab tiuxetan in treat patient with newli diagnos larg bcell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],intern phase ii studi evalu the associ of choprituximab with consolid by earli ibritumomab tiuxetany90 in patient age 65 to 80 year with cd20 larg cell malign lymphoma and no prior therapi
874,NCT00007839,beta alethin in treat patient with lowgrad lymphoma,['beta alethine'],"['1', '2']",phase iii studi to assess the safeti and efficaci of low dose of beta lt in patient with bcell lymphoma
875,NCT00963274,bortezomib and romidepsin in patient with chronic lymphocyt leukemiasmal lymphocyt lymphoma,"['bortezomib', 'romidepsin']",['1'],phase i studi of bortezomib and romidepsin in patient with chronic lymphocyt leukemiasmal lymphocyt lymphoma indol bcell lymphoma peripher tcell lymphoma or cutan tcell lymphoma
878,NCT00244985,rituximab and liposom doxorubicin in treat patient with relaps or refractori nonhodgkin lymphoma,['pegylated liposomal doxorubicin hydrochloride'],"['1', '2']",a phase iii pilot studi of the safeti and efficaci of rituxan chimer anticd20 antibody in combin with doxil liposom doxorubicin chemotherapi in patient with relaps or refractori indol or aggress bcell lymphoma
879,NCT02339922,ixazomib citrat and rituximab in treat patient with indol bcell nonhodgkin lymphoma,['ixazomib citrate'],['2'],a window studi of ixazomib in untreat indol bnhl
880,NCT00322218,studi compar the zevalin regimen with no further treatment in dlbcl patient who are in complet remiss after chopr,['zevalin therapeutic regimen'],['3'],a phase iii openlabel prospective twoarmed multicenter randomized group sequenti studi to evalu the efficaci and safeti of subsequ treatment with the zevalin ibritumomab tiuxetan studi regimen versus observ in patient with diffus larg bcell lymphoma who are in complet remiss after firstlin choprituximab chopr therapi
881,NCT00278421,rituximab and combin chemotherapi in treat patient with nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['3'],random studi compar 4 and 6 cycl of chemotherapi with chop cyclophosphamide doxorubicin vincristin and prednisone at 21day intervals both with 6 cycl of immunotherapi with the monoclon anticd20posit bcell lymphoma age 1860 year have no risk factor ageadjust ipi0 and no larg tumor mass diamet 75cm flyer 6664 study
882,NCT00504751,phase ii studi of viper chemotherapi in relref dlbcl,"['bortezomib', 'dexamethasone', 'ifosfamide', 'mesna', 'cisplatin', 'etoposide', 'rituximab']",['2'],phase ii trial of viper chemotherapi in relaps and refractori diffus larg bcell lymphoma nhl
884,NCT01101581,studi of veltuzumab and 90yepratuzumab in relapsedrefractory aggress nhl,"['veltuzumab', '90y', '90y-epratuzumab tetraxetan', 'veltuzumab']","['1', '2']",phase iii studi of veltuzumab combin with 90yepratuzumab tetraxetan in patient with relapsedrefractory aggress non hodgkin lymphoma
885,NCT01393756,revlimid dose 25 mg in associ with rchop in the treatment follicular lymphoma,"['lenalidomide', 'r']",['2'],a phase ibii studi of escal dose of revlimid in associ with rchop r2chop in the treatment of bcell lymphoma
886,NCT00361621,ph ii chopvelcad in mediastin lbcl,"['bortezomib', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone']",['2'],phase ii studi of choprituxan plus velcad in mediastin larg bcell lymphoma
887,NCT01276717,studi of carfilzomib and vorinostat for relaps or refractori lymphoma,"['drug', 'vorinostat']",['1'],phase i trial of carfilzomib pr171 in combin with vorinostat saha in patient with relapsedrefractori bcell lymphoma
890,NCT01210287,incid of hepat b virus hbv reactiv in hbsag negativehbcab posit lymphoma patient treat with rchop,['nucleoside analog reverse transcriptase inhibitor'],"['2', '3']",incid of hbv reactiv in hbsag negativehbcab posit diffus larg b cell lymphoma or high grade follicular lymphoma patients a prospect studi
891,NCT01421667,a studi of brentuximab vedotin in relaps or refractori nonhodgkin lymphoma,"['brentuximab vedotin', 'rituximab']",['2'],a phase 2 studi of brentuximab vedotin in relaps or refractori nonhodgkin lymphoma nhl
897,NCT00450385,gene in predict outcom of patient with dlbcl treat with rituximab and combin chemotherapi rchop,"['rituximab', 'cyclophosphamide', 'doxorubicin', 'prednisone', 'vincristine']",['2'],phase ii studi to establish gene express model predict surviv of diffus larg bcell lymphoma patient treat with rchop
898,NCT01403636,a studi of investig sar245409 in patient with certain lymphoma or leukemia,['sar245409'],['2'],a phase 2 studi of sar245409 in patient with relaps or refractori mantl cell lymphoma follicular lymphoma chronic lymphocyt leukemiasmal lymphocyt lymphoma or diffus larg b cell lymphoma
899,NCT01987505,mabrella study a studi to evalu the safeti of switch from intraven to subcutan administr of rituximab dure firstlin treatment for lymphoma,['rituximab'],['3'],open label singlearm phase iiib clinic trial to evalu the safeti of switch from intraven rituximab to subcutan rituximab dure first line treatment for cd20 nonhodgkin follicular lymphoma and diffus larg bcell lymphoma
900,NCT00002757,titleless intens therapi for children with nonhodgkin lymphoma,"['cyclophosphamide', 'cytarabine', 'doxorubicin hydrochloride', 'etoposide', 'methotrexate', 'prednisolone', 'prednisone', 'therapeutic hydrocortisone', 'vincristine sulfate']",['3'],fab lmb 96  treatment of matur bcell lymphomaleukemia a sfop lmb 96ccg 5961ukccsg nhl 9600 cooper studi
901,NCT00039195,chemotherapi and rituximab with or without totalbodi irradi and peripher stem cell transplant in treat patient with lymphoma,"['carboplatin', 'cyclophosphamide', 'doxorubicin hydrochloride', 'etoposide', 'ifosfamide', 'prednisone', 'vincristine sulfate']",['2'],riskadapt therapi for patient with untreat ageadjust intern prognost index ii or iii diffus larg b cell lymphoma
902,NCT00472056,rituximab in addit to autolog transplant with beam for patient with lymphoid malign,"['carmustine', 'etoposide', 'cytarabine', 'melphalan', 'rituximab']",['2'],random trial use standard dose versus high dose rituximab in addit to autolog transplant with beam for patient with diffus larg b cell lymphoma
903,NCT00054171,photodynam therapi in treat patient with lymphoma or chronic lymphocyt leukemia,['aminolevulinic acid hydrochloride'],['2'],a pilot studi of short 125 h medium 46 h and long 1824 h applic of 20 topic alapdt for photodynam therapi of cutan t and b cell lymphoma and cutan infiltr of earli cll
904,NCT00451178,an studi of patient with lymphoma who take rchop and enzastaurin compar to patient who take rchop onli,"['enzastaurin', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone']",['2'],an openlabel randomized phase 2 studi of rchop plus enzastaurin versus rchop in the firstlin treatment of patient with intermedi and highrisk diffus larg bcell lymphoma
905,NCT00902018,eltrombopag and the bclextralarg xl pathway in idiopath thrombocytopen purpura itp,['promacta '],['2'],the effect of eltrombopag on platelet survival the role of the bcell lymphoma extra larg bclxl pathway
907,NCT00004197,vaccin therapi plus sargramostim follow chemotherapi in treat patient with previous untreat aggress nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'mitoxantrone hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],a phase ii trial to evalu the rate of immun respons use idiotyp immunotherapi produc by molecular biolog mean for treatment of aggress b cell lymphoma
908,NCT00493454,ibritumomab tiuxetan for treatment of nonfollicular cd20 indol lymphoma,"['zevalin', 'rituximab']",['2'],multicent phase ii studi for zevalin® in patient with relapsedrefractori indol lymphomas extranod margin lymphoma of malt type nodal margin zone bcell lymphoma and splenic margin bcell lymphoma
909,NCT00387959,chemotherapy radiat therapy rituximab and umbil cord blood transplant in treat patient with bcell nonhodgkin lymphoma,"['cyclophosphamide', 'cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']",['2'],a nonmyeloabl condit regimen with peritranspl rituximab and the transplant of unrel donor umbil cord blood in patient with b cell lymphoid malign
910,NCT02597387,clinic trial of mitoxantron hcl liposom inject in patient with relaps dlbcl and ptnkcls,['mitoxantrone hcl liposome injection'],['2'],a singlearm open multicent phase ii clinic trial of mitoxantron hcl liposom inject in subject with relaps diffus larg bcell lymphoma and and peripher tnk lymphoma
912,NCT00425802,chemotherapy totalbodi irradiation rituximab and donor stem cell transplant in treat patient with bcell nonhodgkin lymphoma or chronic lymphocyt leukemia,"['cyclophosphamide', 'cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']",['2'],a nonmyeloabl condit regimen with peritranspl rituximab and the transplant of hematopoiet stem cell from hlacompat relat or unrel donor in patient with b cell lymphoid malign
914,NCT00644371,allogen stem cell transplant sct with nonmyeloabl condit in patient with relaps nonhodgkin lymphoma nhl,['ibritumomab tiuxetan '],['2'],allogen transplant of haematopoiet stem cell follow nonmyeloabl condit with melphalan fludarabine thiotepa rituximab and ibritumomab tiuxetan zevalin in patient with aggress nonhodgkin bcell lymphoma
916,NCT01325194,chemoimmunotherapi with earli central nervous system cns prophylaxi,['liposomal cytarabine'],['2'],dose densifi chemoimmunotherapi with earli cns prophylaxi in patient less than 65 year with high risk aaipi≥ 2 diffus larg bcell lymphoma
918,NCT00265928,bortezomib and rituximab in treat patient with relaps or refractori bcell nonhodgkin lymphoma,"['bortezomib', 'rituximab']",['2'],velcad bortezomib for inject  phase ii studi of bortezomib and rituximab in relaps or refractori nonhodgkin lymphoma
921,NCT00003963,chemotherapi and monoclon antibodi therapi in treat patient with bcell nonhodgkin lymphoma that has relaps follow peripher stem cell transplant,['vinorelbine ditartrate'],['2'],treatment of bcell nhl relaps after transplant with a rituxan vinorelbin combin
922,NCT00004039,combin chemotherapi plus interferon alfa or rituximab in treat patient with stage iii or stage iv lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],phase ii trial of chop chemotherapi and interferon alpha or rituximab anticd20 monoclon antibodi as initi treatment of patient with stage iii and iv highrisk indol bcell lymphoma and intermedi grade bcell lymphoma
924,NCT00003397,peripher stem cell transplant plus combin chemotherapi and monoclon antibodi therapi in treat patient with nonhodgkin lymphoma,"['carmustine', 'cisplatin', 'cyclophosphamide', 'dexamethasone', 'etoposide', 'gemcitabine hydrochloride', 'melphalan', 'paclitaxel']",['2'],autolog stem cell transplant for poor prognosis relapsed or refractori intermediatehigh grade bcell lymphoma use gemcitabin plus high dose bcnu and melphalan follow by anticd20 moab idec c2b8 rituximab rituxan and consolid chemotherapi
925,NCT02481310,combin chemotherapy rituximab and ixazomib citrat in treat patient with nonhodgkin lymphoma,"['cyclophosphamide', 'cytarabine', 'doxorubicin hydrochloride', 'etoposide', 'ixazomib citrate', 'methotrexate', 'prednisone', 'therapeutic hydrocortisone', 'vincristine sulfate']","['1', '2']",a phase iii trial of daepochr plus ixazomib as frontlin therapi for patient with mycaberr lymphoid malignancies the daciphor regimen
926,NCT00080847,s0349 rituximab cyclophosphamide doxorubicin vincristine and prednison with or without oblimersen in treat patient with advanc diffus larg bcell nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'vincristine sulfate', 'prednisone']",['2'],standard dose cyclophosphamide doxorubicin vincristine prednison chop and rituximab or rituximab and g3139 phosphorothio oligonucleotid bcl2 antisens  nsc683428 therapi for young patient  age 60 with advanc stage diffus larg bcell nhl of low and lowintermedi ipi risk
927,NCT01318317,genet engin lymphocyt therapi after peripher blood stem cell transplant in treat patient with highrisk intermediategrade bcell nonhodgkin lymphoma,['plerixafor'],"['1', '2']",phase iii studi of cellular immunotherapi use central memoryenrich cd8 t cell lentivir transduc to express a cd19specif chimer immunoreceptor follow peripher blood stem cell transplant for patient with highrisk intermedi grade blineag nonhodgkin lymphoma
928,NCT01713582,a dosefind studi of the bromodomain brd inhibitor otx015mk8628 in hematolog malign mk8628001,['otx015'],['1'],a phase i dosefind studi of the bromodomain brd inhibitor otx015mk8628 in haematolog malign
929,NCT00080886,rituximab and carmustine cytarabine etoposide and melphalan follow by autolog hematopoiet stem cell transplant in treat patient with bcell nonhodgkin lymphoma,"['carmustine', 'cytarabine', 'etoposide', 'melphalan']",['2'],a phase ii trial of beamrituximabautolog hematopoiet stem cell transplant ahsct for patient with cd20 posit nonhodgkin lymphoma
930,NCT01796470,entospletinib in combin with idelalisib in adult with relaps or refractori hematolog malign,"['entospletinib', 'idelalisib']",['2'],a phase 2 openlabel studi evalu the efficacy safety tolerability and pharmacodynam of gs9973 in combin with idelalisib in subject with relaps or refractori hematolog malign
932,NCT00004031,swog9704 chemoradiotherapi and peripher stem cell transplant compar with combin chemotherapi in treat patient with nonhodgkin lymphoma,"['chop regimen', 'carmustine', 'cyclophosphamide', 'doxorubicin hydrochloride', 'etoposide', 'prednisone', 'vincristine sulfate']",['3'],swog9704 a random phase iii trial compar earli high dose chemoradiotherapi and an autolog stem cell transplant to convent dose chop chemotherapi plus rituximab for cd20 b cell lymphoma with possibl late autolog stem cell transplant for patient with diffus aggress nonhodgkin lymphoma in the highintermedi and high risk intern classif prognost group
937,NCT02732275,a phase 1 multipl ascend dose studi of ds3201b in japanes subject with lymphoma,['ds-3201b'],['1'],a phase 1 multipl ascend dose studi of ds3201b in japanes subject with lymphoma
938,NCT00002682,antibiot therapi and antacid in patient with malt lymphoma of the stomach,"['amoxicillin', 'bismuth subsalicylate', 'clarithromycin', 'metronidazole hydrochloride', 'omeprazole', 'tetracycline hydrochloride']",['2'],current practic studi of antibiot treatment of gastric malt lymphoma
944,NCT00022555,bryostatin 1 plus vincristin in treat patient with recurr or refractori hivrel lymphoma,"['bryostatin 1', 'vincristine sulfate']",['1'],a phase i trial of combin bryostatin1 and vincristin in hivrel bcell neoplasm
945,NCT00491491,zevalinbeam for aggress lymphoma,['ibritumomab tiuxetan'],['3'],spinoza  שפינוזה studi with preparatori induct of zevalin in aggress lymphoma a random phase 3 studi of beam versus 90yttrium ibritumomab tiuxetan zevalin  beam in patient requir autolog hematopoiet stem cell transplant asct for relaps diffus larg bcell lymphoma
946,NCT00086944,oblimersen rituximab and combin chemotherapi in treat patient with relaps or refractori aggress nonhodgkin lymphoma,"['ifosfamide', 'carboplatin', 'etoposide']","['1', '2']",a phase iii studi of g3139 genasense in combin with rice chemotherapi in relaps bcell nonhodgkin lymphoma
947,NCT00005601,combin chemotherapi plus rituximab in treat patient with relaps nonhodgkin lymphoma,"['cisplatin', 'cytarabine', 'dexamethasone', 'sargramostim']",['2'],a phase ii trial of cisplatinum cytosin arabinoside dexamethason dhap with rituxan in patient with relaps cd20 bcell nonhodgkin lymphoma
948,NCT01853631,activ tcell express 2nd or 3rd generat cd19specif car advanc bcell nhl all and cll sagan,"['fludarabine', 'cyclophosphamide']",['1'],phase i studi of activ tcell express second or third generat cd19specif chimer antigen receptor for advanc bcell nonhodgkin lymphoma acut lymphocyt leukemia and chronic lymphocyt leukemia sagan
951,NCT00058292,radiolabel monoclon antibodi therapi and highdos chemotherapi follow by autolog peripher stem cell transplant in treat patient with relaps or refractori nonhodgkin lymphoma,"['carmustine', 'cytarabine', 'etoposide', 'melphalan']",['1'],a phase i trial combin idecy2b8 and highdos beam chemotherapi with hematopoiet progenitor cell transplant in patient with relaps or refractori bcell nonhodgkin lymphoma
952,NCT00496873,evalu of the safeti and efficaci of nipent cytoxan and rituxan,"['cytoxan', 'nipent', 'rituxan']",['2'],a singlecenter openlabel studi to evalu the safeti and efficaci of nipent cytoxan and rituxan pcr in the treatment of previous untreat and treated stage iii or iv lowgrad bcell nonhodgkin lymphoma or bulki lymphoma
953,NCT00040950,biolog therapi plus monoclon antibodi therapi in treat patient with relaps or refractori nonhodgkin lymphoma,['agatolimod sodium'],['1'],a multicenter phase i open label two arm nonrandomized doseescalation studi of the safeti and toler of cpg 7909 in patient receiv rituxan for relaps or refractori bcell nonhodgkin lymphoma
954,NCT00389051,a phase i studi of bendamustin hydrochlorid in patient with indol bcell nonhodgkin lymphoma,['bendamustine hydrochloride'],['1'],a multicenter open studi to assess the tolerability pharmacokinet and antitumor effect of bendamustin hydrochlorid syb l0501 90 or 120 mgm2day administ intraven for two day in patient with indol lymphoma
956,NCT00049036,combin chemotherapi and rituximab in treat patient with hivassoci stage i stage ii stage iii or stage iv nonhodgkin lymphoma,"['etoposide', 'doxorubicin hydrochloride', 'vincristine sulfate', 'prednisone', 'cyclophosphamide']",['2'],a random phase ii trial of epoch given either concurr or sequenti with rituximab in patient with intermediate or highgrad hivassoci bcell nonhodgkin lymphoma
957,NCT00726700,pegfilgrastim and combin chemotherapi with or without rituximab in treat older patient with aggress bcell nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],random phase ii studi about the applic of pegfilgrastim neulasta at day 2 or day 4 within the treatment in patient with aggress nonhodgkin lymphoma age 61 to 80 year with 6 or 8 cycl of chemotherapi with chop cyclophosphamide doxorubicin vincristin and prednisone at 14day interv chop14 both with or without the monoclon anticd20 antibodi rituximab
958,NCT00006241,peripher stem cell transplant in treat patient with relaps low or intermediategrad nonhodgkin lymphoma,['chemotherapy'],['2'],a pivot studi to determin the safeti and efficaci of use bcell high densiti microparticl bcellhdm to deplet bcell from peripher blood stem cell collect without compromis the time to neutrophil and platelet engraft in patient with relaps low or intermedi grade bcell nonhodgkin lymphoma given autolog peripher blood stem cell transplant after highdos chemotherapi
959,NCT00274924,rituximab and combin chemotherapi in treat patient with stage ii stage iii or stage iv diffus larg bcell nonhodgkin lymphoma,"['carboplatin', 'cyclophosphamide', 'doxorubicin hydrochloride', 'etoposide', 'ifosfamide', 'prednisone', 'vincristine']",['2'],responseadapt therapi for aggress nonhodgkin lymphoma base on earli 18f fdgpet scan
960,NCT00026351,pentostatin and rituximab in treat patient with lowgrad nonhodgkin lymphoma or chronic lymphocyt leukemia,['pentostatin'],['2'],phase ii multicent trial of pentostatin and rituximab in patient with previous treat and untreat low grade bcell nonhodgkin lymphoma nhl includ chronic lymphocyt leukemia cll
965,NCT01804686,a longterm extens studi of pci32765 ibrutinib,['pci-32765 '],['3'],a phase 3b multicenter openlabel pci32765 ibrutinib longterm extens studi
967,NCT02580552,safety toler and pharmacokinet of mrg106 in patient with mycosi fungoid mf cll dlbcl or atll,['mrg-106'],['1'],a phase 1 doserang studi to investig the safety tolerability and pharmacokinet of mrg106 follow local intratumoral subcutaneous and intraven administr in subject with various lymphoma and leukemia
970,NCT01722305,pomalidomid and dexamethason in treat patient with relaps or refractori primari central nervous system lymphoma or newli diagnos or relaps or refractori intraocular lymphoma,"['dexamethasone', 'pomalidomide']",['1'],phase i trial of pomalidomid for patient with relapsedrefractori primari cns lymphoma and primari vitreoretin lymphoma
972,NCT02342665,japanes phase ibii copanlisib in relapsed indol bcell nhl,['copanlisib '],"['1', '2']",openlabel uncontrolled singlearm phase ibii studi of intraven copanlisib in japanes patient with indol bcell non hodgkin lymphoma relaps after or refractori to standard therapi
973,NCT01281917,studi of velcad and temsirolimus for relaps or refractori nonhodgkin lymphoma,"['velcade', 'temsirolimus']",['2'],a phase ii studi of velcad and temsirolimus for relaps or refractori bcell nonhodgkin lymphoma
974,NCT01939327,safeti and efficaci of revlimid® lenalidomide with mabthera® rituximab in nonhodgkin lymphoma,['lenalidomide'],['2'],a phase ii singlearm openlabel studi to evalu the safeti and efficaci of combin lenalidomid revlimid® with rituximab in subjet with relaps or refractori diffus larg b cell nonhodgkin lymphoma
976,NCT01729104,phase iii carfilzomib plus lenalidomid and rituximab in the treatment of relapsedrefractori mantl cell lymphoma,"['carfilzomib', 'lenalidomide', 'rituximab']","['1', '2']",a phase iii studi of carfilzomib plus lenalidomid and rituximab in the treatment of relapsedrefractori bcell nonhodgkin lymphoma
977,NCT00077961,rituximab plus campath in patient with relapsedrefractori lowgrad or follicular cd20positive bcell nhl,['campath '],"['1', '2']",phase iii studi of rituximab plus campath in patient with previous treat relaps or refractori lowgrad follicular cd20positive bcell nonhodgkin lymphoma
980,NCT00055640,molecular risk assess in plan treatment for patient with nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],molecular risk guid treatment of diffus larg bcell nonhodgkin lymphoma
983,NCT01868035,iodine131 antib1 antibodi consolid for patient with nonhodgkin lymphoma follow firstlin chop,"['tositumomab', 'iodine i']",['2'],phase ii multicent studi of iodine131 antib1 antibodi consolid for patient with diffus larg bcell nonhodgkin lymphoma follow firstlin chop
985,NCT02594384,a phase i dose escal studi of the safeti and pharmacokinet of lam002a in patient with nonhodgkin lymphoma lam002anhl,"['lam-002a', 'rituximab', 'atezolizumab']",['1'],a phase 1 dose escal studi of the safeti and pharmacokinet of lam002a apilimod dimesyl capsules administ oral in subject with relaps or refractori bcell nonhodgkin lymphoma
986,NCT00024115,bl22 immunotoxin in treat patient with nonhodgkin lymphoma or chronic lymphocyt leukemia,['bl22 immunotoxin'],['1'],phase i studi of recombin bl22 immunotoxin in patient with cd22posit bcell nonhodgkin lymphoma or chronic lymphocyt leukemia
987,NCT00546377,pentostatin cyclophosphamide rituximab and mitoxantron in treat patient with chronic lymphocyt leukemia or other lowgrad bcell cancer,"['cyclophosphamide', 'mitoxantrone hydrochloride', 'pentostatin']","['1', '2']",a phase iii studi of pentostatin cyclophosphamide rituximab and mitoxantron in previous treat patient with chronic lymphocyt leukemia and other low grade bcell neoplasm
988,NCT02500407,a safeti and pharmacokinet studi of btct4465a mosunetuzumab as a singl agent and combin with atezolizumab in nonhodgkin lymphoma nhl and chronic lymphocyt leukemia cll,"['btct4465a ', 'atezolizumab', 'btct4465a ']",['1'],an openlabel multicenter phase iib trial evalu the safeti and pharmacokinet of escal dose of btct4465a as a singl agent and combin with atezolizumab in patient with relaps or refractori bcell nonhodgkin lymphoma and chronic lymphocyt leukemia
989,NCT00003650,combin chemotherapi in treat children with nonhodgkin lymphoma,"['asparaginase', 'cyclophosphamide', 'cytarabine', 'daunorubicin hydrochloride', 'dexamethasone', 'etoposide', 'mercaptopurine', 'methotrexate', 'methylprednisolone', 'mitoxantrone hydrochloride', 'prednisone', 'vincristine sulfate']",['3'],phase iii studi of combin chemotherapi in children with t cell and preb cell nonhodgkin lymphoma
990,NCT00481871,studi of pralatrex  gemcitabin with b12  folic acid to treat relapsedrefractori lymphoprolif malign,"['pralatrexate injection', 'gemcitabine hydrochloride']","['1', '2']",a phase 12a openlabel studi of pralatrex and gemcitabin with vitamin b12 and folic acid supplement in patient with relaps or refractori lymphoprolif malign
993,NCT01897012,alisertib and romidepsin in treat patient with relaps or refractori bcell or tcell lymphoma,"['alisertib', 'romidepsin']",['1'],a phase 1 trial of mln8237 plus romidepsin for relapsedrefractori aggress bcell and tcell lymphoma
994,NCT00166439,trial of oxaliplatin cytosin arabinoside dexamethason with rituxan road in patient with relaps nonhodgkin lymphoma,"['oxaliplatin', 'cytosine arabinoside', 'dexamethasone with rituxan ']",['2'],a phase ii trial of oxaliplatin cytosin arabinoside dexamethason with rituxan road in patient with relaps cd20 bcell nonhodgkin lymphoma
995,NCT00006669,rituximab follow by combin chemotherapi in treat patient with refractori or recurr nonhodgkin lymphoma,"['epoch regimen', 'cyclophosphamide', 'doxorubicin hydrochloride', 'etoposide', 'prednisone', 'vincristine sulfate']",['2'],phase ii trial of epoch and rituxan combin therapi in patient with refractori or relaps cd20 posit intermedi grade bcell nonhodgkin lymphoma
997,NCT02055820,a safeti and pharmacokinet pk studi of venetoclax in particip with nonhodgkin lymphoma,"['venetoclax', 'cyclophosphamide', 'obinutuzumab', 'rituximab', 'doxorubicin', 'vincristine', 'prednisone']","['1', '2']",a phase ibii openlabel studi evalu the safeti and pharmacokinet of gdc0199 abt199 in combin with rituximab r or obinutuzumab g plus cyclophosphamide doxorubicin vincristine and prednison chop in patient with bcell nonhodgkin lymphoma nhl and dlbcl
998,NCT00028665,cyclophosphamid wor wout rituximab and peripher stem cell transplant in patient with recurr nonhodgkin lymphoma,"['carmustine', 'cisplatin', 'cyclophosphamide', 'etoposide']",['2'],random phase ii trial of blymphocyt purg of autolog peripher blood progenitor cell in patient with bcell nonhodgkin lymphoma
999,NCT00807495,studi of alisertib mln8237 in adult with aggress nonhodgkin lymphoma,['alisertib'],['2'],a phase 2 trial of mln8237 an oral aurora a kinas inhibitor in adult patient with aggress nonhodgkin lymphoma
1004,NCT01007292,a studi of ym155 plus rituximab in subject with nonhodgkin lymphoma who have receiv prior treatment,['ym155'],['2'],a phase ii multicenter openlabel studi of ym155 plus rituximab in previous treat subject with cd20posit b cell nonhodgkin lymphoma who are inelig for or have previous receiv an autolog stem cell transplant
1005,NCT01848652,phase ii studi evalu a combin of pegyl liposom doxorubicin and dexamethason for the treatment of immunocompet patient with cerebr lymphoma relaps or refractori to firstlin chemotherapi with high dose methotrex mtxhd and  or highdos cytarabine,['infusion of myocet'],['2'],phase ii studi evalu the combin pegyl liposom doxorubicin and dexamethason for the treatment of immunocompet patient with cerebr lymphoma relaps or refractori to firstlin chemotherapi contain high dose methotrex mtxhd and  or highdos cytarabine
1006,NCT02568553,lenalidomid and blinatumomab in treat patient with relaps nonhodgkin lymphoma,['lenalidomide'],['1'],a phase i trial of the combin of lenalidomid and blinatumomab in patient with relaps or refractori nonhodgkin lymphoma nhl
1007,NCT02142530,carfilzomib plus belinostat in relapsedrefractori nhl,"['carfilzomib', 'belinostat']",['1'],carfilzomib plus belinostat in relapsedrefractori nonhodgkin lymphoma subtypes a phase 1 studi
1008,NCT00006695,monoclon antibodi therapy combin chemotherapy and peripher stem cell transplant in treat patient with relaps or refractori nonhodgkin lymphoma,"['carmustine', 'cytarabine', 'etoposide', 'melphalan']",['2'],beam plus iodine131 antib1 antibodi and autolog hematopoiet stem cell transplant for treatment of recurr diffus larg bcell nonhodgkin lymphoma
1010,NCT01206777,feasibl studi of a 60 minut rapid infus rituximab protocol in patient with bcell malign,['rituximab'],['2'],assess of hypersensit reaction and feasibl of a 60 minut rapid infus rituximab protocol in patient with bcell nonhodgkin lymphoma nhl and chronic lymphocyt leukemia cll at a comprehens cancer center
1012,NCT00032019,combin chemotherapi and monoclon antibodi therapi in treat patient with nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'etoposide', 'prednisone', 'vincristine sulfate']",['2'],phase ii studi of doseadjust epochrituximab epochr chemotherapi for patient with previous untreat aggress cd20 bcell nonhodgkin lymphoma nhl
1018,NCT01410513,studi combin sar245409 with rituximab or bendamustin plus rituximab in patient with indol lymphoma mantl cell lymphoma and chronic lymphocyt leukemia,['sar245409'],['1'],a phase 1b multicenter openlabel dose escal studi of sar245409 to evalu the safety toler and clinic activ of sar245409 in combin with rituximab or bendamustin plus rituximab in patient with relaps or refractori indol bcell nonhodgkin lymphoma mantl cell lymphoma or chronic lymphocyt leukemia
1019,NCT00022932,safeti and efficaci of iodine131 antib1 antibodi for intermedi grade nonhodgkin lymphoma follow first line chop,['iodine-131 anti'],['2'],phase ii multicent studi of iodine131 antib1 antibodi consolid for patient with diffus larg bcell nonhodgkin lymphoma follow firstlin chop
1020,NCT00347971,studi of recombin interleukin 21 in combin with rituxan for nonhodgkin lymphoma,"['recombinant human interleukin 21', 'rituximab']",['1'],phase 1 openlabel doseescal studi to assess the safeti and pharmacokinet of recombin interleukin 21 ril21 administ in combin with rituxan rituximab in subject with bcell non hodgkin lymphoma
1022,NCT00562978,yttrium y 90 ibritumomab tiuxetan etoposide cyclophosphamide and an autolog stem cell transplant in treat patient with nonhodgkin lymphoma,"['cyclophosphamide', 'etoposide']","['1', '2']",a phase iii trial of escal dose of yttrium90label anticd20 monoclon antibodi in combin with highdos etoposid and cyclophosphamid follow by autolog stem cell transplant for patient with relaps bcell nonhodgkin lymphoma
1025,NCT00517049,a studi of pro95780 in combin with rituximab in patient with nonhodgkin lymphoma that has progress follow previous rituximab therapi apm4083g,"['pro95780', 'rituximab']",['2'],a phase ii singlearm openlabel studi of the safety pharmacokinetics and efficaci of multipl dose of pro95780 administ intraven in combin with rituximab in patient with follicular cd20posit bcell nonhodgkin lymphoma that has progress follow previous rituximab therapi
1026,NCT00064116,combin chemotherapi with or without rituximab in treat patient with nonhodgkin lymphoma,['chop regimen'],['3'],random intergroup trial of first line treatment for patient with diffus larg bcell nonhodgkin lymphoma with a choplik chemotherapi regimen with or without the anticd20 antibodi rituximab idecc2b8
1027,NCT00006708,s0019 combin chemotherapi with or without rituximab in treat patient with relaps or refractori nonhodgkin lymphoma,"['carboplatin', 'etoposide', 'ifosfamide']",['3'],a random phase iii trial of ice chemotherapi with or without rituximab for the treatment of relaps or refractori cd20 express aggress bcell nonhodgkin lymphoma in patient not suitabl for high dose therapi and pbsct
1028,NCT01820910,phase ii trial of firstlin doxycyclin for ocular adnex margin zone lymphoma treatment,['doxycycline'],['2'],intern prospect phase 2 trial address the efficaci of firstlin chlamydophila psittacierad therapi with protract administr of doxycyclin follow by erad monitor and antibiot retreat at infect reoccurr in patient with newli diagnos ocular adnex margin zone lymphoma oamzl
1029,NCT00562965,studi compar inotuzumab ozogamicin in combin with rituximab versus defin investig choic in follicular nonhodgkin lymphoma nhl,"['inotuzumab ozogamicin', 'rituximab', 'cyclophosphamide', 'vincristine', 'prednisone', 'mitoxantrone', 'fludarabine', 'dexamethasone']",['3'],an openlabel randomized phase 3 studi of inotuzumab ozogamicin cmc544 administ in combin with rituximab compar to a defin investig choic therapi in subject with relaps or refractory cd22 positive follicular bcell non hodgkin lymphoma
1030,NCT01516606,salvag therapi with high dose oral clarithromycin in relaps or refractori extranod margin zone lymphoma,"['clarithromycin', 'oral', 'high dose']",['2'],phase ii clinic trial on the activ of salvag therapi with high dose oral clarithromycin in patient with relaps or refractori extranod margin zone lymphoma
1031,NCT01427114,rcvp for the treatment of nonconjunctiv ocular adnex malt lymphoma oaml,"['rituximab', 'cyclophosphamide', 'vincristine,', 'prednisolone']",['2'],openlabeled multicent phase ii studi of rituximab cyclophosphamide vincristine and prednisolon rcvp chemotherapi in patient with nonconjunctiv ocular adnex malt lymphoma
1032,NCT01514344,intralesion rituximab for the treatment of conjunctiv indol lymphoma,['intralesional rituximab'],['2'],phase ii studi on activ and toler of intralesion rituximab in patient with relaps or refractori cd20 indol lymphoma of conjunctiva activ of supplement autolog serum in patient not respons to rituximab alon
1033,NCT02393157,obinutuzumab and ice chemotherapi in refractoryrecurr cd20 matur nhl,"['obinutuzumab', 'liposomal ara', 'ifosfamide', 'carboplatin', 'etoposide']",['2'],chemoimmunotherapi with obinutuzumab ifosfamide carboplatin and etoposid oice in children adolesc and young adult with recurr refractori cd20 matur bnhl
1034,NCT00012051,chemotherapi and peripher stem cell transplant with or without monoclon antibodi therapi in treat patient with nonhodgkin lymphoma,"['carmustine', 'cisplatin', 'cytarabine', 'dexamethasone', 'etoposide', 'ifosfamide', 'melphalan', 'methotrexate']",['3'],a randomis phase iii studi on the effect of the chimer anticd20 monoclon antibodi mabthera dure sequenti chemotherapi follow by autolog stem cell transplant in patient with relaps bcell nonhodgkin lymphomahovon 44 study
1035,NCT00923663,trial of lenalidomid in patient with lymphoma of the mucosa associ lymphoid tissu malt type,['lenalidomide'],['2'],phase ii trial of lenalidomid in patient with lymphoma of the mucosa associ lymphoid tissu malt type
1037,NCT01015248,trial of bendamustin and rituximab for patient with previous untreat extranod mucosaassoci lymphoid tissu malt lymphoma,"['rituximab', 'bendamustine']",['2'],multicentric nonrandom phase 2 trial of bendamustin and rituximab for patient with previous untreat extranod mucosaassoci lymphoid tissu malt lymphoma
1038,NCT00400764,a studi of dulanermin in combin with rituximab in subject with follicular and other low grade cd20 nonhodgkin lymphoma,"['dulanermin', 'rituximab']","['1', '2']",a phase ibii openlabel multicent studi of the safety pharmacokinetics and efficaci of dulanermin administ intraven in combin with rituximab to subject with follicular and other lowgrade cd20 bcell nonhodgkin lymphoma that have progress follow previous rituximab therapi
1040,NCT01842672,mitoxantron and clofarabin for treatment of recurr nhl or acut leukemia,"['clofarabine', 'mitoxantrone']","['1', '2']",a pilot studi of mitoxantron in combin with clofarabin mitcl in children adolesc and young adult caya with refractoryrelaps acut leukemia or high grade nonhodgkin lymphoma
1042,NCT01799889,entospletinib in adult with relaps or refractori hematolog malign,"['entospletinib', 'entospletinib sdd']",['2'],a phase 2 openlabel studi evalu the efficacy safety tolerability and pharmacodynam of gs9973 in subject with relaps or refractori hematolog malign
1044,NCT00656812,rituximab plus 2cda in patient with advanc or relaps mucosa associ lymphoid tissu malt lymphoma,"['rituximab', '2-cda']",['2'],phase ii trial of rituximab plus 2cda in patient with advanc or relaps lymphoma of the mucosa associ lymphoid tissu malt
1045,NCT00244855,rituximab and dexamethason in treat patient with lowgrad nonhodgkin lymphoma,['dexamethasone'],['2'],rituximab and dexamethason in cd20 posit low grade and follicular nonhodgkin lymphoma
1046,NCT00453102,yttrium y 90 ibritumomab tiuxetan and rituximab in treat patient with previous untreat margin zone lymphoma,"['rituximab', 'ibritumomab tiuxetan']",['2'],phase ii studi of ibritumomab tiuxetan zevalin® in patient with previous untreat margin zone lymphoma
1047,NCT00373646,thalidomid in mucosa associ lymphoid tissu malt lymphoma patient,"['thalidomide', 'pharmion']",['2'],phase ii trial of thalidomid thalidomid pharmion in patient with advanc or relaps lymphoma of the mucosa associ lymphoid tissu malt
1049,NCT02701517,cyclosporin plus methotrex or alemtuzumab,"['cyclosporine', 'methotrexate', 'cyclosporine', 'campath']",['2'],random trial of cyclosporin  campath1h alemtuzumab vs cyclosporin  methotrex in patient diagnos with matur bcell neoplasm  chronic lymphocyt leukemia and lowgrad lymphoma  receiv allogen hematopoiet stem cell transplant with nonmyeloabl condit regimen
1051,NCT01238146,obatoclax mesylate rituximab and bendamustin hydrochlorid in treat patient with relaps or refractori nonhodgkin lymphoma,"['bendamustine hydrochloride', 'obatoclax mesylate']","['1', '2']",a phase iii trial of rituximab bendamustine and obatoclax in patient with relaps or refractori indol nonhodgkin lymphoma
1052,NCT00006383,liposom vincristin in treat patient with refractori or relaps nonhodgkin lymphoma,['liposomal vincristine sulfate'],['2'],pivot phase ii multicent studi of vincristin sulfat liposom inject in diffus larg bcell nonhodgkin lymphoma that is refractori or relaps after secondlin combin chemotherapi revis titl per 0301 sr pivot phase ii multicent studi of vincristin sulfat liposom inject in aggress nonhodgkin lymphoma that is refractori to or relaps after secondlin combin chemotherapi
1053,NCT00992446,bortezomib and vorinostat as mainten therapi after autolog stem cell transplant in treat patient with nonhodgkin lymphoma,"['bortezomib', 'carmustine', 'cytarabine', 'etoposide', 'melphalan', 'rituximab', 'vorinostat']",['2'],bortezomib and vorinostat as mainten therapi after autolog transplant for nonhodgkin lymphoma use rbeam or beam condit transplant regimen
1054,NCT01285765,evalu a treatment adapt to the pet respons compar to a standard treatment for low risk dlbcl cd 20 patient,['rchop21'],['3'],random phase iii studi evalu the noninferior of a treatment adapt to the earli respons evalu with 18ffdg pet compar to a standard treatment for patient age from 18 to 80 year with low risk aa ipi  0 diffus larg bcell non hodgkin lymphoma cd 20
1057,NCT01959477,dose monitor of busulfan and combin chemotherapi in hodgkin or nonhodgkin lymphoma undergo stem cell transplant,"['busulfan', 'etoposide', 'cyclophosphamide']",['1'],person monitor of intraven busulfan dose for patient with lymphoma undergo autolog stem cell transplantation
1060,NCT01805037,brentuximab vedotin  rituximab as frontlin therapi for pts w cd30 andor ebv lymphoma,['brentuximab vedotin'],"['1', '2']",a phase iii trial of brentuximab vedotin plus rituximab as frontlin therapi for patient with cd30 andor ebv lymphoma
1061,NCT00154440,helicobact – lymphoma – radiat part i eradication part ii radiat,"['proton pump inhibitor', 'clarithromycin', 'amoxicillin', 'metronidazole']",['3'],treatment of lowgrad gastric nonhodgkin lymphoma of mucosaassoci lymphoid tissu malt type stage ie  ii1 helyxstudy
1062,NCT01314014,imexon for relaps follicular and aggress lymphoma,['imexon'],['2'],a phase ii studi of amplimexon® imexon for injection for the treatment of previous treat follicular and aggress lymphoma in adult
1063,NCT01116154,vorinostat and lenalidomid in treat patient with relaps or refractori hodgkin lymphoma or nonhodgkin lymphoma,"['lenalidomide', 'vorinostat']",['1'],a phase i studi of the combin of lenalidomid with the histon deacetylas inhibitor vorinostat in hodgkin and non hodgkin lymphoma
1064,NCT01258998,studi of akt inhibitor mk2206 in patient with relaps lymphoma,['akt inhibitor mk2206'],['2'],phase ii studi of mk2206 in patient with relaps lymphoma
1066,NCT01129193,ar42 in treat patient with advanc or relaps multipl myeloma chronic lymphocyt leukemia or lymphoma,['ar-42'],['1'],phase i studi of ar42 in relaps myeloma chronic lymphocyt leukemia and lymphoma
1067,NCT01177371,highdos busulfan and highdos cyclophosphamid follow by donor bone marrow transplant in treat patient with leukemia myelodysplast syndrome multipl myeloma or recurr hodgkin or nonhodgkin lymphoma,"['busulfan', 'cyclophosphamide', 'methylprednisolone', 'methotrexate', 'cyclosporine']",['2'],highdos busulfan highdos cyclophosphamide and allogen bone marrow transplant for leukemia myelodysplast syndromes multipl myeloma and lymphoma
1068,NCT00088881,rituximab combin chemotherapy and 90yttrium ibritumomab tiuxetan for patient with stage i or ii nonhodgkin lymphoma,"['prednisone', 'cyclophosphamide', 'doxorubicin', 'vincristine']",['2'],a phase ii trial of rchop follow by zevalin radioimmunotherapi for patient with previous untreat stage i and ii cd20 diffus larg cell nonhodgkin lymphoma
1072,NCT00601718,vorinostat rituximab ifosfamide carboplatin and etoposid in treat patient with relaps or refractori lymphoma or previous untreat tcell nonhodgkin lymphoma or mantl cell lymphoma,"['vorinostat', 'ifosfamide', 'carboplatin', 'etoposide']","['1', '2']",a phase iii studi of vorinostat plus rituximab ifosphamide carboplatin and etoposid for patient with relaps or refractori lymphoid malign or untreat t or mantl cell lymphoma
1073,NCT01419795,lenalidomid with or without rituximab in treat patient with progress or relaps chronic lymphocyt leukemia small lymphocyt lymphoma prolymphocyt leukemia or nonhodgkin lymphoma previous treat with donor stem cell transplant,['lenalidomide'],['2'],a phase ii studi investig treatment of postallogen transplant progress or relaps of cllsllpll or nhl with lenalidomid alon or with rituximab
1074,NCT00005950,506u78 in treat patient with recurr or refractori nonhodgkin lymphoma or tcell lymphoma,['nelarabine'],['2'],phase ii studi of 506u78 nsc 686673 for patient with relaps or refractori indol bcell or peripher tcell lymphoma
1075,NCT00499811,vorinostat in treat patient with metastat or unresect solid tumor or lymphoma and liver dysfunct,['vorinostat'],['1'],phase i and pharmacokinet studi of vorinostat for solid tumor and lymphoma in patient with vari degre of hepat dysfunct
1076,NCT00073918,iodin i 131 tositumomab etoposid and cyclophosphamid follow by autolog stem cell transplant in treat patient with relaps or refractori nonhodgkin lymphoma,"['cyclophosphamide', 'etoposide']",['2'],a phase ii trial evalu the efficaci of radioiodin tositumomab anticd20 antibody etoposid and cyclophosphamid follow by autolog transplantation for relaps or refractori nonhodgkin lymphoma
1079,NCT01110135,bendamustin hydrochloride etoposide dexamethasone and filgrastim for peripher blood stem cell mobil in treat patient with refractori or recurr lymphoma or multipl myeloma,"['bendamustine hydrochloride', 'dexamethasone', 'etoposide']",['2'],a phase ii studi of bendamustin b etoposid e dexamethason d and gcsf for peripher blood hematopoiet stem cell mobil bed
1080,NCT02483000,anticd20 radioimmunotherapi befor chemotherapi and stem cell transplant in treat patient with highrisk bcell malign,"['carmustine', 'clearing agent', 'cytarabine', 'etoposide', 'melphalan']",['1'],evalu of pretarget anticd20 radioimmunotherapi combin with beam chemotherapi and autolog stem cell transplant for highrisk bcell malign
1084,NCT02153580,cellular immunotherapi follow chemotherapi in treat patient with recurr nonhodgkin lymphomas chronic lymphocyt leukemia or bcell prolymphocyt leukemia,"['cyclophosphamide', 'bendamustine hydrochloride', 'etoposide', 'fludarabine phosphate']",['1'],phase i studi to evalu cellular immunotherapi use memoryenrich t cell lentivir transduc to express a cd19specific hingeoptimized cd28costimulatori chimer receptor and a truncat egfr follow lymphodeplet chemotherapi in adult patient with cd19 bcell lymphoprolif neoplasm
1088,NCT02086591,a phase ii studi of doxycyclin in relaps nhl,['doxycycline'],['2'],a phase ii studi of doxycyclin in relaps nhl
1089,NCT01789255,vorinostat tacrolimus and methotrex in prevent gvhd after stem cell transplant in patient with hematolog malign,"['vorinostat', 'tacrolimus', 'cyclosporine', 'methotrexate']",['2'],a pilot trial of vorinostat plus tacrolimus and methotrex to prevent graft versus host diseas follow unrel donor hematopoiet stem cell transplant
1092,NCT01658319,methoxyamin and fludarabin phosphat in treat patient with relaps or refractori hematolog malign,"['fludarabine phosphate', 'methoxyamine']",['1'],phase i trial of fludarabin and methoxyamin trc102 for relaps or refractori hematolog malign
1094,NCT01760655,reducedintens condit befor donor stem cell transplant in treat patient with highrisk hematolog malign,"['fludarabine phosphate', 'thiotepa', 'cyclophosphamide', 'tacrolimus', 'mycophenolate mofetil']",['2'],a two step approach to reduc intens allogen hematopoiet stem cell transplant for high risk hematolog malign
1095,NCT01652014,singl or doubl donor umbil cord blood transplant in treat patient with highrisk hematolog malign,"['cyclophosphamide', 'fludarabine phosphate', 'mycophenolate mofetil', 'tacrolimus']",['2'],hematopoiet stem cell transplant use altern donor umbil cord blood option
1096,NCT00458731,bevacizumab and cediranib maleat in treat patient with metastat or unresect solid tumor lymphoma intracrani glioblastoma gliosarcoma or anaplast astrocytoma,['cediranib maleate'],['1'],phase i clinic trial evalu the toxicity pharmacokinet and biolog effect of intraven bevacizumab avastin tm in combin with escal dose of oral azd2171 for patient with advanc malign
1097,NCT01427881,cyclophosphamid for prevent of graftversushost diseas after allogen peripher blood stem cell transplant in patient with hematolog malign,"['cyclophosphamide', 'cyclosporine', 'fludarabine phosphate', 'busulfan']",['2'],a phase ii studi to evalu the efficaci of posttranspl cyclophosphamid for prevent of chronic graftversushost diseas after allogen peripher blood stem cell transplant
1098,NCT01273766,deferasirox in treat iron overload caus by blood transfus in patient with hematolog malign,['deferasirox'],['2'],impact of intervent with deferasirox on the immun function of patient with hematolog diseas and transfusionrel iron overload
1100,NCT01158274,ro4929097 and capecitabin in treat patient with refractori solid tumor,"['gamma-secretase', 'capecitabine']",['1'],a phase 1 studi of ro4929097 nsc749225 in combin with capecitabin in refractori solid tumor
1101,NCT01093586,donor umbil cord blood stem cell transplant in treat patient with hematolog malign,"['busulfan', 'cyclophosphamide', 'anti-thymocyte globulin', 'methylprednisolone', 'cyclosporine', 'mycophenolate mofetil']",['2'],umbil cord blood ucb allogen stem cell transplant for hematolog malign
1102,NCT00058227,alvocidib fludarabin phosphate and rituximab in treat patient with lymphoprolif disord or mantl cell lymphoma,"['alvocidib', 'fludarabine phosphate']",['1'],a phase i studi of flavopiridol fludarabin and rituximab in indol bcell lymphoprolif disord and mantl cell lymphoma
1103,NCT00890747,sunitinib malat in treat hivposit patient with cancer receiv antiretrovir therapi,['sunitinib malate'],['1'],a phase 1pharmacokinet studi of sunitinib in patient with cancer who also have hiv and are on haart therapi
1104,NCT00644189,oral clofarabin for relapsedrefractori nonhodgkin lymphoma,['clofarabine'],"['1', '2']",a phase ii studi of oral clofarabin in patient with relapsedrefractori nonhodgkin lymphoma
1106,NCT00072514,gemcitabin hydrochloride carboplatin dexamethasone and rituximab in treat patient with previous treat lymphoid malign,"['gemcitabine hydrochloride', 'carboplatin', 'dexamethasone']",['2'],a phase ii studi evalu the efficaci of gemcitabine carboplatin and dexamethason and rituximab for previous treat lymphoid malign
1107,NCT00118352,alemtuzumab fludarabin phosphate and totalbodi irradi follow by cyclosporin and mycophenol mofetil in treat patient who are undergo donor stem cell transplant for hematolog cancer,"['fludarabine phosphate', 'cyclosporine', 'mycophenolate mofetil']",['2'],campath alemtuzumab dose escalation lowdos tbi and fludarabin follow by hla class ii mismatch donor stem cell transplant for patient with hematolog malignancies a multicent trial
1109,NCT01261247,panobinostat in treat patient with relaps or refractori nonhodgkin lymphoma,['panobinostat'],['2'],a phase ii studi of the histon deacetylas hdac inhibitor lbh589 panobinostat in patient with relaps or refractori nonhodgkin lymphoma
1110,NCT00058305,bryostatin 1 plus vincristin in treat patient with progress or relaps nonhodgkin lymphoma after bone marrow or stem cell transplant,"['bryostatin 1', 'vincristine sulfate']",['2'],a phase ii studi of bryostatin 1 and vincristin in patient with low or intermedi grade nonhodgkin lymphoma progress or relaps after a prior autolog bone marrow or stem cell transplant
1112,NCT00089011,tacrolimus and mycophenol mofetil in prevent graftversushost diseas in patient who have undergon totalbodi irradi with or without fludarabin phosphat follow by donor peripher blood stem cell transplant for hematolog cancer,"['fludarabine phosphate', 'mycophenolate mofetil', 'tacrolimus']",['2'],a multicent studi of nonmyeloabl condit with tbi or fludarabinetbi for hlamatch relat hematopoiet cell transplant for treatment of hematolog malign with post graft immunosuppress with tacrolimus and mycophenol mofetil
1113,NCT00006251,fludarabin phosphate lowdos totalbodi irradiation and donor stem cell transplant follow by cyclosporine mycophenol mofetil donor lymphocyt infus in treat patient with hematopoiet cancer,"['fludarabine phosphate', 'cyclosporine', 'mycophenolate mofetil']","['1', '2']",induct of mix hematopoiet chimer in patient use fludarabine low dose tbi pbsc infus and posttranspl immunosuppress with cyclosporin and mycophenol mofetil
1117,NCT00049504,haploident donor bone marrow transplant in treat patient with highrisk hematolog cancer,"['cyclophosphamide', 'fludarabine phosphate', 'tacrolimus', 'mycophenolate mofetil']",['2'],nonmyeloabl hematopoiet stem cell transplant for patient with highrisk hematolog malign use related hlahaploident donors a phase ii trial of combin immunosuppress befor and after transplant
1118,NCT00118170,sorafenib in treat patient with metastat or unresect solid tumors multipl myeloma or nonhodgkin lymphoma with or without impair liver or kidney function,['sorafenib tosylate'],['1'],pharmacokinet and phase i studi of sorafenib bay 439006 nsc 724772 ind 69896 for solid tumor and hematolog malign in patient with hepat or renal dysfunct
1119,NCT00006473,oxaliplatin in treat patient with relaps or refractori nonhodgkin lymphoma,['oxaliplatin'],['2'],a phase ii studi of oxaliplatin in relaps and refractori nonhodgkin lymphoma
1120,NCT00068315,bortezomib and fludarabin with or without rituximab in treat patient with relaps or refractori indol nonhodgkin lymphoma or chronic lymphocyt leukemia,"['bortezomib', 'fludarabine phosphate']",['1'],a phase i trial of ps341 and fludarabin for relaps and refractori indol nonhodgkin lymphoma and chronic lymphocyt leukemia
1121,NCT00918333,panobinostat and everolimus in treat patient with recurr multipl myeloma nonhodgkin lymphoma or hodgkin lymphoma,"['panobinostat', 'everolimus']","['1', '2']",a phase iii studi of the histon deacetylas hdac inhibitor lbh589 panobinostat in combin with mtor inhibitor rad001 everolimus in patient with relaps multipl myeloma or lymphoma
1122,NCT00019708,geldanamycin analogu in treat patient with advanc solid tumor or nonhodgkin lymphoma,['tanespimycin'],['1'],a phase i and pharmacolog studi of 17allylamino17demethoxygeldanamycin aag nsc 330507 in adult patient with solid tumor
1123,NCT00060112,oblimersen and gemcitabin in treat patient with advanc solid tumor or lymphoma,['gemcitabine hydrochloride'],['1'],a phase i studi of oblimersen genasense™ g3139 in combin with gemcitabin in advanc malign
1124,NCT00101244,sb715992 in treat patient with metastat or unresect solid tumor or hodgkin or nonhodgkin lymphoma,['ispinesib'],['1'],a phase i openlabel doseescal studi of sb715992 administ day 13 of a 21day cycl in patient with solid tumor
1125,NCT00293345,3ap and gemcitabin in treat patient with advanc solid tumor or lymphoma,"['gemcitabine hydrochloride', 'triapine']",['1'],a phase i studi of a prolong infus of triapin in combin with a fix dose rate of gemcitabin in patient with advanc solid tumor and lymphoma
1126,NCT01251575,sirolimus cyclosporine and mycophenol mofetil in prevent graftversushost diseas in treat patient with blood cancer undergo donor peripher blood stem cell transplant,"['cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil', 'sirolimus']",['2'],a phase ii studi to assess immunosuppress with sirolimus combin with cyclosporin csp and mycophenol mofetil mmf for prevent of acut gvhd after nonmyeloabl hla class i or ii mismatch donor hematopoiet cell transplantation a multicent trial
1127,NCT00348985,pxd101 and bortezomib in treat patient with advanc solid tumor or lymphoma,"['belinostat', 'bortezomib']",['1'],a phase 1 studi of pxd101 in combin with bortezomib ps341 in patient with advanc solid tumor and lymphoma
1128,NCT01035463,lenalidomid mainten therapi after high dose beam with or without rituximab,"['lenalidomide', 'carmustine', 'etoposide', 'cytarabine', 'melphalan']","['1', '2']",phase iii studi of lenalidomid mainten follow beam  rituximab for chemoresist or high risk nonhodgkin lymphoma
1129,NCT01075321,everolimus and lenalidomid in treat patient with relaps or refractori nonhodgkin or hodgkin lymphoma,"['everolimus', 'lenalidomide']","['1', '2']",a phase iii clinic trial of the mtor inhibitor rad001 everolimus in combin with lenalidomid revlimid for patient with relaps or refractori lymphoid malign
1131,NCT00275080,vorinostat and decitabin in treat patient with advanc solid tumor or relaps or refractori nonhodgkin lymphoma acut myeloid leukemia acut lymphocyt leukemia or chronic myelogen leukemia,"['vorinostat', 'decitabine']",['1'],a phase 1 studi of vorinostat suberoylanilid hydroxam acid saha in combin with decitabin in patient with advanc solid tumors relaps or refractori nonhodgkin lymphoma acut myeloid leukemia acut lymphocyt leukemia or chronic myelogen leukemia in blast crisi
1132,NCT00112723,flavopiridol in treat patient with relaps or refractori lymphoma or multipl myeloma,['alvocidib'],"['1', '2']",a phase iii studi of flavopiridol administ as a 30minut bolus follow by a 4hour infus in lymphoma and multipl myeloma
1133,NCT00354185,pxd101 and 17nallylamino17demethoxygeldanamycin in treat patient with metastat or unresect solid tumor or lymphoma,"['tanespimycin', 'belinostat']",['1'],a phase i studi of pxd101 in combin with 17aag in advanc malign
1134,NCT00089271,17dmag in treat patient with metastat or unresect solid tumor or lymphoma,['alvespimycin hydrochloride'],['1'],a phase i studi of 17dimethylaminoethylamino17demethoxygeldanamycin 17dmag nsc 707545 in patient with advanc solid tumor
1135,NCT01460134,a studi of cdx1127 varlilumab in patient with select solid tumor type or hematolog cancer,['cdx-1127'],['1'],a phase 1 openlabel doseescalation safeti and pharmacokinet studi of cdx1127 in patient with select refractori or relaps hematolog malign or solid tumor
1137,NCT00098891,ms275 and isotretinoin in treat patient with metastat or advanc solid tumor or lymphoma,"['entinostat', 'isotretinoin']",['1'],a phase i studi of an oral histon deacetylas inhibitor ms275 nsc 706995 ind 61198 in combin with 13cisretino acid in metastat progress cancer
1138,NCT01529827,fludarabin phosphate melphalan and lowdos totalbodi irradi follow by donor peripher blood stem cell transplant in treat patient with hematolog malign,"['fludarabine phosphate', 'melphalan', 'tacrolimus', 'mycophenolate mofetil', 'methotrexate']",['2'],a phase ii trial of reduc intens allogen stem cell transplant with fludarabine melphalan and low dose total bodi irradi
1140,NCT01484015,prolong or standard infus of cefepim hydrochlorid in treat patient with febril neutropenia,['cefepime hydrochloride'],['1'],prolong infus compar to standard infus cefepim as empir treatment of febril neutropenia a pilot studi
1141,NCT00096005,tanespimycin and bortezomib in treat patient with advanc solid tumor or lymphoma,"['tanespimycin', 'bortezomib']",['1'],a phase i trial of 17allylaminogeldanamycin 17aag and ps341 in advanc malign
1142,NCT01384513,a twostep approach to reduc intens bone marrow transplant for patient with hematolog malign,"['fludarabine', 'busulfan', 'cyclophosphamide ', 'tacrolimus', 'mycophenolate mofetil']",['2'],a two step approach to reduc intens allogen hematopoiet stem cell transplant for patient with hematolog malign
1143,NCT00077155,cilengitid emd 121974 in treat patient with advanc solid tumor or lymphoma,['cilengitide'],['1'],a phase i studi of continu infus emd 121974 in patient with solid tumor
1145,NCT01159067,deferasirox for treat patient who have undergon allogen stem cell transplant and have iron overload,['deferasirox'],['2'],deferasirox treatment and labil plasma iron in iron overload patient who have undergon allogen hematopoiet stem cell transplant
1146,NCT00891072,gossypol paclitaxel and carboplatin in treat patient with solid tumor that are metastat or cannot be remov by surgeri,"['paclitaxel', 'carboplatin']",['1'],a phase 1 studi of rgossypol ascenta at101 in combin with paclitaxel and carboplatin in solid tumor
1149,NCT01044745,rituximab in prevent acut graftversushost diseas in patient undergo a donor stem cell transplant for hematolog cancer,"['rituximab', 'mycophenolate mofetil', 'tacrolimus', 'anti-thymocyte globulin', 'cyclophosphamide', 'fludarabine phosphate', 'busulfan']",['2'],rituximab for prevent of acut graftversushost diseas gvhd after unrel donor allogen hematopoiet cell transplant hct
1150,NCT00003970,genet test plus irinotecan in treat patient with solid tumor or lymphoma,['irinotecan hydrochloride'],['1'],a phase i clinic trial to investig the correl between ugt1a1 genotyp and irinotecan cpt11 pharmacokinet and toxic in cancer patient
1151,NCT00004241,17nallylamino17demethoxygeldanamycin in treat patient with advanc epitheli cancer malign lymphoma or sarcoma,['tanespimycin'],['1'],a phase i trial of week 17allylamino17 demethoxygeldanamycin
1154,NCT00795769,ondansetron in prevent nausea and vomit in patient undergo stem cell transplant,['ondansetron'],['2'],prevent of dmsorel nausea and vomit by prophylact administr of ondansetron for patient receiv autolog cryopreserv peripher blood stem cell
1158,NCT00054483,bortezomib in treat patient with advanc cancer and kidney dysfunct,['bortezomib'],['1'],a phase i pharmacokinet studi of ps341 in patient with advanc malign and vari degre of renal dysfunct for the ctepsponsor organ dysfunct work group
1159,NCT00489203,beclomethason dipropion in prevent acut graftversushost diseas in patient undergo a donor stem cell transplant for hematolog cancer,"['beclomethasone dipropionate', 'placebo', 'tacrolimus', 'methotrexate']",['2'],a phase ii studi to evalu the efficaci of oral beclomethason dipropion for prevent of acut gvhd after hematopoiet cell transplant with myeloabl condit regimen
1161,NCT00343798,a pilot studi to evalu the coinfus of ex vivo expand cord blood cell with an unmanipul cord blood unit in patient undergo cord blood transplant for hematolog malign,"['cyclophosphamide', 'fludarabine phosphate', 'cyclosporine', 'mycophenolate mofetil']",['1'],a pilot studi to evalu the coinfus of ex vivo expand umbil cord blood progenitor with an unmanipul cord blood graft in patient undergo umbil cord blood transplant for hematolog malign
1163,NCT00103272,17nallylamino17demethoxygeldanamycin and bortezomib in treat patient with relaps or refractori hematolog cancer,"['tanespimycin', 'bortezomib']",['1'],a phase i studi of ps341 velcade bortezomib in combin with 17allylamino17demethoxygeldanamycin 17aag in patient with relaps or refractori hematolog malign
1166,NCT00078858,mycophenol mofetil and cyclosporin in reduc graftversushost diseas in patient with hematolog malign or metastat kidney cancer undergo donor stem cell transplant,"['fludarabine phosphate', 'cyclosporine', 'mycophenolate mofetil']","['1', '2']",prolong mycophenol mofetil and truncat cyclosporin postgraft immunosuppress to reduc lifethreaten gvhd after unrel donor peripher blood cell transplant use nonmyeloabl condit for patient with hematolog malign and renal cell carcinoma  a multicent trial
1167,NCT00025415,imatinib mesyl in treat patient with advanc cancer and liver dysfunct,['imatinib mesylate'],['1'],a phase i pharmacokinet studi of sti571 in patient with advanc malign and vari level of liver dysfunct
1168,NCT00040846,alemtuzumab fludarabin phosphate and lowdos total bodi irradi befor donor stem cell transplant in treat patient with hematolog malign,"['fludarabine phosphate', 'mycophenolate mofetil', 'cyclosporine']",['2'],campath® alemtuzumab dose escalation lowdos tbi and fludarabin follow by hla class i mismatch donor stem cell transplant for patient with hematolog malign  a multicent trial
1169,NCT01953692,a trial of pembrolizumab mk3475 in particip with blood cancer mk3475013keynote013,['lenalidomide'],['1'],a phase ib multicohort trial of mk3475 pembrolizumab in subject with hematolog malign
1170,NCT00051597,a safetyefficaci studi of sgn30 antibody in patient with refractori or recurr cd30 hematolog malign,['sgn-30 '],"['1', '2']",a phase iii multidos studi of sgn30 in patient with refractori or recurr cd30 hematolog malign
1172,NCT00980304,r retreat in 1st relaps dlbcl,['rituximab'],['2'],a multicenter open label phase ii trial of rituximab in combin with ice as salvag therapi in the relaps dlbcl patient after 1st line induct treatment of 68 cycl of rchoplik chemo
1176,NCT01994382,phase 12a dose escal studi in cll sll or nhl,['cerdulatinib '],"['1', '2']",a phase 12a openlabel multidose multicent escal and exploratori studi of cerdulatinib prt062070 in patient with relapsedrefractori chronic lymphocyt leukemia cllsmall lymphocyt lymphoma sll or b cell or t cell nonhodgkin lymphoma nhl
1179,NCT01744912,ublituximab in combin with lenalidomid in patient with bcell lymphoid malign,"['ublituximab', 'lenalidomide']","['1', '2']",phase iii studi of ublituximab in combin with lenalidomid revlimid® in patient with bcell lymphoid malign who have relaps or are refractori after cd20 direct antibodi therapi
1182,NCT02532257,studi of ibrutinib in combin with rituximab and lenalidomid in previous untreat subject with follicular lymphoma and margin zone lymphoma,"['lenalidomide', 'rituximab', 'ibrutinib']",['2'],an open label phase 2 studi of ibrutinib in combin with rituximab and lenalidomid in previous untreat subject with follicular lymphoma and margin zone lymphoma
1186,NCT02337985,gene therapi and combin chemotherapi in treat patient with aidsrel nonhodgkin lymphoma,"['prednisone', 'etoposide', 'doxorubicin hydrochloride', 'vincristine sulfate', 'cyclophosphamide']",['1'],safeti and feasibl of stem cell gene transfer follow repoch for nonhodgkin lymphoma in aid patient use peripher blood stemprogenitor cell treat with a lentivirus vectorencod multipl antihiv rnas
1187,NCT01121757,epigenet modul in relapsedrefractori follicular lymphoma and margin zone lymphoma,"['azacitidine', 'lenalidomide']",['2'],a phase 2 studi evalu the efficaci of epigenet modul in relapsedrefractori follicular lymphoma and margin zone lymphoma
1189,NCT00566332,trial compar chlorambucil to fludarabin in patient with advanc waldenström macroglobulinemia,"['chlorambucil', 'fludarabine']",['3'],random trial compar the efficaci of chlorambucil to fludarabin in patient with advanc waldenström macroglobulinemialymphoplasmacyt lymphoma or splenic margin zone lymphoma
1191,NCT00117156,fludarabin and rituximab for the treatment of margin zone nonhodgkin lymphoma,"['fludarabine', 'rituximab']",['2'],a phase ii studi of fludarabin and rituximab for the treatment of margin zone nonhodgkin lymphoma
1195,NCT01921387,radiolabel monoclon antibodi and combin chemotherapi befor stem cell transplant in treat patient with highrisk lymphoid malign,"['carmustine', 'cytarabine', 'etoposide', 'melphalan']","['1', '2']",a phase iii studi evalu escal dose of 90ybc8dota anticd45 antibodi follow by beam chemotherapi and autolog stem cell transplant for highrisk lymphoid malign
1198,NCT02278796,a trial compar the two highdos chemotherapi beeam and beam given befor autolog stem cell transplant asct in lymphoma patient bebtrial,"['beeam', 'beam']",['2'],a random phase ii trial compar beeam with beam as condit regimen for autolog stem cell transplant asct in lymphoma patient bebtrial
1201,NCT02722668,ucb transplant for hematolog diseas use a non myeloabl prep,"['fludarabine', 'cyclophosphamide', 'mmf', 'sirolimus']",['2'],transplant of umbil cord blood from unrel donor in patient with hematolog diseas use a nonmyeloabl prepar regimen
1202,NCT00697346,studi of mln8237 in particip with advanc hematolog malign,['alisertib'],['1'],an openlabel phase 1 studi of mln8237 a novel aurora a kinas inhibitor in patient with advanc hematolog malign
1203,NCT01163201,tregulatori cell and cd3 deplet doubl umbil cord blood transplant in hematolog malign,"['fludarabine', 'cyclophosphamide']","['1', '2']",optim of the t regulatori cell and t effector cell dose in recipi of doubl ucb transplant for treatment of hematolog malign
1204,NCT02661035,allo hsct use ric for hematolog diseas,"['allopurinol', 'fludarabine', 'cyclophosphamide', 'atg', 'tacrolimus', 'mmf']",['2'],allogen hematopoiet stem cell transplant use reduc intens condit ric for the treatment of hematolog diseas mt201532
1205,NCT00880815,fludarabine bendamustine and rituximab in treat particip with lymphoid cancer undergo stem cell transplant,"['bendamustine', 'fludarabine', 'methotrexate', 'tacrolimus']",['1'],fludarabine bendamustine and rituximab fbr nonmyeloabl allogen condit for patient with lymphoid malign
1206,NCT01028716,donor peripher blood stem cell transplant in treat patient with hematolog malign,"['cyclophosphamide', 'fludarabine phosphate', 'mycophenolate mofetil', 'tacrolimus']",['2'],nonmyeloabl hematopoiet cell transplant hct for patient with hematolog malign use related hlahaploident donors a phase ii trial of peripher blood stem cell pbsc as the donor sourc
1208,NCT02376699,safeti studi of seacd40 in cancer patient,"['iv sea', 'pembrolizumab', 'sc sea']",['1'],a phase 1 openlabel doseescal studi of seacd40 in adult patient with advanc malign
1210,NCT01177397,studi to assess safety pharmacokinetics and efficaci of oral cc223 for patient with advanc solid tumors nonhodgkin lymphoma or multipl myeloma,['cc-223'],"['1', '2']",a phase 12 multicenter openlabel dose find studi to assess the safety tolerability pharmacokinet and preliminari efficaci of the mtor kinas inhibitor cc223 administ oral to subject with advanc solid tumors nonhodgkin lymphoma or multipl myeloma
1211,NCT00017381,monoclon antibodi therapi and peripher stem cell transplant in treat patient with nonhodgkin lymphoma,['cyclophosphamide'],['1'],dose find studi of idecy2b8 with autolog stem cell support
1213,NCT00093314,humaxcd20 in chronic lymphocyt leukemia,['humax-cd20'],"['1', '2']",an openlabeled international multicenter dose escalating phase iii trial of humaxcd20 a fulli human monoclon anticd20 antibody in patient with relaps or refractori chronic lymphocyt leukemia
1216,NCT02227108,studi in pediatr with relaps or refractori pediatr acut lymphoblast leukemia pall or lymphoblast lymphoma,['moxetumomab pasudotox'],['2'],a phase 2 multicenter singlearm studi of moxetumomab pasudotox in pediatr subject with relaps or refractori pediatr acut lymphoblast leukemia pall or lymphoblast lymphoma of bcell origin
1217,NCT01231412,graftversushost diseas prophylaxi in treat patient with hematolog malign undergo unrel donor peripher blood stem cell transplant,"['cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil', 'sirolimus']",['3'],a random phase iii studi to determin the most promis postgraft immunosuppress for prevent of acut gvhd after unrel donor hematopoiet cell transplant use nonmyeloabl condit for patient with hematolog malignancies a multicent trial
1218,NCT00789776,fludarabin phosphate cyclophosphamide totalbodi irradiation and donor bone marrow transplant follow by donor natur killer cell therapy mycophenol mofetil and tacrolimus in treat patient with hematolog cancer,"['cyclophosphamide', 'fludarabine phosphate', 'mycophenolate mofetil', 'tacrolimus']","['1', '2']",a phase iii studi evalu the safeti and efficaci of ad a singl prophylact donor lymphocyt infus dli of natur killer cell earli after nonmyeloablative hlahaploident hematopoiet cell transplant  a multi center trial
1223,NCT00075478,totalbodi irradi with or without fludarabin phosphat follow by donor stem cell transplant in treat patient with hematolog cancer,"['fludarabine phosphate', 'mycophenolate mofetil', 'cyclosporine']",['3'],a multicent phase iii studi compar nonmyeloabl condit with tbi versus fludarabinetbi for hlamatch relat hematopoiet cell transplant for treatment of hematolog malign
1224,NCT01527045,donor atorvastatin treatment in prevent sever acut gvhd after nonmyeloabl peripher blood stem cell transplant in patient with hematolog malign,"['atorvastatin calcium', 'cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']",['2'],donor statin treatment for prevent of sever acut gvhd after nonmyeloabl hematopoiet cell transplant
1225,NCT01326702,veliparib bendamustin hydrochloride and rituximab in treat patient with relaps or refractori lymphoma multipl myeloma or solid tumor,"['bendamustine hydrochloride', 'veliparib']","['1', '2']",a phase 1b2a studi of abt888 in combin with bendamustin  rituximab in lymphoma multipl myeloma and solid tumor
1228,NCT00608361,dasatinib in treat patient with solid tumor or lymphoma that are metastat or cannot be remov by surgeri,['dasatinib'],['1'],phase i pharmacokinet studi of dasatinib bms354825 nsc732517 in patient with advanc malign and vari level of liver dysfunct
1231,NCT01938001,rituximab plus lenalidomid for patient with relaps  refractori indol nonhodgkin lymphoma follicular lymphoma and margin zone lymphoma,"['rituximab', 'lenalidomide', 'placebo']",['3'],a phase 3 doubleblind random studi to compar the efficaci and safeti of rituximab plus lenalidomid cc5013 versus rituximab plus placebo in subject with relapsedrefractori indol lymphoma
1235,NCT00373906,velcad in malt lymphoma patient,['bortezomib '],['2'],phase ii trial pf bortezomib in patient with advanc or relaps lymphoma of the mucosa associ lymphoid tissu malt type
1236,NCT02424968,cd8 memori tcell as consolid therapi after donor nonmyeloabl hematopoiet cell transplant in treat patient with leukemia or lymphoma,"['cyclosporine', 'mycophenolate mofetil']",['2'],post transplant infus of allogen cd8 memori tcell as consolid therapi after nonmyeloabl allogen hematopoiet cell transplant in patient with leukemia and lymphoma
1238,NCT01500538,a pilot studi of oral vorinostat plus oral eltrombopag support in patient with lymphoma veil,"['eltrombopag', 'vorinostat']",['2'],a pilot studi of oral vorinostat plus oral eltrombopag support in patient with lymphoma veil
1239,NCT01460602,velcade nipent rituxan vnr in subject with relaps follicular margin zone and mantl cell lymphoma,"['mtd of velcade', 'nipent', 'rituxan established in part 1']","['1', '2']",phase 12 studi of velcad bortezomib nipent pentostatin and rituxan rituximab vnr in subject with relaps follicular margin zone and mantl cell lymphoma
1240,NCT02440685,a phase 12 studi to evalu asn002 in relapsedrefractori lymphoma and advanc solid tumor,"['asn002 dose escalation', 'asn002 rd']","['1', '2']",a phase 12 openlabel uncontrolled multipl dose escalation cohort expans studi to evalu the safety tolerability pharmacokinet and preliminari efficaci of asn002 in relapsedrefractori lymphoma myelofibrosis chronic lymphocyt leukemia and advanc solid tumor
1241,NCT01254578,lenalidomid after donor bone marrow transplant in treat patient with highrisk hematolog cancer,['lenalidomide'],['1'],a phase 1 studi of lenalidomid mainten follow allogen hematopoiet cell transplant in patient with select high risk hematolog malign
1242,NCT02599194,18ffspg petct for cancer patient on therapi,['fluorine f 18 l'],['2'],an exploratori studi of the role of 18ffspg petct imag for cancer patient receiv therapi
1244,NCT02208037,novel approach for graftversushost diseas prevent compar to contemporari control bmt ctn 1203,"['tacrolimus ', 'tacrolimus ', 'methotrexate ', 'methotrexate ', 'maraviroc', 'bortezomib', 'mycophenolate mofetil', 'cyclophosphamide']",['2'],a multicent phase ii trial random novel approach for graftversushost diseas prevent compar to contemporari control bmt ctn 1203 progress i
1248,NCT00933985,obatoclax mesylate vincristin sulfate doxorubicin hydrochloride and dexrazoxan hydrochlorid in treat young patient with relaps or refractori solid tumors lymphoma or leukemia,"['dexrazoxane hydrochloride', 'doxorubicin hydrochloride', 'obatoclax mesylate', 'liposomal vincristine sulfate']",['1'],a phase i studi of obatoclax pan antiapoptot bcl2 famili small molecul inhibitor in combin with vincristinedoxorubicindexrazoxane in children with relapsedrefractori solid tumor or leukemia
1251,NCT02576275,a studi of duvelisib in combin with rituximab and bendamustin vs placebo in combin with rituximab and bendamustin in subject with previouslytr indol nonhodgkin lymphoma bravura,"['duvelisib', 'placebo', 'rituximab', 'bendamustine']",['3'],a phase 3 randomized doubleblind studi of duvelisib administ in combin with rituximab and bendamustin vs placebo administ in combin with rituximab and bendamustin in subject with previouslytr indol nonhodgkin lymphoma
1252,NCT00323323,chop and campath1h in previous untreat aggress tnkcell lymphoma,"['chop', 'alemtuzumab']",['1'],a phase i studi of chop and campath1h in previous untreat aggress tnkcell lymphoma
1253,NCT00801281,firstlin rcvp vs rchop induct immunochemotherapi for indol lymphoma and r maintenance,"['rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'prednisone 1', 'prednisone 2']",['3'],firstlin rcvp vs rchop induct immunochemotherapi for indol lymphoma and r maintenancea multicentre phase iii random studi by the plrg
1254,NCT01306643,safeti and efficaci studi of idelalisib gs1101 cal101 in patient with previous treat lowgrad lymphoma,['idelalisib'],"['1', '2']",singleag idelalisib for previous treat lowgrad lymphoma a phase 12 studi of safety efficacy and flowcytometr assess of tumorcel signal event
1255,NCT00695786,lenalidomid in combin with rituximab in treat particip with stage iiiiv indol nonhodgkin lymphoma,['lenalidomide'],['2'],a phase ii studi of revlimid in combin with rituximab as initi treatment for patient with indol nonhodgkin lymphoma nhl
1257,NCT00991211,bendamustin plus rituximab versus chop plus rituximab,"['bendamustine', 'standard chemotherapy chop', 'ritiximab']",['3'],prospect randomis multicent studi for therapi optim first line of advanc progredient low malign nonhodgkin lymphoma and mantl cell lymphoma
1258,NCT00253630,vorinostat in treat patient with lowgrad nonhodgkin lymphoma,['vorinostat'],['2'],a phase ii studi of suberoylanilid hydroxam acid saha in indol nonhodgkin lymphoma
1260,NCT02258555,safety pharmacodynamics pharmacokinetics and efficaci of gs9901 in adult with relaps or refractori follicular lymphoma margin zone lymphoma chronic lymphocyt leukemia or small lymphocyt lymphoma,['gs-9901'],['1'],a phase 1b doseescal studi evalu the safety pharmacodynamics pharmacokinetics and efficaci of gs9901 in subject with relaps or refractori follicular lymphoma margin zone lymphoma chronic lymphocyt leukemia or small lymphocyt lymphoma
1261,NCT00877214,signific of durat of mainten therapi with rituximab in nonhodgkin lymphoma,"['rituximab', 'rituximab ']",['3'],prospect random multicent studi in firstlin treatment of advanc progredi follicular and other indol and mantl cell lymphoma
1262,NCT00180895,rituximab in children and adolesc with relaps and refractori bcell nhll3all,['rituximab'],['2'],a phase ii studi of mabthera rituximab in children and adolesc with relaps and refractori bcell nhll3all
1263,NCT01292135,safeti and toler studi of pci32765 combin with fludarabinecyclophosphamiderituximab fcr and bendamustinerituximab br in chronic lymphocyt leukemia cll,['pci-32765'],['1'],a phase 1b multicenter openlabel parallelgroup safeti studi of a bruton tyrosin kinas btk inhibitor pci 32765 in combin with chemotherapi in subject with chronic lymphocyt leukemiasmal lymphocyt lymphoma
1264,NCT01381692,bortezomib rituximab and dexamethason with or without temsirolimus in treat patient with untreat or relaps waldenstrom macroglobulinemia or relaps or refractori mantl cell or follicular lymphoma,"['bortezomib', 'dexamethasone', 'temsirolimus']","['1', '2']",a random phase iii studi of bortezomib rituximab dexamethason and temsirolimus in patient with relaps waldenstrom macroglobulinemia and relapsedrefractori mantl cell follicular margin zone or small lymphocyt lymphoma phase i and untreatedrelaps waldenstrom macroglobulinemia phase ii
1265,NCT00538187,obatoclax and bortezomib in treat patient with aggress relaps or recurr nonhodgkin lymphoma,"['obatoclax mesylate', 'bortezomib']",['1'],phase i studi of gx15070 nsc  729280 and bortezomib in aggress relapsedrecurr nonhodgkin lymphoma
1266,NCT00438880,agatolimod sodium rituximab and yttrium y 90 ibritumomab tiuxetan in treat patient with recurr or refractori nonhodgkin lymphoma,['agatolimod sodium'],"['1', '2']",a phase iii trial of cpg 7909 rituximab immunotherapy and y90 zevalin radioimmunotherapi for patient with previous treat cd20 nonhodgkin lymphoma
1267,NCT00711828,rituximab cyclophosphamide bortezomib and dexamethason in treat patient with relaps or refractori lowgrad follicular lymphoma waldenstrom macroglobulinemia or mantl cell lymphoma,"['bortezomib', 'cyclophosphamide', 'dexamethasone']",['2'],a phase 2 clinic trial of rituximab cyclophosphamide bortezomib velcade and dexamethason rcybord in relaps low grade and mantl cell lymphoma
1269,NCT01728207,phase i dose escal studi of immu114 in relaps or refractori nhl and cll,['immu-114'],['1'],a phase i dose escal studi of immunotherapi with immu114 in patient with nonhodgkin lymphoma nhl and chronic lymphocyt leukemia cll
1271,NCT01076543,lenalidomid and temsirolimus in treat patient with relaps or refractori hodgkin lymphoma or nonhodgkin lymphoma,"['lenalidomide', 'temsirolimus']","['1', '2']",phase iii investig of temsirolimus plus lenalidomid in relaps nonhodgkin lymphoma
1272,NCT00082888,tipifarnib in treat patient with relaps or refractori lymphoma,['tipifarnib'],['2'],phase ii evalu of fti r115777 in treatment of relaps and refractori lymphoma
1274,NCT01421524,studi of cc122 to evalu the safety tolerability and effect for patient with advanc solid tumors nonhodgkin lymphoma or multipl myeloma,['cc-122'],['1'],a phase 1a1b multicenter openlabel dose find studi to assess the safety tolerability pharmacokinet and preliminari efficaci of the pleiotrop pathway modifi cc122 administ oral to subject with advanc solid tumors nonhodgkin lymphoma or multipl myeloma
1277,NCT01231919,mk2206 in treat younger patient with recurr or refractori solid tumor or leukemia,['akt inhibitor mk2206'],['1'],a phase i studi of mk2206 an akt inhibitor in pediatr patient with recurr or refractori solid tumor or leukemia
1278,NCT01700946,therapi for pediatr relaps or refractori precursor bcell acut lymphoblast leukemia and lymphoma,"['dexamethasone', 'vincristine sulfate', 'clofarabine', 'cyclophosphamide', 'etoposide', 'pegaspargase', 'methotrexate', 'mercaptopurine', 'cytarabine', 'mitoxantrone', 'teniposide', 'vinblastine', 'therapeutic hydrocortisone']",['2'],a phase ii studi of therapi for pediatr relaps or refractori precursor bcell acut lymphoblast leukemia and lymphoma
1279,NCT00723099,donor umbil cord blood transplant in treat patient with hematolog cancer,"['cyclophosphamide', 'cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']",['2'],transplant of umbil cord blood in patient with hematolog malign use a reducedintens prepar regimen a multicent trial coordin by the fhcrc
1280,NCT00719888,umbil cord blood transplant cyclophosphamide fludarabin phosphate and totalbodi irradi in treat patient with hematolog diseas,"['cyclophosphamide', 'cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']",['2'],transplant of umbil cord blood for patient with hematolog diseas with cyclophosphamidefludarabinetot bodi irradi myeloabl prepar regimen
1281,NCT00105001,tacrolimus and mycophenol mofetil with or without sirolimus in prevent acut graftversushost diseas in patient who are undergo donor stem cell transplant for hematolog cancer,"['fludarabine phosphate', 'tacrolimus', 'mycophenolate mofetil', 'sirolimus']",['2'],a random phase ii studi to determin the most promis postgraft immunosuppress for prevent of acut gvhd after unrel donor gcsf mobil peripher blood mononuclear cell gpbmc transplant use nonmyeloabl condit for patient with hematolog malign a multicent trial
1282,NCT01232556,a studi of inotuzumab ozogamicin plus rituximab for relapsedrefractori aggress nonhodgkin lymphoma patient who are not candid for intens highdos chemotherapi,"['inotuzumab ozogamicin', 'rituximab', 'rituximab', 'gemcitabine', 'rituximab +bendamustine']",['3'],an openlabel randomized phase 3 studi of inotuzumab ozogamicin administ in combin with rituximab compar to defin investig choic therapi in subject with relaps or refractori cd22posit aggress nonhodgkin lymphoma who are not candid for intens highdos chemotherapi
1283,NCT02203526,phase 1 studi of ibrutinib and immunochemotherapi use doseadjustedtemozolomide etoposide doxil dexamethasone ibrutinibrituximab dateddir in primari cns lymphoma,"['ibrutinib', 'teddi', 'cytarabine', 'tedd']",['1'],phase 1 studi of ibrutinib and immunochemotherapi use doseadjustedtemozolomide etoposide doxil dexamethasone ibrutinibrituximab dateddir in primari cns lymphoma
1284,NCT00052923,stem cell transplant with or without rituximab in treat patient with relaps or progress bcell diffus larg cell lymphoma,"['carmustine', 'cyclophosphamide', 'etoposide']",['3'],random phase iii trial of rituximab nsc 687451 and autolog stem cell transplant for b cell diffus larg cell lymphoma
1285,NCT01300026,amg 319 lymphoid malign fih,['amg 319'],['1'],a phase 1 firstinhuman studi evalu the safety tolerability pharmacokinet and pharmacodynam of amg 319 in adult subject with relaps or refractori lymphoid malign
1290,NCT00187161,treatment of burkitt lymphomaleukemia and b larg cell nhl,"['prednison', 'vincristine', 'cytarabine', 'methotrexate', 'etoposide', 'cyclophosphamide', 'doxorubicin']",['2'],small noncleav cell sncc nonhodgkin lymphoma nhl larg cell nhl bcell and bcell acut lymphoblast leukemia ball studi ii
1293,NCT00582725,rchop  gmcsf for previous untreat lcl in elder,['r-chop+gm'],['2'],phase ii trial of rituximabchop rchop plus gmcsf for previous untreat diffus larg cell lymphoma in the elder
1296,NCT00006436,epoch and rituximab to treat nonhodgkin lymphoma in patient with hiv infect,['epoch'],['2'],shortcours epochrituximab in untreat cd20 hivassoci lymphoma
1297,NCT02669017,studi of adct402 in patient with relaps or refractori bcell lineag non hodgkin lymphoma bnhl,['adct-402'],['1'],a phase 1 doseescal studi to evalu the tolerability safety pharmacokinetics and antitumor activ of adct402 in patient with relaps or refractori bcell lineag non hodgkin lymphoma bnhl
1301,NCT01786096,a safeti studi of sgncd19a for leukemia and lymphoma,['sgn-cd19a'],['1'],a phase 1 openlabel doseescal studi of sgncd19a in patient with blineag acut lymphoblast leukemia and high aggress lymphoma
1303,NCT00691652,clofarabin and rituximab in treat patient with relaps nonhodgkin lymphoma,['clofarabine'],"['1', '2']",phase iii studi of oral clofarabin  rituximab in relaps b cell nhl
1306,NCT00471367,phase i openlabel doseescalation safeti and pk studi of azd4877,['azd4877'],['1'],a phase i openlabel multicenter doseescal studi to assess the safety toler and pharmacokinet of azd4877 administ twice a week in adult patient with advanc solid malign includ lymphoma
1308,NCT02626455,studi of copanlisib in combin with standard immunochemotherapi in relaps indol nonhodgkin lymphoma inhl,"['copanlisib ', 'placebo', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'bendamustine', 'prednisone']",['3'],a phase iii randomized doubleblind control multicent studi of intraven pi3k inhibitor copanlisib in combin with standard immunochemotherapi versus standard immunochemotherapi in patient with relaps indol nonhodgkin lymphoma inhl
1309,NCT00057811,rituximab rasburicase and combin chemotherapi in treat young patient with newli diagnos advanc bcell leukemia or lymphoma,"['doxorubicin hydrochloride', 'cyclophosphamide', 'methotrexate', 'rasburicase', 'leucovorin calcium', 'prednisone', 'methylprednisolone', 'cytarabine', 'etoposide', 'vincristine sulfate', 'hydrocortisone sodium succinate']",['2'],a pilot studi to determin the toxic of the addit of rituximab to the induct and consolid phase and the addit of rasburicas to the reduct phase in children with newli diagnos advanc bcell leukemialymphoma treat with lmbfab therapi
1311,NCT02685670,competit transfer of αcd19tcrzcd28 and αcd19tcrzcd137 cart cell for bcell leukemialymphoma,"['fludarabine', 'cyclophosphamide']","['1', '2']",a phase iii studi of competit transfer of αcd19tcrzcd28 and αcd19tcrzcd137 chimer antigen receptor tcell in patient with refractori cd19 blineag leukemialymphoma
1317,NCT01105247,safeti of pci32765 in chronic lymphocyt leukemia,['pci-32765'],"['1', '2']",a phase 1b2 fixeddos studi of bruton tyrosin kinas btk inhibitor pci32765 in chronic lymphocyt leukemia
1319,NCT00275431,phase ii safeti and efficaci studi of singleag at101 in patient with relaps or refractori bcell malign,['at-101'],['2'],a phase ii open label multicent studi of singleag at101 in patient with relaps or refractori bcell malign follicular lymphoma mantl cell lymphoma diffus larg cell lymphoma or small lymphocyt lymphomachron lymphocyt leukemia
1320,NCT00003163,peripher stem cell transplant in treat patient with multipl myeloma or other bcell cancer,"['cyclophosphamide', 'melphalan']",['2'],myelobl therapi with autolog hematopoiet stem cell transplant in patient with multipl myeloma and bcell malign
1321,NCT00295932,bortezomib rituximab cyclophosphamide and prednison in treat patient with relaps or refractori indol nonhodgkin lymphoma,"['bortezomib', 'cyclophosphamide', 'prednisone']","['1', '2']",a phase ii studi of the novel proteasom inhibitor bortezomib in combin with rituximab cyclophosphamid and prednison in patient with relapsedrefractori indol bcell lymphoprolif disord and mantl cell lymphoma mcl
1322,NCT00004086,radiolabel monoclon antibody combin chemotherapy and peripher stem cell transplant in treat patient with recurr or refractori bcell cancer,"['cisplatin', 'cytarabine', 'etoposide', 'ifosfamide']",['1'],a phase i trial of a combin regimen of chemotherapi and 90ylabeled human ll2 anticd22 antibodi with peripher stem cell rescu for the treatment of relaps or refractori nonhodgkin lymphoma
1323,NCT01686165,belinostat and yttrium y 90 ibritumomab tiuxetan in patient wrelaps aggress bcell nhl,['belinostat'],['2'],a phase ii exploratori studi of pxd101belinostat follow by zevalin in patient with relaps aggress highrisk lymphoma
1324,NCT02454270,a dose escal studi of duvortuxizumab in particip with relaps or refractori bcell malign,"['part 1 ', 'part 2 ']",['1'],a phase 1 firstinhuman openlabel dose escal studi of duvortuxizumab a human cd19 x cd3 dualaffin retarget dart® protein in subject with relaps or refractori bcell malign
1328,NCT00837174,relaps andor refractori nonhodgkin lymphoma studi,['vorinostat in combination with bortezomib'],['2'],phase ii studi of combin vorinostat and bortezomib in patient with relaps andor refractori nonhodgkin lymphoma
1329,NCT00058461,combin chemotherapi and rituximab in treat young patient with recurr or refractori nonhodgkin lymphoma or acut lymphoblast leukemia,"['ifosfamide', 'etoposide', 'carboplatin', 'methotrexate', 'cytarabine']",['2'],a phase ii studi of rituximab ind 7028 and ifosfamide carboplatin and etoposid ice chemotherapi in children with recurrentrefractori bcell cd20 nonhodgkin lymphoma and bcell acut lymphoblast leukemia
1330,NCT02733042,a studi to determin dose safety and efficaci of durvalumab as monotherapi and in combin therapi in subject with lymphoma or chronic lymphocyt leukemia,"['durvalumab', 'lenalidomide', 'rituximab', 'ibrutinib', 'bendamustine']","['1', '2']",a phase 12 openlabel multicent studi to assess the safeti and toler of durvalumab antipdl1 antibody as monotherapi and in combin therapi in subject with lymphoma or chronic lymphocit leukemia
1332,NCT02181218,phase i studi of romidepsin gemcitabine oxaliplatin and dexamethason in patient with relapsedrefractori aggress lymphoma,"['romidepsin', 'gemcitabine', 'oxaliplatin', 'dexamethasone', 'pegfilgrastim']",['1'],a multicent phase i dosefind and preliminari efficaci studi of the histon deacetylas inhibitor romidepsin istodax in combin with gemcitabin gemzar oxaliplatin eloxatin and dexamethason for the treatment of adult with relapsedrefractori aggress lymphoma
1333,NCT00100737,compar interleukin2 il2 combin with rituximab rituxan to rituximab alon in subject with nonhodgkin lymphoma nhl,"['interleukin-2', 'rituximab']",['2'],a phase 2 randomized openlabel control trial of the addit of 8 week sc administr of aldesleukin rhinterleukin2 il2 to 4 week of iv administr of rituximab in the treatment of rituximab naïv subject with follicular nonhodgkin lymphoma refractori or relaps after previous chemotherapi
1334,NCT00199082,trial for the treatment of newli diagnos matur bcell acut lymphoblast leukemia ball burkitt nonhodgkin lymphoma nhl and other highgrad lymphoma in adult,"['adriamycin', 'cyclophosphamide', 'cytarabine', 'dexamethasone', 'vp16', 'ifosfamide', 'methotrexate', 'g-csf', 'rituximab', 'vincristine']",['4'],multicent studi to optimis therapi of ball burkitt nhl and highgrad nonhodgkin lymphoma in adult amend 7
1337,NCT00289562,forodesin hydrochlorid bcx1777 for bcell acut lymphoblast leukemia,['forodesine hydrochloride '],"['1', '2']",a phase iii multicenter openlabel repeatdos studi of forodesin hydrochlorid infus in patient with bcell acut lymphoblast leukemia with an option of extend use of forodesin hydrochlorid
1340,NCT00003151,antibiot therapi in treat patient with low grade gastric lymphoma,"['amoxicillin', 'clarithromycin', 'metronidazole hydrochloride', 'omeprazole', 'tetracycline hydrochloride']",['2'],a phase ii clinic trial of antihelicobact pylori treatment in endoscop diagnos lowgrad local gastric lymphoma
1342,NCT00126646,bl22 immunotoxin in treat patient with refractori chronic lymphocyt leukemia prolymphocyt leukemia or nonhodgkin lymphoma,['bl22 immunotoxin'],['1'],phase i studi of bl22 a recombin immunotoxin for chronic lymphocyt leukemia and cd22 lymphoma
1346,NCT01860937,tlymphocyt genet target to the bcell specif antigen cd19 in pediatr and young adult patient with relaps bcell acut lymphoblast leukemia,['cyclophosphamide based chemotherapy regimens'],['1'],a phase i trial of tlymphocyt genet target to the bcell specif antigen cd19 in pediatr and young adult patient with relaps bcell acut lymphoblast leukemia
1347,NCT00052416,thalidomid in treat patient with asymptomatic indol nonhodgkin lymphoma or chronic lymphocyt leukemia,['thalidomide'],['1'],thalidomid in indol nonhodgkin lymphoma a feasibl studi
1349,NCT00005580,bryostatin  fludarabin in treat patient with chronic lymphocyt leukemia or relaps indol nonhodgkin lymphoma,"['bryostatin 1', 'fludarabine phosphate']",['1'],phase i studi of bryostatin 1 nsc 339555 and fludarabin in patient with chronic lymphocyt leukemia and indol nonhodgkin lymphoma
1350,NCT00002908,bryostatin 1 in treat patient with relaps nonhodgkin lymphoma or chronic lymphocyt leukemia,"['bryostatin 1', 'vincristine sulfate']",['2'],phase ii clinic evalu of bryostatin 1 in patient with relaps nonhodgkin lymphoma and cll
1351,NCT00006252,fludarabin and cyclophosphamid follow by peripher stem cell transplant in treat patient with leukemia or lymphoma,"['fludarabine phosphate', 'cyclophosphamide', 'g-csf']",['2'],minim ablat and cellular immun therapi of chronic lymphocyt leukemia prolymphocyt leukemia lowgrad nonhodgkin lymphoma and mantl cell lymphoma with allogen donor stem cell
1354,NCT00671112,everolimus and bortezomib in treat patient with relaps or refractori lymphoma,"['bortezomib', 'everolimus']",['1'],a phase 1 trial of the combin of everolimus rad001 and bortezomib velcade for relaps or refractori lymphoma
1355,NCT01181271,tandem autoallo transplant for lymphoma,"['busulfan ', 'etoposide ', 'cyclophosphamide ', 'mesna ', 'neupogen', 'fludarabine ', 'busulfan ', 'tacrolimus', 'sirolimus', 'methotrexate']",['2'],sequenti myeloabl autolog stem cell transplant follow by allogen nonmyeloabl stem cell transplant for patient with poor risk lymphoma
1357,NCT00511043,ptk787 in refractori or relaps diffus larg cell lymphoma,['ptk787'],['2'],phase ii open label studi of ptk787zk222584 in adult patient with refractori or relaps diffus larg cell lymphoma
1359,NCT02216890,safeti studi of sgncd70a in cancer patient,['sgn-cd70a'],['1'],a phase 1 trial of sgncd70a in patient with cd70posit malign
1363,NCT00962507,panobinostat and everolimus in treat patient with relaps or refractori lymphoma or multipl myeloma,"['everolimus', 'panobinostat']",['1'],a phase i studi evalu the combin of the deacetylas inhibitor lbh589 plus the mtor inhibitor rad001 in relaps and refractori adult patient with lymphoma
1365,NCT00101205,oxaliplatin ifosfamid and etoposid in treat young patient with recurr or refractori solid tumor or lymphoma,"['oxaliplatin', 'etoposide']",['1'],a phase i trial of the combin of oxaliplatin nsc 266046 ind 57004 ifosfamide and etoposid in recurr or refractori pediatr solid tumor and lymphoma
1366,NCT02432235,studi of adct301 in patient with relaps or refractori hodgkin and nonhodgkin lymphoma,['adct-301'],['1'],a phase 1 adapt doseescal studi to evalu the tolerability safety pharmacokinetics and antitumor activ of adct301 in patient with relaps or refractori hodgkin lymphoma and nonhodgkin lymphoma
1367,NCT00612716,donor stem cell transplant in treat patient with previous treat lymphoma multipl myeloma or chronic lymphocyt leukemia,"['busulfan', 'cyclophosphamide']",['2'],unrel or partial match allogen donor stem cell for lymphoma myeloma and chronic lymphocyt leukemia
1369,NCT00474929,sorafenib and everolimus in treat patient with relaps or refractori lymphoma or multipl myeloma,"['rad001', 'sorafenib']","['1', '2']",a phase iii studi of the raf kinasevegfr inhibitor sorafenib in combin with the mtor inhibitor rad001 everolimus in patient with relaps nonhodgkin lymphoma hodgkin lymphoma or multipl myeloma
1371,NCT01609816,dasatinib for modul immun system after autolog stem cell transplant for multipl myeloma nonhodgkin or hodgkin lymphoma,['dasatinib'],"['1', '2']",phase iii studi of dasatinib in recipi of autolog stem cell transplant for hematolog malignancies
1372,NCT00470405,pemetrex and oxaliplatin in treat patient with metastat solid tumor or lymphoma,"['oxaliplatin', 'pemetrexed disodium']",['1'],a phase i studi of alimta plus oxaliplatin administ everi other week in the treatment of patient with metastat cancer
1373,NCT02167360,studi of efficaci and safeti of ctl019 in adult all patient,['ctl019'],['2'],a phase ii singl arm multicent trial to determin the efficaci and safeti of ctl019 in adult patient with relaps and refractori bcell acut lymphoblast leukemia
1375,NCT00734890,vandetanib and bevacizumab in treat patient with advanc solid tumor or lymphoma,['vandetanib'],['1'],phase i studi of vandetanib zd 6474 and bevacizumab combin therapi evalu the vegf and egf signal transduct pathway in adult with solid tumor and lymphoma
1379,NCT00646139,kx2391 in treat patient with advanc solid tumor or lymphoma that did not respond to treatment,['src kinase inhibitor kx2'],['1'],a combin rise singledos rsd and rise multipledos rmd phase 1 studi to evalu safety toler and pharmacokinet of kx2391 in patient with advanc malign that are refractori to convent therapi
1380,NCT00048737,safeti and efficaci of 90i zevalin in nonmyeloabl transplant for lymphoid malign,"['zevalin radioimmunotherapy', 'rituximab', 'fludarabine', 'cyclophosphamide']","['1', '2']",safeti and efficaci of 90i zevalin in nonmyeloabl transplant for lymphoid malign
1382,NCT00003166,bryostatin and vincristin in bcell malign,"['bryostatin 1', 'vincristine sulfate']",['1'],a phase i trial of combin bryostatin 1 nsc 339555 and vincristin in bcell malign
1383,NCT01643603,dasatinib for immun modul after donor stem cell transplant for hematolog malign,['dasatinib'],"['1', '2']",phase iii studi of dasatinib in recipi of allogen stem cell transplant for hematolog malignancies
1387,NCT00818961,donor stem cell transplant in treat patient with highrisk hematolog cancer,"['busulfan', 'cyclophosphamide', 'fludarabine phosphate', 'methotrexate', 'tacrolimus']",['2'],reduc intens allogen stem cell transplant with match unrel donor for patient with hematolog malign
1390,NCT01118013,donor stem cell transplant in treat patient with relaps hematolog malign or secondari myelodysplasia previous treat with highdos chemotherapi and autolog stem cell transplant,"['busulfan', 'fludarabine phosphate', 'methotrexate', 'mycophenolate mofetil', 'tacrolimus']",['2'],reducedintens allogen hematopoiet cell transplant as second transplant for patient with diseas relaps or myelodysplasia after prior autolog transplant
1393,NCT01116232,sirolimus tacrolimus thymoglobulin and rituximab as graftversushostdiseas prophylaxi in patient undergo haploident and hla partial match donor hematopoiet cell transplant,"['sirolimus', 'tacrolimus']",['2'],a pilot phase ii studi of sirolimus tacrolimus thymoglobulin and rituximab as graftversushostdiseas prophylaxi in patient undergo haploident and hla partial match donor hematopoiet cell transplant
1394,NCT01101412,antimicrobi solut or salin solut in maintain cathet patenc and prevent catheterrel blood infect in patient with malign,"['edetate calcium disodium', 'ethanol', 'trimethoprim-sulfamethoxazole']","['1', '2']",multicenter prospective randomized doubleblinded control clinic trial to evalu the safeti and effect of an antimicrobi cathet lock solut in maintain cathet patenc and prevent cathet relat blood stream infect crbsi
1395,NCT00827099,umbil cord blood ucb transplant fludarabine melphalan and antithymocyt globulin atg in treat patient with hematolog cancer,"['fludarabine phosphate', 'melphalan', 'mycophenolate mofetil', 'tacrolimus']",['2'],transplant of two partial match umbil cord blood unit follow reduc intens condit to enhanc engraft and limit transplantrel mortal in adult with hematolog malign
1396,NCT00799136,a feasibl studi of coadminist combin antiretrovir therapi cart and repoch chemotherapi for the manag of arl,"['r-epoch', 'cart']",['2'],feasibl studi of coadminist combin antiretrovir therapi cart and repoch chemotherapi for the manag of acquir immunodefici syndrom aidsrel lymphoma
1403,NCT00800150,total marrow and total lymph node irradiation fludarabine and melphalan follow by donor stem cell transplant in treat patient with advanc hematolog cancer that has not respond to treatment,"['fludarabine phosphate', 'melphalan']",['1'],phase i studi of escal dose of radiat therapi use helic tomotherapi in combin with fludarabin flu and melphalan mel as a prepar regimen for allogen hematopoiet stem cell hsc transplant in patient with advanc and hematolog malign who are not elig for fulli myeloabl regimen
1405,NCT02215629,dose escal studi in acut myeloid or bcell acut lymphoblast leukemia,['vs-4718'],['1'],a phase i dose escal studi of vs4718 a focal adhes kinas inhibitor in subject with relaps or refractori acut myeloid leukemia or bcell acut lymphoblast leukemia
1412,NCT00719563,american ginseng in treat patient with fatigu caus by cancer,['american ginseng'],['3'],the use of american ginseng panax quinquefolius to improv cancerrel fatigue a randomized doubleblind placebocontrol phase iii studi
1414,NCT01316744,ketamin hydrochlorid and best pain manag in treat cancer patient with neuropath pain,['ketamine hydrochloride'],['3'],a random doubleblind control trial of ketamin versus placebo in conjunct with best pain manag in neuropath pain in cancer patient
1416,NCT00589563,sirolimus tacrolimus and antithymocyt globulin in prevent graftversushost diseas in patient undergo a donor stem cell transplant for hematolog cancer,"['cyclophosphamide', 'etoposide', 'fludarabine phosphate', 'melphalan', 'methotrexate', 'sirolimus', 'tacrolimus']",['2'],a phase ii studi of sirolimus tacrolimus and thymoglobulin as graftversushost prophylaxi in patient undergo unrel donor hematopoiet cell transplant
1417,NCT00383565,fr901228 in treat patient with relaps or refractori nonhodgkin lymphoma,['romidepsin'],['2'],a phase ii studi of depsipeptide a histon deacetylas inhibitor in relaps or refractori mantl cell or diffus larg cell nonhodgkin lymphoma
1419,NCT01685021,studi of fcoptim anticd19 antibodi mor00208 to treat bcell acut lymphoblast leukemiaball,['mor00208 '],['2'],a phase iia singlearm openlabel studi of mor00208 a human fcengin anticd19 antibody in patient with relapsedrefractori bcell acut lymphoblast leukemia ball
1421,NCT00006362,ps341 in treat patient with advanc cancer,['bortezomib'],['1'],a phase i and pharmacolog studi of the proteasom inhibitor ps341 in patient with advanc solid tumor and bcell lymphoprolif disord
1422,NCT00237627,doxorubicin hydrochlorid liposom and bortezomib in treat patient with refractori hematolog cancer or malign solid tumor or metastat breast cancer,"['ps-341', 'doxil', 'velcade']","['1', '2']",a phase i evalu of the combin of pegyl liposom doxorubicin doxil® with ps341 in patient with refractori hematolog and solid malign
1424,NCT00001237,pilot protocol for the treatment of patient with small noncleav and diffus larg cell lymphoma,['granulocyte-macrophage colony stimulating factor '],['2'],pilot protocol for the treatment of patient with small noncleav and diffus larg cell lymphoma
1431,NCT00293488,sl11047 in treat patient with relaps or refractori lymphoma,['polyamine analogue pg11047'],['1'],an open label phase i studi evalu safety toler and pharmacokinet of sl11047 in patient with refractori lymphoma
1432,NCT00081809,a safeti and effect studi of vaccin therapi in patient with indol lymphoma,['autologous human tumor'],['2'],a phase ii trial of activ specif immunotherapi in patient with indol lymphoma use autolog lymphomaderiv heat shock proteinpeptid complex hsppc96
1436,NCT00002829,bone marrow transplant in treat patient with lymphoma,"['cyclophosphamide', 'etoposide', 'mesna']",['2'],autolog and allogen bone marrow transplant for low grade lymphoma
1437,NCT01429025,rituximab bendamustin hydrochloride and lenalidomid in treat patient with refractori or relaps indol nonhodgkin lymphoma,"['bendamustine', 'lenalidomide']",['1'],a pilotfeas phase i studi of bendamustine rituximab and lenalidomid in patient with refractoryrelaps indol nhl
1438,NCT00784927,lenalidomide rituximab cyclophosphamide and dexamethason in treat patient with previous untreat lowgrad nonhodgkin lymphoma,"['cyclophosphamide', 'dexamethasone', 'lenalidomide']",['2'],a phase 2 studi of lenalidomide rituximab cyclophosphamid and dexamethason lrcd for untreat low grade nonhodgkin lymphoma requir therapi
1441,NCT00720876,vorinostat and rituximab in treat patient with indol nonhodgkin lymphoma,['vorinostat'],['2'],a phase ii studi of vorinostat suberoylanilid hydroxam acid plus rituximab in indol nonhodgkin lymphoma
1443,NCT00381680,lowdos or highdos vincristin and combin chemotherapi in treat young patient with relaps bcell acut lymphoblast leukemia,"['vincristine sulfate', 'prednisone', 'doxorubicin hydrochloride', 'pegaspargase', 'cytarabine', 'methotrexate', 'dexamethasone', 'etoposide', 'cyclophosphamide', 'leucovorin calcium', 'asparaginase', 'mercaptopurine']",['3'],intens treatment for intermediaterisk relaps of childhood bprecursor acut lymphoblast leukemia all a random trial of vincristin strategi
1444,NCT01207388,confirmatori phase ii studi of blinatumomab mt103 in patient with minim residu diseas of bprecursor acut lymphoblast leukemia all,['blinatumomab'],['2'],a confirmatori multicenter singlearm studi to assess the efficacy safety and toler of the bite® antibodi blinatumomab in adult patient with minim residu diseas mrd of bprecursor acut lymphoblast leukemia blast
1445,NCT01307267,a studi of pf05082566 as a singl agent and in combin with rituximab,"['pf-05082566', 'rituximab']",['1'],a phase 1 studi of pf05082566 as a singl agent in patient with advanc cancer and in combin with rituximab in patient with nonhodgkin lymphoma nhl
1446,NCT02721407,anticd22 cart therapi for cd19refractori or resist lymphoma patient,['retroviral vector'],['1'],a phase i studi of anticd22tcrz41bb tcell in patient with cd22posit recurr lymphoma that is resist or refractori to prior anticd22tcrzcd28 immunotherapi
1448,NCT02303392,selinexor and ibrutinib in treat patient with relaps or refractori chronic lymphocyt leukemia or aggress nonhodgkin lymphoma,"['selinexor', 'ibrutinib']",['1'],a dose escal studi of selinexor kpt330 a select inhibitor of nuclear export and ibrutinib a bruton tyrosin kinas inhibitor in patient with relaps and refractori chronic lymphocyt leukemia or aggress nonhodgkin lymphoma
1449,NCT00278161,rituximab cyclophosphamide and pegfilgrastim in treat patient with leukemia or nonhodgkin lymphoma,['cyclophosphamide'],['2'],phase ii studi of high dose cyclophosphamid and rituximab in low grade and mantl cell lymphoma
1450,NCT00589381,fenretinid lymxsorb™ in treat patient with recurr or resist solid tumor or lymphoma,['fenretinide lipid matrix'],['1'],phase i trial of fenretinid 4hpr nsc 374551 lymxsorb™ lxs oral powder 4hprlxs oral powder 4hpr in adult with solid tumor and lymphoma
1451,NCT00392691,melphalan yttrium y 90 ibritumomab tiuxetan and rituximab follow by autolog stem cell transplant in treat older patient with nonhodgkin lymphoma that has relaps or not respond to previous treatment,"['ibritumomab tiuxetan', 'rituximab', 'melphalan', 'vinorelbine tartrate ']",['1'],ibritumomab tiuxetan and highdos melphalan as condit regimen befor autolog stem cell transplant for elder patient with lymphoma in relaps or resist to chemotherapy a multicent phase i trial
1452,NCT01719250,buparlisib in treat patient with relaps or refractori nonhodgkin lymphoma,['buparlisib'],['1'],a pilot studi of the pi3k inhibitor bkm120 in patient with relaps lymphoma
1454,NCT00551239,fludarabin and rituximab with or without pixantron in treat patient with relaps or refractori indol nonhodgkin lymphoma,"['fludarabine phosphate', 'pixantrone dimaleate']",['3'],a random phase iii trial compar the combin of fludarabine bbr 2778 pixantrone and rituximab fpr with the combin of fludarabin and rituximab fr in the treatment of patient with relaps or refractori indol nonhodgkin lymphoma
1455,NCT00238433,busulfan melphalan and thiotepa in treat patient who are undergo an autolog stem cell transplant for hodgkin or nonhodgkin lymphoma,"['busulfan', 'melphalan', 'thiotepa']",['2'],a phase ii studi to evalu the safeti and efficaci of iv busulfan melphalan and thiotepa bumeltt follow by autolog pbsc infus for patient with hodgkin diseas and nonhodgkin lymphoma
1457,NCT00436618,everolimus in treat patient with lymphoma that has relaps or not respond to previous treatment,['everolimus'],['2'],phase ii trial of everolimus rad001 in relapsedrefractori lymphoma
1459,NCT00278382,sorafenib in treat patient with recurr nonhodgkin lymphoma,['sorafenib tosylate'],['2'],a phase 2 studi of bay 439006 ind 69896 in chemosensit relaps aggress nonhodgkin lymphoma
1461,NCT00002779,fludarabin plus octreotid in treat patient with relaps lowgrad nonhodgkin lymphoma,"['fludarabine phosphate', 'octreotide acetate']",['2'],phase ii trial of fludarabin and sandostatin for relaps lowgrad nonhodgkin lymphoma
1462,NCT00003663,rituximab and dexamethason in treat patient with recurr or refractori indol nonhodgkin lymphoma,['dexamethasone'],['2'],rituximab anticd20 monoclon antibodi and dexamethason in the treatment of relaps indol lymphoma
1463,NCT00003605,rituximab plus cyclophosphamid in treat patient with indol stage iii or stage iv nonhodgkin lymphoma,['cyclophosphamide'],['2'],rituximab anticd20 monoclon antibodi plus oral cyclophosphamid as initi treatment of indol lymphoma
1464,NCT00002725,bryostatin1 in treat patient with recurr nonhodgkin lymphoma,"['bryostatin 1', 'chemotherapy']",['2'],phase ii evalu of bryostatin1 nsc 339555 in nonhodgkin lymphoma
1465,NCT00183976,pegyl liposom doxorubicin doxil with rituximab in relaps aidsrel nonhodgkin lymphoma,['pegylated liposomal doxorubicin '],['2'],a pilot phase ii studi of pegyl liposom doxorubicin doxil with rituximab in relaps aidsrel nonhodgkin lymphoma
1467,NCT00005613,peripher stem cell transplant in treat patient with nonhodgkin lymphoma or hodgkin diseas,"['cyclophosphamide', 'etoposide', 'bcnu']",['2'],a prospective compar trial of allogen versus autolog stem cell transplant for high risk lymphoma
1468,NCT00003639,combin chemotherapi with or without interferon alfa in treat patient with lowgrad nonhodgkin lymphoma,"['chlorambucil', 'dexamethasone', 'idarubicin']",['3'],randomis control trial of cid chlorambucil idarubicin dexamethasone versus cd chlorambucil dexamethasone for induct of remiss in low grade nonhodgkin lymphoma kiel classification follow by randomis control assess of standard dose interferon versus low dose interferon versus no further therapi as mainten treatment after remiss induct
1469,NCT00003143,combin chemotherapi with or without amifostin in treat patient with recurr or refractori nonhodgkin lymphoma or hodgkin diseas undergo stem cell transplant,"['amifostine', 'dhap']",['2'],a random studi of ethyol amifostine with platinum base salvag chemotherapi in patient with lymphoma undergo autolog stem cell transplant
1471,NCT00004112,combin chemotherapi with or without rituximab in treat patient with newli diagnos nonhodgkin lymphoma,"['chop regimen', 'cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['3'],a phase iii random trial of chop chemotherapi plus rituxan idecc2b8 versus chop chemotherapi alon for newli diagnosed previous untreated aggress nonhodgkin lymphoma
1472,NCT00002481,combin chemotherapi and radiat therapi plus bone marrow transplant in treat patient with relaps or refractori nonhodgkin lymphoma,"['cisplatin', 'cyclophosphamide', 'cytarabine', 'dexamethasone', 'etoposide']",['2'],phase ii studi of highdos cytarabine cisplatin and dexamethason follow by cyclophosphamide etoposide total bodi irradiation and autolog bone marrow rescu in patient with relaps or refractori nonhodgkin lymphoma
1474,NCT00021372,paclitaxel and estramustin in treat patient with relaps or refractori nonhodgkin lymphoma,"['estramustine phosphate sodium', 'paclitaxel']",['2'],phase ii studi of paclitaxel and estramustin phosphat in patient with relaps nonhodgkin lymphoma
1477,NCT00007852,rituximab and combin chemotherapi follow by bone marrow or peripher stem cell transplant in treat patient with relaps or refractori nonhodgkin lymphoma,"['carmustine', 'cytarabine', 'etoposide', 'melphalan']",['2'],a phase ii trial of rituxan and beam highdos chemotherapi and autolog peripher blood progenitor transplant for lymphoma
1480,NCT00109824,decitabin with or without valproic acid in treat patient with relaps or refractori nonhodgkin lymphoma,"['decitabine', 'valproic acid']",['1'],a phase i studi of decitabin in combin with valproic acid in patient with relapsedrefractori nonhodgkin lymphoma
1482,NCT00003245,irinotecan in treat patient with recurr or refractori nonhodgkin lymphoma,['irinotecan hydrochloride'],['2'],phase ii studi of irinotecan for the treatment of relaps or refractori nonhodgkin lymphoma
1483,NCT00004908,radiat therapi and cyclophosphamid plus peripher stem cell transplant in treat patient with recurr or refractori hodgkin diseas or nonhodgkin lymphoma,['cyclophosphamide'],['2'],autolog blood stem cell transplant in patient with hodgkin diseas and nonhodgkin lymphoma with highdos cyclophosphamide total bodi irradi and involvedfield radiat therapi
1485,NCT00390117,at7519m in treat patient with advanc or metastat solid tumor or refractori nonhodgkin lymphoma,['cdki at7519'],['1'],a phase i studi of at7519m given twice week in patient with advanc incur malign
1486,NCT00443976,aurora kinas inhibitor at9283 in treat patient with advanc or metastat solid tumor or nonhodgkin lymphoma,['aurora kinase inhibitor at9283'],['1'],a phase i studi of at9283 given as a 24 hour infus on day 1 and 8 everi three week in patient with advanc incur malign
1487,NCT00008021,monoclon antibodi therapy chemotherapy and peripher stem cell transplant in treat patient with refractori nonhodgkin lymphoma,"['cyclosporine', 'paclitaxel']",['1'],a phase i studi of 90ydotapeptidelym1 with peripher blood stem cell support paclitaxel and cyclosporin a in patient with nonhodgkin lymphoma
1488,NCT00005998,peripher stem cell transplant with special treat stem cell in treat patient with nonhodgkin lymphoma or hodgkin diseas,"['carmustine', 'cyclophosphamide', 'cytarabine', 'dexamethasone', 'etoposide', 'filgrastim', 'mitoxantrone hydrochloride', 'retrovirus vector ln']",['2'],autolog transplant for nonhodgkin lymphoma and hodgkin diseas use retrovir mark peripher blood progenitor cell obtain after in vivo mobil use hematopoiet cytokin plus chemotherapi
1489,NCT00352443,s0528 lapatinib and everolimus in treat patient with advanc solid tumor or nonhodgkin lymphoma,"['everolimus', 'lapatinib ditosylate']",['1'],phase i studi evalu the combin of lapatinib gw572016 nsc727989 and everolimus rad001 in patient with advanc solid tumor
1491,NCT00009776,monoclon antibodi therapy paclitaxel and cyclosporin in treat patient with recurr or refractori nonhodgkin lymphoma,"['cyclosporine', 'paclitaxel']",['1'],combin modal radioimmunotherapi for nonhodgkin lymphoma with three cycl of 90ydotapeptidelym1 paclitaxel and cyclosporin a
1492,NCT00002697,combin chemotherapi plus radiat therapi follow by peripher stem cell transplant in treat patient with nonhodgkin lymphoma,"['carboplatin', 'etoposide', 'ifosfamide']",['2'],high dose chemoradiotherapi with peripher blood progenitor cell transplant for patient with primari refractory relaps and poor prognosi nonhodgkin lymphoma
1493,NCT00052936,combin chemotherapi with or without rituximab in treat older patient with nonhodgkin lymphoma,"['chop regimen', 'cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['3'],randomis studi compar 6 and 8 cycl of chemotherapi with chop  cyclophosphamide doxorubicin vincristin and prednisone at 14day interv chop14 both with or without the monoclon anticd20 antibodi rituximab in patient age 61 to 80 year with aggress nonhodgkin lymphoma
1494,NCT00004192,colonystimul factor to reliev neutropenia in patient with recurr nonhodgkin lymphoma,"['cisplatin', 'cytarabine', 'etoposide', 'methylprednisolone']",['2'],a randomized multicenter openlabel studi of singl dose filgrastimsd01 versus daili filgrastim follow eshap chemotherapi for nonhodgkin lymphoma
1495,NCT00005993,biolog therapi follow peripher stem cell transplant in treat patient with nonhodgkin lymphoma hodgkin disease or advanc breast cancer,"['aldesleukin', 'filgrastim', 'recombinant human stem cell factor']",['1'],immunotherapi with subcutan il2 and stem cell factor scf for patient with lymphoma or breast cancer after autolog transplant
1496,NCT00057954,reducedintens regimen befor allogen transplant for patient with relaps nonhodgkin or hodgkin lymphoma,"['pentostatin', 'cyclosporin ', 'mycophenolate mofetil ', 'methotrexate ']",['2'],a phase ii studi of reduc intens allogen bone marrow transplant for the treatment of relaps nonhodgkin and hodgkin lymphoma
1500,NCT00006373,combin chemotherapi follow by bone marrow or peripher stem cell transplant in treat patient with nonhodgkin lymphoma or hodgkin lymphoma,"['etoposide', 'ifosfamide', 'topotecan hydrochloride', 'mesna']",['2'],a phase ii studi of intensivedos topotecan ifosfamidemesna and etoposid vepesidtime follow by autolog stem cell rescu in high risk lymphoma
1501,NCT00003414,graftversushost diseas in treat patient with recurr or refractori lymphoma or hodgkin diseas,"['busulfan', 'cyclophosphamide', 'cyclosporine']",['3'],random trial of autolog gvhd for refractori lymphoma
1504,NCT00045500,ucn01 and prednison in treat patient with solid tumor or lymphoma,"['7-hydroxystaurosporine', 'prednisone']",['1'],a phase i trial of ucn01 and prednison in patient with refractori solid tumor and lymphoma
1506,NCT00088868,17dimethylaminoethylamino17demethoxygeldanamycin 17dmag in treat patient with an advanc solid tumor or lymphoma,['alvespimycin hydrochloride'],['1'],a phase i studi of 17dimethylaminoethylamino17demethoxygeldanamycin 17dmag with evalu of hsp90 client protein in subject with solid tumor and lymphoma
1508,NCT00791011,phase 1b lymphoma studi of amg 655 in combin with bortezomib or vorinostat,['amg 655'],['1'],a phase 1b studi to evalu the safeti and toler of amg 655 in combin with bortezomib or vorinostat in subject with relaps or refractori lymphoma
1509,NCT00002552,chemotherapi plus bone marrow transplant in treat patient with refractori nonhodgkin lymphoma hodgkin disease or multipl myeloma,"['carmustine', 'cyclophosphamide', 'cytarabine', 'etoposide', 'leucovorin calcium', 'methotrexate', 'perfosfamide', 'therapeutic hydrocortisone']",['2'],autologous allogeneic or syngen bone marrow transplant in hodgkin disease nonhodgkin lymphoma and multipl myeloma
1510,NCT00002946,penclomedin in treat patient with solid tumor or lymphoma,['penclomedine'],['1'],a phase i trial of oral penclomedin
1511,NCT00004057,paclitaxel plus l778123 in treat patient with recurr or refractori solid tumor or lymphoma,"['l-778,123', 'paclitaxel']",['1'],a phase i and pharmacokinet studi evalu the safety tolerability and maxim toler dose of combin therapi with paclitaxel and l778123 in patient with recurr or refractori solid malign
1512,NCT00002909,phenylbutyr in treat patient with refractori solid tumor or lymphoma,"['chemotherapy', 'oral sodium phenylbutyrate']",['1'],a phase i clinic and pharmacolog evalu of phenylbutyr in patient with refractori solid tumors studi of continu exposur oral phenylbutyr on a three time daili schedul
1513,NCT00018954,chemotherapi in treat patient with acut lymphoblast leukemia and diffus nonhodgkin lymphoma,"['asparaginase', 'cyclophosphamide', 'cytarabine', 'daunorubicin hydrochloride', 'doxorubicin hydrochloride', 'etoposide', 'ifosfamide', 'mercaptopurine', 'methotrexate', 'prednisone', 'vincristine sulfate']",['2'],pilot multin protocol in acut lymphoblast leukemia and diffus nonhodgkin lymphoma
1514,NCT00023816,carbendazim in treat patient with advanc solid tumor or lymphoma,['carbendazim'],['1'],third phase i and pharmacokinet studi of fb642 administ oral to patient with advanc solid tumor
1515,NCT00007865,combin chemotherapi plus rituximab in treat patient with recurr or refractori nonhodgkin lymphoma,"['carboplatin', 'etoposide', 'ifosfamide']",['2'],a phase ii trial of ifosfamide carboplatin and etoposid ice chemotherapi in combin with rituximab as salvag therapi
1516,NCT00004907,chemotherapi and radiat therapi plus bone marrow or peripher stem cell transplant in treat patient with relaps or refractori tcell lymphoma hodgkin lymphoma or nonhodgkin lymphoma,"['busulfan', 'cyclophosphamide', 'etoposide']","['1', '2']",highdos chemoradiotherapi with stem cell allogen cellular rescu in patient with relaps or refractori hematolog malign  a phase iii studi
1517,NCT00027937,combin chemotherapy peripher stem cell transplantation and biolog therapi in treat patient with solid tumor or lymphoma,"['busulfan', 'cyclophosphamide', 'melphalan', 'paclitaxel', 'thiotepa']",['2'],a phase ii studi of mobil chemotherapi with gmcsf and gcsf follow by high dose therapi combin with il2 activ autolog peripher blood stem cell follow by sequenti il2 therapi as treatment for solid tumor and lymphoma
1518,NCT02129062,ibrutinib in treat patient with relaps or refractori bcell acut lymphoblast leukemia,['ibrutinib'],['2'],a phase 2 studi to determin the efficaci of the btk inhibitor ibrutinib pci32765 in patient with relaps or refractori precursorb lymphoblast leukemia ball
1519,NCT02101853,blinatumomab in treat younger patient with relaps bcell acut lymphoblast leukemia,"['asparaginase', 'cyclophosphamide', 'cytarabine', 'dexamethasone', 'etoposide', 'leucovorin calcium', 'mercaptopurine', 'methotrexate', 'mitoxantrone hydrochloride', 'pegaspargase', 'therapeutic hydrocortisone', 'thioguanine', 'vincristine sulfate']",['3'],riskstratifi random phase iii test of blinatumomab nsc765986 in first relaps of childhood blymphoblast leukemia ball
1522,NCT00004075,17nallylamino17demethoxygeldanamycin in treat patient with solid tumor that cannot be remov by surgeri,['tanespimycin'],['1'],a phase i trial of 17allylaminogeldanamycin 17aag in solid tumor and lymphoma patient
1523,NCT00324597,amg 706 and gemcitabin in treat patient with advanc solid tumor or lymphoma,"['gemcitabine hydrochloride', 'motesanib diphosphate']",['1'],a phase ib openlabel sequential dosefinding studi of amg 706 in combin with gemcitabin to treat subject with solid tumor
1526,NCT00049400,s0355 ixabepilon in treat patient with advanc solid tumor or lymphoma and liver dysfunct,['bms-247550'],['1'],a phase i pharmacokinet studi of epothilon b analogu bms247550 nsc 710428d in patient with advanc malign and vari level of liver dysfunct
1527,NCT00004002,ps341 in treat patient with advanc solid tumor or lymphoma,['bortezomib'],['1'],phase i trial of ps341 in advanc cancer
1529,NCT00019838,ucn01 and fludarabin in treat patient with recurr or refractori lymphoma or leukemia,"['7-hydroxystaurosporine', 'fludarabine phosphate']",['1'],phase i and pharmacokinet studi of ucn01 and fludarabin in relaps or refractori lowgrad lymphoid malign
1530,NCT00047021,combin chemotherapi in treat patient with recurr or refractori leukemia or lymphoma,"['cytarabine', 'mitoxantrone hydrochloride']",['2'],a pilot studi of cytarabin and highdos mitoxantron for relaps or refractori hematolog malign
1531,NCT00005021,combin chemotherapi with or without biolog therapi in treat patient with refractori solid tumor or lymphoma,"['carboplatin', 'paclitaxel', 'topotecan hydrochloride']",['1'],phase i evalu of topotecan in combin with paclitaxel and carboplatin
1532,NCT00016172,zd0473 and doxorubicin in treat patient with advanc solid tumor or lymphoma,"['pegylated liposomal doxorubicin hydrochloride', 'picoplatin']",['1'],a phase i studi of zd0473 and doxil in patient with advanc refractori cancer
1533,NCT00003368,irinotecan in treat patient with solid tumor or lymphoma who have abnorm liver or kidney function or who have receiv radiat therapi to the pelvi,['irinotecan hydrochloride'],['1'],phase i studi of irinotecan for patient with abnorm liver or renal function or with prior pelvic radiat therapi
1534,NCT01490723,zevalincontain nonmyeloabl condit for stem cell transplant sct,"['rituximab', '111in ibritumomab', '90y ibritumomabtiuxetan', 'fludarabine', 'bendamustine', 'thymoglobulin', 'tacrolimus', 'methotrexate', 'mycophenolate', 'g-csf']",['2'],doseintens yttrium90 ibritumomab tiuxetan zevalincontain nonmyeloabl condit for allogen stem cell transplant in bcell malign
1535,NCT00659568,metformin and temsirolimus in treat patient with metastat or unresect solid tumor or lymphoma,"['metformin hydrochloride', 'temsirolimus']",['1'],a phase i studi of temsirolimus in combin with metformin in advanc solid tumour
1536,NCT00002625,topotecan and radiat therapi in treat patient with solid tumor or lymphoma,['topotecan hydrochloride'],['1'],phase i studi of topotecan and thorac radiat
1537,NCT00003056,prevent of graftversushost diseas in patient with advanc leukemia or lymphoma who are elig for peripher stem cell transplant,"['cyclosporine', 'cyclosporine', 'methotrexate']",['3'],peripher blood stem cell transplant in patient with advanc malign elig for allogen transplant from match relat donors a random studi of cyclosporinemethotrex or cyclosporinetcel deplet cd34 cell selection for gvhd prophylaxi
1538,NCT00020579,ms275 in treat patient with advanc solid tumor or lymphoma,['entinostat'],['1'],a phase i studi of an oral histon deacetylas inhibitor ms275 in refractori solid tumor and lymphoma
1541,NCT00003956,combin chemotherapi in treat patient with advanc cancer,"['fluorouracil', 'leucovorin calcium', 'lonafarnib']",['1'],a phase i studi of continu oral administr of sch 66336 and 5fluorouracilleucovorin 5fulv in patient with advanc cancer
1542,NCT00025129,vnp40101m in treat patient with advanc solid tumor or lymphoma,['laromustine'],['1'],a phase i trial of vnp4010m a novel alkyl agent for patient with advanc or metastat cancer
1543,NCT00003993,bryostatin 1 and interleukin2 in treat patient with refractori solid tumor or lymphoma,['bryostatin 1'],['1'],a phase lb trial of the combin of bryostatin1 and low dose interleukin2 evalu of the function and molecular status of human monocyt as antigen present cell
1545,NCT00002862,perillyl alcohol in treat patient with refractori cancer,['perillyl alcohol'],['1'],a phase i studi of perillyl alcohol in patient with refractori malign nsc 641066
1547,NCT00005626,phase ii trial with correl laboratori studi of singl agent irinotecan camptosar cpt11,['irinotecan'],['2'],phase ii trial with correl laboratori studi of singl agent irinotecan camptosar cpt11 in newli diagnos and relaps indol lymphoprolif malign
1549,NCT00002553,chemotherapi plus radiat therapi and biolog therapi in treat patient with hematolog cancer,['cyclophosphamide'],['2'],treatment of patient with hematolog malign use marrow transplant from unrel donor match for hla or incompat for one hla locus antigen
1550,NCT01408160,immunotoxin therapi and cytarabin in treat patient with relaps or refractori bcell acut lymphoblast leukemia,['cytarabine'],['1'],a phase 1 studi of the deglycosyl ricin a chaincontain combin anticd19 and anticd22 immunotoxin combotox in combin with highdos cytarabin in adult relaps or refractori blineag acut lymphoblast leukemia
1551,NCT00019019,carboxyamidotriazol and paclitaxel in treat patient with advanc solid tumor or refractori lymphoma,"['carboxyamidotriazole', 'paclitaxel']",['1'],a phase i studi of the combin of cai and paclitaxel in adult patient with refractori cancer or lymphoma
1552,NCT00003567,gene therapi and chemotherapi in treat patient with advanc solid tumor or nonhodgkin lymphoma,"['o6-benzylguanine', 'carmustine', 'temozolomide']",['1'],mutant mgmt gene transfer into human hematopoiet progenitor to protect hematopoiesi dure o6benzylguanin bg nsc 637037 and carmustin follow by temozolomid therapi of advanc solid tumor
1553,NCT00005590,levofloxacin to prevent infect follow chemotherapi in treat patient with solid tumor or lymphoma,['levofloxacin'],['3'],a randomized prospect doubleblind placebocontrol trial of prophylact oral levofloxacin follow chemotherapi for lymphoma and solid tumor
1554,NCT00052572,ixabepilon in treat patient with relaps or refractori lymphoprolif disord,['ixabepilone'],['2'],a multicent phase ii studi of bms 247550 epothilon b analogue in indol lymphoprolif disord
1557,NCT00002759,irinotecan plus cyclosporin and phenobarbit in treat patient with solid tumor or lymphoma,"['cyclosporine', 'irinotecan hydrochloride', 'phenobarbital']",['1'],a phase i studi of irinotecan cpt11 with pharmacokinet modul by cyclosporin a and phenobarbit
1558,NCT00003885,arsenic trioxid in treat patient with recurr or refractori acut leukemia chronic myeloid leukemia myelodysplasia lymphoma or myeloma,['arsenic trioxide'],['2'],phase ii studi of arsenic trioxid in relapsedrefractori acut leukemia and blast crisi of chronic myeloid leukemia
1559,NCT00002657,swog9239 reduct of immunosuppress plus interferon alfa and combin chemotherapi in treat patient with malign tumor that develop after organ transplant,"['cyclophosphamide', 'cytarabine', 'doxorubicin hydrochloride', 'etoposide', 'methotrexate', 'prednisone', 'vincristine sulfate']",['2'],phase ii trial of sequenti modif of immunosuppression interferon alpha and promacecytabom for treatment of postcardiac transplant lymphoproliferation
1561,NCT00003294,chemotherapi given with amifostin and filgrastim in treat patient with recurr or metastat cancer,"['amifostine trihydrate', 'carboplatin', 'paclitaxel']",['1'],initi clinic evalu of the combin of paclitaxel and carboplatin with modul of toxic with gcsf and amifostin
1562,NCT00513474,rasburicas in prevent graftversushost diseas in patient with hematolog cancer or other diseas undergo donor stem cell transplant,"['busulfan', 'cyclophosphamide', 'cyclosporin-a', 'etoposide', 'methotrexate', 'rasburicase', 'sirolimus', 'tacrolimus', 'fludarabine', 'allopurinol']",['1'],rasburicas to prevent graft versushost diseas
1563,NCT00004061,biolog therapi in treat patient undergo radiat therapy chemotherapy and peripher stem cell transplant for hematolog cancer,"['cyclophosphamide', 'etoposide', 'ifosfamide']",['2'],a random doubleblind placebocontrol trial of recombin human keratinocyt growth factor rhukgf in patient with hematolog malign undergo total bodi irradi tbi and highdos chemotherapi with autolog peripher blood
1564,NCT00003289,ucn01 in treat patient with advanc cancer,['7-hydroxystaurosporine'],['1'],a phase i and pharmacolog studi of ucn01 nsc638850
1565,NCT00317785,totalbodi irradi and cyclophosphamid in treat patient who are undergo donor stem cell transplant for hematolog cancer and other diseas,"['cyclophosphamide', 'cyclosporine', 'methotrexate', 'mycophenolate mofetil', 'sirolimus', 'tacrolimus']",['2'],a phase ii trial of total bodi irradi plus metabolismbas cyclophosphamid dose as prepar therapi for allogen hematopoiet cell transplant for patient with hematolog malign
1566,NCT02378038,pnt2258 for treatment of patient with richter transform brighton,['pnt2258'],['2'],a phase ii studi of pnt2258 in patient with richter transform rt
1567,NCT00816413,donor stem cell transplant pentostatin and totalbodi irradi in treat patient with hematolog cancer,"['cyclosporine', 'mycophenolate mofetil', 'pentostatin']","['1', '2']",t cellreduc unrel donor allogen peripher blood stem cell transplant with pentostatin and lowdos total bodi irradi
1569,NCT00787761,earli administr of atg follow by cyclophosphamide busulfan and fludarabin befor a donor stem cell transplant in patient with hematolog cancer,"['busulfan', 'cyclophosphamide', 'fludarabine phosphate', 'methotrexate', 'tacrolimus']",['2'],preadministr of rabbit antithymocyt globulin to optim donor tcell engraft follow reduc intens allogen peripher blood progenitor cell transplant from matchedrel donor
1570,NCT00740467,stem cell transplant in treat patient with hematolog cancer or other disord,"['busulfan', 'cyclophosphamide', 'cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']",['2'],allograft of hematopoiet stem cell with reducedintens condit from a hlahaploident famili donor phase ii studi of combin immunosuppress befor and after transplant
1573,NCT00445497,earli hospit discharg or standard inpati care in cancer patient receiv antibiot for febril neutropenia,"['amoxicillin-clavulanate potassium', 'ciprofloxacin']",['3'],a prospect randomis phase iii trial of earli hospit discharg versus standard inpati manag of cancer patient with lowrisk febril neutropenia receiv oral antibiotics oral antibiot for neutropen sepsi give earli hospit discharg orange
1576,NCT00006221,bms247550 in treat patient with advanc cancer,['ixabepilone'],['1'],a phase i studi of bms247550 nsc 710428 given week x 3 everi 4 week in patient with advanc malign
1577,NCT00005639,azacitidin plus phenylbutyr in treat patient with advanc or metastat solid tumor that have not respond to previous treatment,"['azacitidine', 'sodium phenylbutyrate']",['1'],a phase i dose escal to maxim toler dose trial of 5azacytidin 5 ac nsc 102816 in combin with sodium phenylbutyr pb nsc 657802 in patient with refractori solid tumor
1578,NCT00031941,cc5013 in treat patient with cancer that has not respond to previous therapi,['lenalidomide'],['1'],a multidos phase i studi of oral cc5013 a thalidomid derivative in patient with refractori metastat cancer
1579,NCT00004189,rebeccamycin analog and cisplatin with or without filgrastim in treat patient with advanc cancer,"['becatecarin', 'cisplatin']",['1'],a phase i and pharmacokinet studi of sequenc of nsc 655649 rebeccamycin analogue and cisplatin without and with granulocyt colonystimul factor support everi 21 day
1580,NCT00004105,combin chemotherapi in treat patient with advanc cancer,"['estramustine phosphate sodium', 'paclitaxel', 'vinorelbine ditartrate']","['1', '2']",a phase iii studi of paclitaxel estramustin phosphate and vinorelbin paclevin
1583,NCT00806767,fludarabine busulfan and antilymphocyt globulin follow by donor stem cell transplant in treat older patient with hematolog cancer,"['busulfan', 'fludarabine phosphate']",['2'],phase ii studi of allogen transplant of hematopoiet stem cell from a compat famili donor in the treatment of patient over 55 year with hematolog malign
1584,NCT00006019,phenylbutyr plus azacitidin in treat patient with acut myeloid leukemia myelodysplasia nonhodgkin lymphoma multipl myeloma nonsmal cell lung cancer or prostat cancer,"['azacitidine', 'sodium phenylbutyrate']",['2'],pilot studi of sodium phenylbutyr plus azacytidin
1588,NCT00691015,sirolimus tacrolimus and antithymocyt globulin in prevent graftversushost diseas in patient with hematolog cancer who are undergo donor stem cell transplant,"['busulfan', 'carmustine', 'cyclophosphamide', 'cytarabine', 'etoposide', 'fludarabine phosphate', 'melphalan', 'anti-thymocyte globulin iv']",['2'],a phase ii studi of sirolimus tacrolimus and thymoglobulin® as graftversushost diseas prophylaxi in patient undergo unrel donor hematopoiet cell transplant
1590,NCT00755040,cyclosporin eye drop in prevent graftversushost diseas of the eye in patient who have undergon donor stem cell transplant for hematolog cancer or bone marrow failur disord,['cyclosporine ophthalmic emulsion'],['3'],random placebo control doubl blind studi of restasi versus placebo in primari prevent of ocular gvhd after allogen stem cell transplant
1591,NCT01775475,intraven chemotherapi or oral chemotherapi in treat patient with previous untreat stage iiiiv hivassoci nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'vincristine sulfate', 'prednisone', 'lomustine', 'etoposide', 'procarbazine hydrochloride']",['2'],randomized phase ii trial of chop vs oral chemotherapi with concomit antiretrovir therapi in patient with hivassoci lymphoma in subsaharan africa
1592,NCT00049699,vnp40101m in treat patient with advanc or metastat cancer,['laromustine'],['1'],a phase i trial of vnp40101m a novel alkyl agent administ week for patient with advanc or metastat cancer
1593,NCT00003395,arsenic trioxid in treat patient with advanc hematolog cancer,['arsenic trioxide'],['1'],doserang studi of arsenic trioxid in advanc hematolog cancer
1595,NCT00301951,lowdos fludarabine busulfan and antithymocyt globulin follow by donor umbil cord blood transplant in treat patient with advanc hematolog cancer,"['busulfan', 'fludarabine phosphate', 'mycophenolate mofetil', 'tacrolimus']",['1'],pilot studi of reducedintens umbil cord blood transplant in adult patient with advanc hematopoiet malign
1596,NCT00019344,flavopiridol in treat patient with refractori cancer,['alvocidib'],['1'],a phase i trial of daili bolus flavopiridol for five consecut day in patient with refractori neoplasm
1597,NCT00004114,chemotherapi plus peripher stem cell transplant in treat patient with advanc hematolog cancer,"['cyclophosphamide', 'cytarabine', 'fludarabine phosphate']",['1'],nonmyeloabl chemotherapi follow by unrel allogen stem cell transplant in patient with advanc hematolog malignancies a pilot studi
1598,NCT00019513,combin chemotherapi in treat patient with recurrent refractory or metastat solid tumor or lymphoma,"['fluorouracil', 'gemcitabine hydrochloride', 'leucovorin calcium']",['1'],a phase i studi of week gemcitabin in combin with infusion 5fluorouracil and oral calcium leucovorin in adult cancer patient
1600,NCT00448201,reducedintens busulfan and fludarabin with or without antithymocyt globulin follow by donor stem cell transplant in treat patient with hematolog cancer or other diseas,"['busulfan', 'fludarabine phosphate', 'methotrexate', 'tacrolimus']",['2'],allogen hematopoiet cell transplant for patient with hematolog disord who are inelig or inappropri for treatment with a more intens therapeut regimen
1601,NCT00448357,allogen hematopoiet cell transplant for patient with busulfexbas regimen,"['busulfan', 'fludarabine phosphate', 'tacrolimus', 'methotrexate']","['1', '2']",allogen hematopoiet cell transplant for patient with hematolog disord who are undergo doseadjust treatment with a maxim intens busulfexbas therapeut regimen
1602,NCT00661999,darbepoetin alfa with or without iron in treat anemia caus by chemotherapi in patient with cancer,['sodium ferric gluconate complex in sucrose'],['3'],a phase iii random studi of the effect of parenter iron oral iron or no iron supplement on the erythropoiet respons to darbepoetin alfa for cancer patient with chemotherapyassoci anemia
1604,NCT00611351,busulfan cyclophosphamide and antithymocyt globulin follow by donor stem cell transplant in treat patient with hematolog cancer,"['busulfan', 'cyclophosphamide', 'mycophenolate mofetil', 'tacrolimus']",['2'],match unrel donor allogen hematopoiet stem cell transplant with a condit regimen of target busulfan cyclophosphamide and thymoglobulin
1605,NCT00544115,donor peripher stem cell transplant in treat patient with advanc hematolog cancer or other disord,"['busulfan', 'cyclophosphamide', 'cyclosporine', 'etoposide', 'fludarabine phosphate', 'melphalan', 'methotrexate', 'mycophenolate mofetil', 'sirolimus', 'tacrolimus']",['2'],a phase ii trial of allogen peripher blood stem cell transplant from match unrel donor in patient with advanc hematolog malign and hematolog disord
1606,NCT00104923,fenretinid in treat patient with refractori or relaps hematolog cancer,['fenretinide'],['1'],phase i trial of intraven fenretinid 4hpr for patient with hematolog malign
1612,NCT00424242,pemetrex disodium in the cerebrospin fluid of patient with leptomening metastas,['pemetrexed'],['1'],a pharmacokinet studi of pemetrex in the cerebrospin fluid of patient with leptomening metastas
1613,NCT00365287,combin chemotherapi and totalbodi irradi befor donor umbil cord blood transplant in treat patient with advanc hematolog cancer metastat breast cancer or kidney cancer,"['anti-thymocyte globulin', 'cyclophosphamide', 'cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']","['1', '2']",transplant of umbil cord blood from unrel donor in patient with hematolog diseas use a nonmyeloabl prepar regimen
1614,NCT00416624,epoetin alfa or darbepoetin alfa in treat patient with anemia caus by chemotherapi,"['darbepoetin alfa', 'epoetin alfa']",['2'],rc05cb a pilot random comparison of standard week epoetin alfa to every3weekepoetin alfa and everi 3week darbepoetin alfa
1615,NCT00410657,alemtuzumab and glucocorticoid in treat newli diagnos acut graftversushost diseas in patient who have undergon a donor stem cell transplant,"['methylprednisolone', 'prednisone']",['2'],a phase ii studi to evalu lowdos alemtuzumab as a glucocorticoidspar agent for initi system treatment of acut graftversushost diseas
1616,NCT00002502,combin chemotherapi and bone marrow transplant in treat patient with leukemia or myelodysplast syndrom,"['busulfan', 'cyclophosphamide', 'cytarabine']",['2'],busulfan and cyclophosphamid for cytoreduct of patient with acut and chronic leukemia and myelodysplast syndrom undergo allogen bone marrow transplant who cannot be treat with total bodi irradi
1617,NCT00005854,bone marrow transplant in treat patient with hematolog cancer,"['cyclophosphamide', 'cyclosporine', 'methotrexate']",['2'],transplant of hla haploident marrow cell after ex vivo exposur to recipi alloantigen in presenc of ctla4ig  a phase ii studi of toler induct in donor t cell by blockad of the cd80cd86cd28 costimulatori signal
1618,NCT00134017,combin chemotherapy bone marrow transplant and post transplant cyclophosphamid for hematolog cancer,"['busulfan', 'cyclophosphamide']",['2'],hla match relat and unrel bone marrow transplant with busulfancyclophosphamid and post transplant cyclophosphamid for hematolog malign
1619,NCT00134004,fludarabine cyclophosphamide and totalbodi irradi in treat patient who are undergo a donor bone marrow transplant for hematolog cancer,"['cyclophosphamide', 'fludarabine phosphate', 'mycophenolate mofetil', 'tacrolimus']",['2'],a phase ii trial of nonmyeloabl condit and transplant of partial hlamismatch bone marrow for patient with hematolog malign
1620,NCT00003396,peripher stem cell transplant in treat patient with hematolog cancer,"['cyclophosphamide', 'melphalan']",['2'],evalu of allogen peripher blood stem cell transplant from a relat donor without graftversushost prophylaxi in patient with high risk of relaps
1621,NCT00003269,amifostin follow by high dose chemotherapi in treat patient with hematolog cancer or solid tumor,"['amifostine trihydrate', 'cisplatin', 'cyclophosphamide', 'etoposide']",['2'],a phase ii openlabel trial evalu the efficaci of amifostin in patient with cancer receiv outpati doseintens cyclophosphamide etoposide and cisplatin dicep chemotherapi
1624,NCT00002818,highdos cytarabin plus deoxycytidin in treat with acut myelogen leukemia or other hematolog malign,"['cytarabine', 'deoxycytidine']",['1'],phase i and clinic pharmacokinet deescal studi of 2deoxycitidin administ as a continu infus in conjunct with a continu infus of highdos arac in patient with refractori acut myelogen leukemia
1625,NCT00006098,ps341 in treat patient with hematolog cancer,['bortezomib'],['1'],a phase i studi of ps341 in patient with hematolog malign
1626,NCT00006350,mycophenol mofetil tacrolimus daclizumab and donor peripher stem cell transplant in treat patient with hematolog cancer,"['mycophenolate mofetil', 'tacrolimus']",['2'],allogen hematopoiet stem cell transplant for hematolog malign after a nonmyeloabl condit regimen from hlamatch sibl donor
1628,NCT00005946,chemotherapi plus donor white blood cell infus in treat patient with relaps hematolog cancer follow donor peripher stem cell transplant,"['cyclophosphamide', 'etoposide']",['1'],a pilot studi of combin chemotherapi and donor lymphocyt infus for hematolog malign in relaps after allogen bone marrow transplant
1629,NCT00003572,totalbodi irradiation tacrolimus and mycophenol mofetil plus bone marrow transplant in treat patient with hematolog cancer,"['mycophenolate mofetil', 'tacrolimus']",['2'],nonmyeloabl allogen bone marrow transplant for hematolog malign
1630,NCT00004145,chemotherapi plus biolog therapi follow by peripher stem cell transplant in treat patient with hematolog cancer,"['cyclophosphamide', 'fludarabine phosphate']",['2'],allogen peripher blood stem cell transplant use a nonmyeloabl prepar regimen for patient with hematolog malign
1633,NCT00324324,moxifloxacin in prevent bacteri infect in patient who have undergon donor stem cell transplant,"['moxifloxacin hydrochloride', 'placebo']",['3'],randomized doubl blinded placebocontrol trial of antibacteri prophylaxi for the prevent of bacteri infect in the postengraft phase after allogen hematopoeit stem cell transplant
1634,NCT01925131,s1312 inotuzumab ozogamicin and combin chemotherapi in treat patient with relaps or refractori acut leukemia,"['cyclophosphamide', 'vincristine sulfate', 'prednisone']",['1'],s1312 a phase i studi of inotuzumab ozogamicin nsc772518 in combin with cvp cyclophosphamide vincristine prednisone for patient with relapsedrefractori cd22posit acut leukemia includ ball mix phenotyp leukemia and burkitt leukemia
1635,NCT00002989,combin chemotherapi with or without idarubicin and peripher stem cell transplant in treat patient with leukemia or myelodysplast syndrom,"['busulfan', 'cyclophosphamide', 'idarubicin', 'melphalan']",['3'],a random phase iii studi to assess intensif of the condit regimen for allogen stem cell transplant allosct for leukemia or myelodysplast syndrom with a high risk of relaps
1636,NCT00301912,busulfan and fludarabin befor donor stem cell transplant in treat patient with hematolog cancer,"['busulfan', 'fludarabine phosphate', 'methotrexate', 'tacrolimus']",['2'],phase ii studi evalu busulfan and fludarabin as prepar therapi in adult with hematopoiet disord undergo match unrel donor stem cell transplant
1640,NCT00281879,donor stem cell transplant or donor white blood cell infus in treat patient with hematolog cancer,"['busulfan', 'carmustine', 'cyclophosphamide', 'cyclosporine', 'cytarabine', 'etoposide', 'fludarabine phosphate', 'melphalan', 'methotrexate', 'methylprednisolone', 'mycophenolate mofetil', 'tacrolimus']",['2'],transplant of unrel donor hematopoiet stem cell for the treatment of hematolog malign
1643,NCT00006340,ganciclovir plus arginin butyr in treat patient with cancer or lymphoprolif disord associ with the epstein barr virus,"['arginine butyrate', 'ganciclovir']",['1'],a phase i trial of butyr and ganciclovir in ebvassoci malign
1647,NCT00245037,busulfan fludarabine and totalbodi irradi in treat patient who are undergo a donor stem cell transplant for hematolog cancer,"['busulfan', 'cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil', 'granulocyte colony', 'phenytoin', 'methotrexate']","['1', '2']",a phase iii nonmyeloabl allogen hematopoiet stem cell transplant for the treatment of patient with hematolog malign use busulfan fludarabin and total bodi irradi
1649,NCT00062140,totalbodi irradiation cyclophosphamide and stem cell transplant in treat patient with hematolog cancer,['cyclophosphamide'],['1'],a phase i trial of total bodi irradiation cyclophosphamid doseadjust base on it metabolism and hematopoiet stem cell transplant for patient with hematolog malign
1650,NCT00003661,chemotherapy radiat therapy and umbil cord blood transplant in treat patient with hematolog cancer,"['busulfan', 'cyclosporine', 'melphalan', 'methylprednisolone']",['2'],a pilot studi of unrel umbil cord blood transplant in children and adult with hematolog malign
1651,NCT00002750,melphalan in patient with neoplast mening,['melphalan'],['1'],phase i of intrathec melphalan in patient with recurr neoplast mening
1652,NCT00003270,chemotherapy radiat therapy and umbil cord blood transplant in treat patient with hematolog cancer,"['busulfan', 'cyclophosphamide', 'cyclosporine', 'methylprednisolone']",['2'],cord blood transplant for hematolog malign and bone marrow failur syndrom
1654,NCT00008307,combin chemotherapi follow by donor bone marrow transplant or peripher stem cell transplant in treat patient with hematolog cancer or genet disord,"['cyclosporine', 'fludarabine phosphate', 'melphalan', 'methylprednisolone', 'mycophenolate mofetil']",['2'],nonabl chemotherapeut condit befor allogen stem cell transplant
1655,NCT00994500,vorinostat and bortezomib in treat young patient with refractori or recurr solid tumors includ central nervous system tumor and lymphoma,"['vorinostat', 'bortezomib']",['1'],a phase i studi of vorinostat and bortezomib in children with refractori or recurr solid tumors includ cns tumor and lymphoma
1656,NCT00109993,campath1h  fk506 and methylprednisolon for gvhd,"['methylprednisolone', 'tacrolimus']",['2'],phase ii clinic trial incorpor alemtuzumab campath1h in combin with fk506 and methylprednisolon for treatment of sever acut graft vs host diseas
1657,NCT00004239,506u78 in treat patient with hematolog cancer and kidney or liver impair,['compound 506u78'],['1'],a phase i studi of compound 506u78 nsc 686673 in patient with hematolog malign and renal or hepat impair
1658,NCT00020865,levofloxacin compar with cefepim in treat cancer patient with fever and neutropenia,"['cefepime hydrochloride', 'levofloxacin']",['3'],multicenter doubleblind random studi to compar the safeti and efficaci of levofloxacin with that of cefepim in the treatment of fever and neutropenia  phase iiib
1660,NCT00004132,growth factor to prevent oral mucos in patient with hematolog cancer,"['cyclophosphamide', 'etoposide', 'ifosfamide']",['2'],a randomized doubleblind placebocontrol trial of recombin human keratinocyt growth factor rhukgf in patient with hematolog malign undergo total bodi irradi tbi and highdos chemotherapi with autolog peripher blood progenitor cell pbpc transplant
1662,NCT00005852,bone marrow transplant in treat patient with sever aplast anemia or reject of previous bone marrow transplant,"['cyclophosphamide', 'cyclosporine', 'methylprednisolone']",['2'],allogen bone marrow transplant for marrow failur state
1663,NCT00096096,tacrolimus and mycophenol mofetil in prevent acut graftversushost diseas in patient with advanc hematolog cancer who are undergo donor stem cell transplant,"['mycophenolate mofetil', 'tacrolimus']",['2'],a phase ii studi of the combin of tacrolimus and mycophenol mofetil for the prevent of acut graftversushost diseas
1665,NCT00538850,fentanyl sublingu spray in treat patient with breakthrough cancer pain,"['fentanyl sublingual spray', 'placebo']",['3'],a randomized doubleblind placebocontrol multicent studi to evalu the safeti and efficaci of fentanyl sublingu spray fentanyl sl spray for the treatment of breakthrough cancer pain
1666,NCT00003425,phase iii studi of escalatingdos melphalan wautolog scs  amifostin cytoprotect,"['amifostine trihydrate', 'cyclophosphamide', 'melphalan']","['1', '2']",phase iii studi of escal dose melphalan with autolog pluripot hematopoiet stem cell support and amifostin cytoprotect in cancer patient
1668,NCT00003331,combin chemotherapi in treat patient with advanc cancer,"['fluorouracil', 'leucovorin calcium', 'topotecan hydrochloride']",['1'],a phase i studi of low dose continu infus topotecan in combin with 5fluorouracil and leucovorin for advanc malign
1669,NCT00003398,bone marrow transplant in treat patient with hematolog cancer,"['cyclophosphamide', 'thiotepa']",['4'],evalu of allogen marrow transplant deplet of tcell by cd34 select in patient undergo transplant with an unrel match or 1 antigen mismatch donor or a 1 antigen mismatch relat donor
1670,NCT00004036,combin chemotherapi plus amifostin in treat patient with advanc cancer,"['amifostine trihydrate', 'carboplatin', 'cyclophosphamide']",['1'],phase i trial of high dose chemotherapi use amifostin for invivo protect of gmcsf prime progenitor cell
1671,NCT00002980,decitabin in treat patient with melanoma or other advanc cancer,['decitabine'],['1'],a phase i studi of the biolog and clinic effect of 5aza2deoxycytidin dac in patient with advanc malign
1673,NCT00003406,combin chemotherapi follow by peripher stem cell transplant in treat patient with refractori cancer,"['carboplatin', 'docetaxel', 'ifosfamide']","['1', '2']",a phase iii intensivedos ifosfamide carboplatin and taxoter ict combin chemotherapi follow by autolog stem cell rescu for patient with refractori malign
1674,NCT00080925,tcelldeplet allogen stem cell transplant after immunoabl induct chemotherapi and reducedintens transplant condit in treat patient with hematolog malign,"['cyclophosphamide', 'cyclosporine', 'cytarabine', 'doxorubicin hydrochloride', 'etoposide', 'fludarabine phosphate', 'prednisone', 'vincristine sulfate']",['1'],tcell depleted reducedintens allogen stem cell transplant from haploident relat donor for hematolog malign
1676,NCT00004258,emd 121974 in treat patient with local advanc or metastat cancer,['cilengitide'],['1'],a phase i trial of emd 121974 in patient with advanc or metastat cancer
1678,NCT00089037,sirolimus tacrolimus and methotrex in prevent acut graftversushost diseas in patient with hematolog cancer who are undergo donor stem cell transplant,"['methotrexate', 'sirolimus', 'tacrolimus']","['1', '2']",a phase iii studi of sirolimus in addit to tacrolimus and methotrex for the prevent of acutegraftversushost diseas in patient undergo hematopoiet stem cell transplant from unrel donor
1681,NCT00003805,prevent of infect in patient with hematolog cancer and persist fever caus by a low white blood cell count,"['piperacillin sodium', 'piperacillin-tazobactam', 'tazobactam sodium', 'vancomycin']",['3'],vancomycin versus placebo in persist febril granulocytopen patient given piperacillintazobactam
1683,NCT00006083,dalteparin to prevent complic in cancer patient receiv chemotherapi through a cathet,['fragmin'],['3'],a phase iii randomized doubleblind placebocontrol studi to evalu the effect of fragmin 5000 iu subcutaneously in prevent catheterrel complic when given daili to cancer patient with central venous cathet
1684,NCT00005634,suberoylanilid hydroxam acid in treat patient with advanc solid tumor that have not respond to previous therapi,['vorinostat'],['1'],phase i clinic and pharmacolog studi of suberoylanilid hydroxam acid saha msk390 in patient with advanc solid tumor
1686,NCT00006042,cyclophosphamid plus bone marrow transplant in treat patient with hematolog cancer,"['cyclophosphamide', 'fludarabine phosphate', 'mycophenolate mofetil', 'tacrolimus']",['1'],nonmyeloabl allogen bone marrow transplant for hematolog malign use haploident donors a phase i trial of pretranspl cyclophosphamid
1688,NCT00003116,highdos chemotherapi plus peripher stem cell transplant in treat patient with hematolog cancer,"['busulfan', 'cyclophosphamide', 'cyclosporine']",['2'],allogen peripher blood progenitor cell transplant use histocompat siblingmatch donor cell after highdos busulfancyclophosphamid as therapi for hematolog malign
1689,NCT00027560,melphalan fludarabine and alemtuzumab follow by peripher stem cell transplant in treat patient with hematolog cancer,"['cyclosporine', 'fludarabine phosphate', 'melphalan']",['2'],phase ii trial of nonmyeloabl regimen combin melphalan fludarabine and anticd52 monoclon antibodi campath1h follow by an unmodifi hematopoiet cell transplant from an hla compat relat or unrel donor for treatment of lymphohematopoiet malign
1690,NCT00006348,ondansetron in treat patient with advanc cancer and chronic nausea and vomit not caus by cancer treatment,['ondansetron'],['3'],phase iii randomized doubleblind placebocontrol crossov trial of ondansetron in the control of chronic nausea and vomit not due to antineoplast therapi in patient with advanc cancer
1691,NCT00010283,beclomethason in treat patient with graftversushost diseas of the esophagus stomach small intestine or colon,['beclomethasone dipropionate'],"['1', '2']",oral beclomethason dipropion capsul for treatment of intestin graftversushost disease compassion use in patient with contraindict to highdos immunosuppress therapi
1692,NCT00019656,perifosin in treat patient with refractori solid tumor or hematolog cancer,['perifosine'],['1'],a phase i trial of oral perifosin with differ load schedul in patient with refractori neoplasm
1693,NCT00005967,tipifarnib in treat patient with advanc hematolog cancer,['tipifarnib'],['1'],a dose find studi of r115777 nsc 702818 in patient with advanc hematolog malign
1694,NCT00003335,umbil cord blood transplant in treat patient with highrisk hematolog cancer,"['busulfan', 'cyclosporine', 'melphalan', 'methylprednisolone']",['2'],a pilot studi of unrel umbil cord blood transplant in patient with high risk hematolog malign
1699,NCT00004904,stem cell transplant in treat patient with hematolog cancer,"['cladribine', 'cyclophosphamide', 'etoposide', 'methylprednisolone', 'tacrolimus']",['1'],phase i studi of t cell deplet tcd partial match relat donor pmrd hematopoiet stem cell transplant for high risk hematolog diseas use intens pre and post transplant immunosuppress and megados cd34 veto cell
1701,NCT00005804,bone marrow transplant in treat patient with hematolog cancer,['cyclophosphamide'],['2'],treatment of patient with hematolog malign use marrow transplant from unrel donor incompat for one hla locus antigen
1704,NCT00357084,methotrex and glucocorticoid in treat patient with newli diagnos acut graftversushost diseas after donor stem cell transplant,"['methotrexate', 'methylprednisolone', 'prednisone']",['2'],a phase ii studi to evalu efficaci and toler of methotrex in combin with glucocorticoid for the treatment of newli diagnos acut graftversushost diseas after nonmyeloabl hematopoiet cell transplant
1705,NCT00042900,pyroxamid in treat patient with advanc cancer,['pyroxamide'],['1'],a phase i clinic and pharmacolog studi of pyroxamid nsc 696085 in patient with advanc malign
1706,NCT00054236,combin chemotherapi follow by umbil cord blood transplant in treat patient with hematolog cancer or sever aplast anemia,"['cyclophosphamide', 'fludarabine phosphate', 'methylprednisolone']",['1'],pilot studi of multipl umbil cord blood unit transplant follow nonmyeloabl condit in patient with hematolog disord or sever aplast anemia
1707,NCT00053196,donor stem cell transplant in treat patient with relaps hematolog cancer,"['busulfan', 'fludarabine phosphate', 'methotrexate', 'mycophenolate mofetil', 'tacrolimus', 'allopurinol']",['2'],nonmyeloabl allogen hematopoiet cell transplant for patient with diseas relaps or myelodysplasia after prior autolog transplant
1708,NCT00053989,peripher stem cell transplant in treat patient with hematolog cancer or aplast anemia,"['cyclophosphamide', 'fludarabine phosphate', 'methylprednisolone', 'mycophenolate mofetil', 'tacrolimus']",['2'],nonmyeloabl allogen peripher blood stem cell transplant for hematolog malign and aplast anemia
1709,NCT00064311,ravuconazol in prevent fungal infect in patient undergo allogen stem cell transplant,['ravuconazole'],"['1', '2']",a phase iii safety toler and pharmacokinet studi of ravuconazol for prophylaxi of invas fungal infect in patient undergo nonmyeloabl allogen hematopoiet stem cell transplant
1713,NCT00004232,bone marrow and peripher stem cell transplant in treat patient with hematolog cancer,"['cyclosporine', 'methylprednisolone', 'prednisone']",['1'],augment bone marrow with cd34 enrich peripher blood hematopoiet stem cell for allogen transplant of hematolog malign
1715,NCT00060255,highdos chemotherapy totalbodi irradiation and autolog stem cell transplant or bone marrow transplant in treat patient with hematolog cancer or solid tumor,"['busulfan', 'carboplatin', 'carmustine', 'cyclophosphamide', 'etoposide', 'melphalan', 'thiotepa']",['2'],autolog blood and marrow transplant for hematolog malign and select solid tumor
1716,NCT01943682,safeti studi of cpx351 in children with relaps leukemia or lymphoma,['cpx-351'],['1'],a phase ipilot studi of cpx351 for children adolesc and young adult with recurr or refractori hematolog malign
1718,NCT00003816,combin chemotherapi and donor stem cell transplant in treat patient with aplast anemia or hematolog cancer,"['busulfan', 'carboplatin', 'cyclophosphamide', 'etoposide', 'fludarabine phosphate', 'melphalan', 'thiotepa']","['2', '3']",allogen blood or marrow transplant for hematolog malign and aplast anemia
1719,NCT00003687,treatment for chronic pain in patient with advanc cancer,"['dextromethorphan hydrobromide', 'morphine sulfate']",['3'],a phase iii doubleblind equival studi of two differ formul of slowreleas morphin follow by a random between dextromethorphan or placebo plus statex sr for chronic cancer pain relief in termin ill patient
1720,NCT00006379,nonabl allo hsct for hematolog malign or saa,"['cyclophosphamide', 'fludarabine phosphate']",['2'],purineanalogcontain nonmyeloabl allogen stem cell transplant for treatment of hematolog malign and sever aplast anemia
1723,NCT00036790,motexafin gadolinium and doxorubicin in treat patient with advanc cancer,"['doxorubicin hydrochloride', 'motexafin gadolinium']",['1'],an openlabel phase i dose escal trial to evalu the safeti and pharmacokinet of motexafin gadolinium and doxorubicin chemotherapi in the treatment of advanc malign
1725,NCT00110045,caspofungin acet in treat aspergillosi in patient with hematolog cancer or in patient who have undergon a stem cell transplant,['caspofungin acetate'],['2'],a multicenter open phase ii studi to estim the activ and safeti of caspofungin casp in the firstlin treatment of probabl and proven invas aspergillosi ia in patient with hematolog malign hm or recipi of autolog haematopoiet stem cell transplant and those with allogen haematopoiet stem cell transplant hsct
1727,NCT01961063,gene therapi after frontlin chemotherapi in treat patient with aidsrel nonhodgkin lymphoma,['busulfan'],['1'],safeti and feasibl of gene transfer after frontlin chemotherapi for nonhodgkin lymphoma in aid patient use peripher blood stemprogenitor cell treat with a lentivirus vectorencod multipl antihiv rnas
1728,NCT02585947,to compar the efficaci of a prophylact use of tenofovir by durat for the nonhodgkin lymphoma,['tenofovir'],['4'],a multicent studi to compar the efficaci of a prophylact use of tenofovir by durat for the nonhodgkin lymphoma patient with isol antihbcposit who will be treat with rituximab base chemotherapi
1729,NCT00131937,sorafenib tosyl in treat patient with recurr aggress nonhodgkin lymphoma,['sorafenib tosylate'],['2'],a phase ii studi of sorafenib bay 439006 in recurr aggress nonhodgkin lymphoma
1730,NCT00089141,mycophenol mofetil mmf for treatment of chronic graftversushost diseas gvhd,"['mycophenolate mofetil', 'placebo']",['3'],a random studi to evalu the efficaci of mycophenol mofetil ad to the system immunosuppress regimen first use for treatment of chronic graftversushost diseas
1731,NCT00217412,vorinostat with or without isotretinoin in treat young patient with recurr or refractori solid tumors lymphoma or leukemia,"['vorinostat', 'isotretinoin']",['1'],a phase 1 studi of saha nsc 701852 in pediatr patient with recurr or refractori solid tumor includ lymphomas and leukemia follow by a phase i studi of saha in combin with 13cisretino acid for patient with select recurrentrefractori solid tumor
1733,NCT00004230,captopril in treat patient undergo bone marrow or stem cell transplant,"['captopril', 'cyclophosphamide']",['3'],phase iii studi of captopril in patient undergo autolog bone marrowstem cell transplant
1734,NCT00014391,ribavirin with or without monoclon antibodi therapi in treat patient who develop rsv pneumonia follow peripher stem cell transplant,['ribavirin'],['3'],a random doubleblind placebocontrol phase iii studi to evalu the safeti and efficaci of palivizumab combin with aerosol ribavirin compar to ribavirin alon to treat rsv pneumonia in patient with bone marrow transplant bmt
1735,NCT00003883,itraconazol compar with fluconazol to prevent infect in patient undergo peripher stem cell or bone marrow transplant,"['fluconazole', 'itraconazole']",['3'],a randomized compar studi of itraconazol versus fluconazol for prevent of aspergillus infect in peripher blood stem cell and marrow transplant recipi
1737,NCT00101270,oxaliplatin and irinotecan in treat young patient with refractori solid tumor or lymphoma,"['irinotecan hydrochloride', 'oxaliplatin']",['1'],a phase i studi of oxaliplatin nsc 266046 ind 57004 and irinotecan in pediatr patient with refractori solid tumor and lymphoma
1738,NCT00073944,bcx1777 in treat patient with refractori cancer,['forodesine hydrochloride'],['1'],phase i pharmacolog studi of oral and intraven bcx1777 in patient with refractori tcell and nontcel malign
1739,NCT00008359,caspofungin acet compar with amphotericin b liposom in treat patient with persist fever and neutropenia follow cancer treatment,"['caspofungin acetate', 'liposomal amphotericin b']",['3'],a multicenter doubleblind randomized compar studi to evalu the safety tolerability and efficaci of mk0991 versus amphotericin b liposom for inject as empir therapi in patient with persist fever and neutropenia
1741,NCT00058019,ixabepilon in treat patient with relaps or refractori aggress nonhodgkin lymphoma,['ixabepilone'],['2'],a phase ii studi of epothilon b analog bms247550 nsc 710428 in patient with relaps aggress nonhodgkin lymphoma
1742,NCT00003938,liposom amphotericin b in treat granulocytopenia and persist unexplain fever in cancer patient,['liposomal amphotericin b'],['3'],a strateg studi to determin the optim moment to initi system antifung therapi with ambisom in granulocytopen cancer patient with unexplain fever refractori to empir antibacteri
1744,NCT00049296,thalidomid and docetaxel in treat patient with advanc cancer,"['docetaxel', 'thalidomide']",['1'],phase i pharmacokinet trial of thalidomid and docetaxel a regimen base on antiangiogen therapeut principl
1746,NCT00045292,valacyclovir in prevent cytomegalovirus infect in patient who are undergo donor stem cell transplant,"['acyclovir', 'acyclovir sodium', 'valacyclovir']",['3'],a phase iii multicent studi of cytomegalovirus prophylaxi with valacyclovir for the prevent of serious fungal and bacteri infect among cytomegalovirus seroneg recipi of cytomegalovirus seroposit sx stem cell transplant
1747,NCT00086840,cci779 in treat patient with relaps or refractori chronic lymphocyt leukemia,['temsirolimus'],['2'],a phase ii studi of cci779 in patient with relapsed refractori or transform chronic lymphocyt leukemia
1749,NCT02228512,studi of pomalidomid combin with modifi daepoch and rituximab in kshvassoci lymphoma,"['pomalidomide', 'rituximab', 'prednisone', 'etoposide', 'doxorubicin', 'vincristine', 'cyclophosphamide']","['1', '2']",phase iii studi of pomalidomid combin with modifi daepoch and rituximab in kshvassoci lymphoma primari effus lymphoma and larg cell lymphoma aris in kshvassoci multicentr castleman disease
1752,NCT00002649,interleukin2 or observ follow radiat therapy combin chemotherapy and peripher stem cell transplant in treat patient with recurr nonhodgkin lymphoma,"['cyclophosphamide', 'etoposide']",['3'],total bodi irradiation etoposide cyclophosphamid and autolog peripher blood stem cell transplant follow by random to therapi with interleukin2 versus observ for patient with nonhodgkin lymphoma
1755,NCT01516593,short term intensifi chemoimmunotherapi in hivposit patient with burkitt lymphoma,"['induction phase', 'consolidation phase ', 'intensification phase', 'beam conditioning']",['2'],phase ii studi on safeti and activ of a short term intensifi chemoimmunotherapi combin in hivposit patient affect by burkitt lymphoma
1758,NCT01290120,chemotherapi plus rituximab combin for adult lymphoblast leukemia ball and burkitt nonhodgkin lymphoma,['chemotherapy-rituximab combination'],['2'],multicentr studi to optim therapi of burkitt leukemia ball and nonhodgkin lymphoma
1759,NCT02240719,everolimus and bendamustin hydrochlorid in treat patient with relaps or refractori hematolog cancer,"['everolimus', 'bendamustine hydrochloride']",['1'],phase i studi of everolimus  bendamustin in patient with relapsedrefractori hematolog malign
1762,NCT00669877,rituximab and hypercvad cyclophosphamide vincristine adriamycin and dexamethasone for burkitt and burkitt like leukemialymphoma,"['rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'dexamethasone', 'g-csf', 'cytarabine', 'methotrexate']",['2'],rituximab and hypercvad cyclophosphamide vincristine adriamycin and dexamethasone for burkitt and burkitt like leukemialymphoma
1763,NCT00392834,rituximab and combin chemotherapi in treat patient with newli diagnosed hivassoci burkitt lymphoma,"['cyclophosphamide', 'cytarabine', 'doxorubicin hydrochloride', 'etoposide', 'ifosfamide', 'leucovorin calcium', 'liposomal cytarabine', 'methotrexate', 'therapeutic hydrocortisone', 'vincristine sulfate']",['2'],prospect phase ii studi of a high dose short cours regimen rcodoxmivac includ cns penetr and intens it prophylaxi in hivassoci burkitt and atyp burkitt lymphoma
1764,NCT00392990,doxorubicin hydrochlorid liposom and rituximab with combin chemotherapi in treat patient with newli diagnos burkitt lymphoma or burkittlik lymphoma,"['regimen a', 'regimen b']",['2'],a multicent phase ii studi incorpor doxil® and rituximab into the magrath regimen for hivneg and hivposit patient with newli diagnos burkitt and burkittlik lymphoma
1765,NCT00217503,bortezomib and antivir therapi follow by effus drainage bevacizumab and combin chemotherapi in treat patient with primari effus lymphoma,"['bortezomib', 'cyclophosphamide', 'doxorubicin hydrochloride', 'etoposide', 'ganciclovir', 'valganciclovir', 'zidovudine']",['2'],primari effus lymphoma a pilot trial of bevacizumab and modifi doseadjust infusion cde chemotherapi preced by a brief prephas assess of target oncolyt virotherapi with bortezomib zidovudin and valganciclovir
1766,NCT00002003,phase ii studi of novantroner mitoxantrone and etoposid in patient with hiv associ larg cell and immunoblast lymphoma,"['mitoxantrone hydrochloride', 'etoposide']",['2'],phase ii studi of novantroner mitoxantrone and etoposid in patient with hiv associ larg cell and immunoblast lymphoma
1767,NCT00002524,combin chemotherapi in treat patient with aidsrel lymphoma,"['cisplatin', 'cyclophosphamide', 'cytarabine', 'doxorubicin hydrochloride ', 'etoposide', 'fluorouracil', 'ifosfamide', 'leucovorin calcium', 'methotrexate', 'methylprednisolone', 'pentamidine', 'prednisone', 'trimethoprim-sulfamethoxazole', 'vincristine sulfate', 'zidovudine ']",['2'],pilot studi in aidsrel lymphoma
1768,NCT00388193,rituximab combin with chemotherapi in burkitt lymphoma,['rituximab'],['2'],burkimabstudi multicent of optim of the treatment of llab and the burkitt lymphoma in adult patient from 15 year old
1769,NCT00126243,efficaci of rituximab and cyclophosphamide doxorubicin vincristine prednison chop in patient with hiv associ nonhodgkin lymphoma,"['rituximab', 'chop']",['2'],multicenter open label phase ii trial to evalu the efficaci and safeti of treatment with rituximab  chop regimen in patient with hiv relat nonhodgkin lymphomas anr 085 rituximab
1770,NCT00126191,intens chemotherapi and rituximab in the treatment of burkitt lymphoma,"['rituximab', 'cyclophosphamide', 'doxorubicin', 'vincristine', 'methotrexate', 'leucovorin', 'ifosfamide', 'etoposide', 'cytarabine', 'mesna']",['2'],phase ii studi of intens chemotherapi and rituximab in burkitt lymphoma
1771,NCT00024128,peripher stem cell transplant follow by infus of white blood cell in treat patient with aidsrel lymphoma,"['cyclophosphamide', 'cyclosporine']",['2'],delay donor leukocyt infus in patient receiv allogen pbsc follow condit with nonmyeloabl regimen for aidsrel lymphoma nhl and hd
1772,NCT00002571,swog9320 combin chemotherapy radiat therapy and antivir therapi in treat patient with aidsrel lymphoma,"['cyclophosphamide', 'cytarabine', 'doxorubicin hydrochloride', 'etoposide', 'leucovorin calcium', 'methotrexate', 'prednisone', 'trimethoprim-sulfamethoxazole', 'vincristine sulfate', 'intrathecal cytarabine']",['2'],studi of promacecytabom with trimethoprim sulfamethoxazole zidovudin azt and granulocyt coloni stimul factor gcsf in patient with aidsrel lymphoma phase ii
1773,NCT00621036,vaccin therapi and gmcsf in treat patient with cns lymphoma,"['methotrexate', 'thiotepa']",['2'],a phase 2 openlabel studi to evalu the efficaci and safeti of patientspecif immunotherapy recombin idiotyp conjug to klh idklh and administ with gmcsf in patient with cns lymphoma
1775,NCT00310128,combin chemotherapi follow by rituximab and yttrium y 90 ibritumomab tiuxetan in treat patient with relaps or refractori aidsrel nonhodgkin lymphoma,"['cisplatin', 'cytarabine', 'etoposide', 'methylprednisolone', 'rituximab', 'yttrium y 90 ibritumomab tiuxetan']",['2'],phase ii studi of induct therapi compris etoposide methylprednisolone cytarabine and cisplatin eshap follow by consolid therapi compris rituximab and yttrium y 90 ibritumomab tiuxetan in patient with relaps or refractori aidsrel nonhodgkin lymphoma
1776,NCT00267865,chemotherapi and haart to treat aidsrel primari brain lymphoma,"['methotrexate', 'rituximab', 'leucovorin']",['2'],aidsrel primari central nervous system lymphoma a phase ii pilot studi of highdos intraven methotrex with rituximab leucovorin rescu and high activ antiretrovir therapi
1777,NCT00133991,combin chemotherapi and rituximab in treat patient with newli diagnos burkitt lymphoma or leukemia,"['cyclophosphamide', 'cytarabine', 'methotrexate', 'prednisone', 'hydrocortisone', 'vincristine', 'leucovorin']",['2'],phase ii studi of intensifi cvp rituximab and high dose cyclophosphamid for adult burkitt or burkittlik lymphoma
1778,NCT02443831,carpall immunotherapi with cd19 car tcell for cd19 haematolog malign,"['lymphodepletion with fludarabine', 'lymphodepletion with cyclophosphamide']",['1'],immunotherapi with cd19 car redirect tcell for high risk relaps paediatr cd19 acut lymphoblast leukaemia and other haematolog malign
1779,NCT01088763,gammasecretas inhibitor ro4929097 in treat young patient with relaps or refractori solid tumors cns tumors lymphoma or tcell leukemia,"['gamma-secretase', 'dexamethasone']",['1'],a phase 12 studi of ro4929097 an oral small molecul inhibitor of gammasecretase in children with relapsedrefractori solid or cns tumors lymphoma or tcell leukemia
1780,NCT00005824,chemotherapi follow by peripher stem cell transplant in treat patient with recurr or refractori aidsrel lymphoma,"['busulfan', 'cyclophosphamide']",['2'],pilot studi of the safeti and feasibl of autolog peripher blood stem cell transplant for patient with relaps aidsrel lymphoma
1782,NCT00871546,sch 727965 in patient with mantl cell lymphoma or bcell chronic lymphocyt leukemia studi p04715,"['sch 727965', 'bortezomib']",['2'],a random phase 2 studi of sch 727965 in subject with relaps or refractori mantl cell lymphoma mcl or bcell chronic lymphocyt leukemia bcll
1784,NCT00040690,combin chemotherapi in treat patient with burkitt lymphoma or burkitt leukemia,"['cyclophosphamide', 'cytarabine', 'doxorubicin hydrochloride', 'etoposide', 'ifosfamide', 'leucovorin calcium', 'methotrexate', 'vincristine sulfate']",['2'],a clinicopatholog studi in burkitt and burkittlik nonhodgkin lymphoma
1785,NCT00039130,rituximab chemotherapy and filgrastim in treat patient with burkitt lymphoma or burkitt leukemia,"['cyclophosphamide', 'cytarabine', 'dexamethasone', 'doxorubicin hydrochloride', 'etoposide', 'ifosfamide', 'leucovorin calcium', 'methotrexate', 'prednisone', 'vincristine sulfate', 'allopurinol']",['2'],phase ii studi of rituximab and short duration high intens chemotherapi with gcsf support in previous untreat patient with burkitt lymphomaleukemia
1787,NCT00598624,clinic trial to evalu the safeti and efficaci of treosulfan base condit prior to allogen haematopoiet stem cell transplant hsct,['treosulfan iv'],['2'],clinic phase ii trial to evalu the safeti and efficaci of treosulfan base condit prior to allogen haematopoiet stem cell transplant in patient with haematolog malign
1789,NCT00001563,epoch chemotherapi  il12 for previous untreat and epoch plus rituximab for previous treat patient with aidsassoci lymphoma,['epoch'],['2'],epoch chemotherapi plus rituximab for previous treat patient with aidsassoci lymphoma
1794,NCT02199184,burkitt leukemia  doseadjust etoposide prednisone vincristine cyclophosphamide and ofatumumab epoch  o,"['ofatumumab', 'etoposide', 'doxorubicin', 'vincristine', 'cyclophosphamide', 'prednisone', 'rituximab', 'pegfilgrastim', 'g-csf']",['2'],phase ii studi of the dose adjust epoch regimen in combin with ofatumumabrituximab as therapi for patient with newli diagnos or relapsedrefractori burkitt leukemia or relapsedrefractori acut lymphoblast leukemia
1795,NCT01513603,trial of cladribine cytarabine mitoxantrone filgrastim clagm in relaps acut lymphoblast leukemia,['clag-m'],['2'],phase ii trial of clagm in relaps all
1798,NCT00060372,ipilimumab after allogen stem cell transplant in treat patient with persist or progress cancer,"['ipilimumab', 'therapeutic allogeneic lymphocytes']",['1'],ctla4 blockad with mdx010 to induc graftversusmalign effect follow allogen hematopoiet stem cell transplant
1800,NCT01219816,multicentr studi,['epratuzumab'],['2'],phase ii multicenter open label prospect to evalu efficaci and toler of a chemoimmunotherapi with hypercvad or vincristinedexamethason plus the anticd22 monovlon antobodi epratuzumab for the treatment of adult relapsedrefractori cd22 bacut lymphoblast leukaemia patient  chepral study a graall study
1801,NCT00412243,clofarabin and cyclophosphamid combin in acut lymphoblast leukemia patient,"['clofarabine', 'cyclophosphamide']","['1', '2']",phase iii studi of clofarabin plus cyclophosphamid for relaps and refractori acut lymphoblast leukemia all
1802,NCT00363272,ispinesib in treat young patient with relaps or refractori solid tumor or lymphoma,['ispinesib'],['1'],a phase 1 studi of ispinesib sb715992 in pediatr patient with relaps or refractori solid tumor
1804,NCT01564277,rasburicas and allopurinol in treat patient with hematolog malign,"['rasburicase', 'allopurinol']",['2'],efficaci and safeti of two compar singl low dose of rasburicas follow by allopurinol in adult patient with malign
1805,NCT01184885,a pilot studi to determin the safeti and toler of sirolimus given with hypercvad chemotherapi,"['hyper-cvad', 'sirolimus']",['1'],a pilot studi of hyperfraction cyclophosphamide vincristine doxorubicin and dexamethason hypercvad with sirolimus for the treatment of adult acut lymphoblast leukemia and aggress lymphoid malign
1807,NCT00776373,rapamycin in with highdos etoposid and cytarabin in relapsedrefractori aggress lymphoid malign,"['rapamycin', 'high dose etoposide', 'cytarabine']","['1', '2']",a phase iii openlabel singl institut studi evalu rapamycin in combin with highdos etoposid and cytarabin in relaps or refractori aggress lymphoid malign
1808,NCT00005811,topotecan hydrochlorid in treat children with mening cancer that has not respond to previous treatment,['topotecan hydrochloride'],['2'],a phase ii studi of intrathec topotecan nsc 609699 in patient with refractori mening malign
1810,NCT00001379,treatment and natur histori studi of lymphomatoid granulomatosi,"['rituxan', 'epoch']",['2'],treatment and natur histori studi of lymphomatoid granulomatosi
1812,NCT00702052,safeti and efficaci of rad001 in patient with mantl cell lymphoma who are refractori or intoler to velcade® therapy,['rad001'],['2'],an openlabel singlearm phase ii studi of rad001 in patient with mantl cell lymphoma who are refractori or intoler to velcade® bortezomib
1813,NCT00413075,studi of oral pxd101 in patient with advanc solid tumor or lymphoma,['oral belinostat'],['1'],open label dose escal trial of oral pxd101 in patient with advanc solid tumor
1814,NCT00596804,safeti studi of differ dose of ha20 veltuzumab in cd20 nonhodgkin lymphoma,['veltuzumab'],"['1', '2']",a phase i studi of immunotherapi with ha20 administ onc week for 4 consecut week in patient with cd20 non hodgkin lymphoma
1815,NCT01317901,a studi of tru016 in combin with rituximab and bendamustin in subject with relaps indol lymphoma,"['tru-016', 'bendamustine', 'rituximab']",['1'],a phase 1 studi of tru016 in combin with rituximab and bendamustin in subject with relaps indol lymphoma
1817,NCT02144623,pretreat with valproat prior to immunotherapi target cluster of differenti antigen 20 in chronic lymphocyt leukemia,['valproate'],['1'],pretreat with valproat prior to immunotherapi target cluster of differenti antigen 20 in chronic lymphocyt leukemia
1818,NCT00383994,immunotherapi with nk cell rituximab and rhugmcsf in nonmyeloabl allogen stem cell transplant,"['gm-csf', 'rituximab']",['1'],immunotherapi with nk cell rituximab and rhugmcsf in nonmyeloabl allogen stem cell transplant
1819,NCT02392039,studi of loratadin for pegfilgrastim induc bone pain in patient with aggress lymphoma,"['pegfilgrastim', 'loratadine']",['1'],randomized placebo control studi of loratadin for pegfilgrastim induc bone pain in patient with aggress lymphoma
1820,NCT02718755,phase ii studi of fludarabine cytarabin arac and erwinas iv in patient with relaps or refractori hematolog malign,"['fludarabine', 'cytarabine', 'erwinase']",['2'],phase ii studi of fludarabine cytarabin arac and erwinas iv in patient with relaps or refractori hematolog malign
1822,NCT02186821,ceritinib ldk378 for patient whose tumor have aberr in alk or ros1 signature,['ceritinib '],['2'],modular phase ii studi to link target therapi to patient with pathway activ tumors modul  7 ceritinib ldk378 for patient whose tumor have aberr in alk or ros1
1823,NCT00602693,tregulatori cell infus post umbil cord blood transplant in patient with advanc hematolog cancer,"['allopurinol', 'fludarabine phosphate', 'cyclophosphamide', 'sirolimus']",['1'],phase i studi of infus of umbil cord blood ucb deriv cd25cd4 tregulatori treg cell after nonmyeloabl cord blood transplant
1826,NCT02446457,studi of rituximab plus pembrolizumab mk3475 in subject with relaps follicular lymphoma,"['rituximab', 'pembrolizumab', 'lenalidomide']",['2'],phase ii studi of rituximab plus pembrolizumab mk3475 in subject with relaps follicular lymphoma
1827,NCT02420795,studi of oral onc201 in patient with relapsedrefractori nonhodgkin lymphoma,['onc201'],"['1', '2']",phase iii studi of oral onc201 in patient with relapsedrefractori nonhodgkin lymphoma
1828,NCT00785330,allohnhl flubucy,"['standard gvhd prophylaxis', 'rituximab']",['2'],open multicentral randomis phase ii studi of allogen stem cell transplant after pretreat with fludarabin busulfan cyclophospahmid and gvhdprophylaxi with or without rituximab in patient with recidiv of high grade nonhodgkin lymphoma in special risk situat in the age of 18  65
1829,NCT00244946,combin chemotherapi follow by autolog stem cell transplant and white blood cell infus in treat patient with nonhodgkin lymphoma,"['carmustine', 'cytarabine', 'etoposide', 'melphalan']",['1'],immun consolid with activ t cell arm with okt3 x rituxan anticd3 x anticd20 bispecif antibodi cd20bi after peripher blood stem cell transplant for high risk cd20 nonhodgkin lymphoma
1830,NCT02274506,infus of allogeneic 3rd parti cd19specif t cell,"['cyclophosphamide', 'fludarabine']",['1'],infus of allogeneic 3rd parti cd19specif t cell for patient with refractori cd19 blineag lymphoid malign
1831,NCT01998035,romidepsin plus oral 5azacitidin in relapsedrefractori lymphoid malign,"['romidepsin', 'oral 5']","['1', '2']",phase iiia studi of the oral 5azacitidin in combin with the histon deacetylas inhibitor romidepsin for the treatment of patient with replaps and refractori lymphoid malign
1833,NCT01947140,pralatrex  romidepsin in relapsedrefractori lymphoid malign,"['pralatrexate', 'romidepsin']","['1', '2']",phase iiia studi of the novel antifol agent pralatrex in combin with the histon deacetylas inhibitor romidepsin for the treatment of patient with relaps and refractori lymphoid malign and multipl myeloma
1836,NCT00980395,bortezomib cladribine and rituximab in treat patient with advanc mantl cell lymphoma or indol lymphoma,"['rituximab', 'bortezomib', 'cladribine']",['2'],a phase ii openlabel studi of bortezomib velcade cladribin and rituximab vcr in advanced newli diagnos and relapsedrefractori mantl cell and indol lymphoma
1837,NCT02238522,phase 1 studi evalu zen003365 in relapsedrefractori lymphoprolif malign or relapsedrefractori aml,['zen003365'],['1'],phase 1 openlabel dose escal and expans studi of zen003365 in subject with relaps or refractori lymphoprolif malign or acut myeloid leukemia
1838,NCT02118311,treg cell for agvhd in nonmyeloabl ucb transplant,"['fludarabine', 'cyclophosphamide']",['2'],t regulatori cell for suppress of acut graftvshostdiseas in recipi of a nonmyeloabl umbil cord blood transplant for treatment of hematolog malign
1839,NCT01353625,studi to assess safeti and toler of oral cc115 for patient with advanc solid tumors and hematolog malignancies,['cc-115'],['1'],a phase 1a1b multicenter open label dosefind studi to assess the safety tolerability pharmacokinet and preliminari efficaci of the dual dnapk and tor kinas inhibitor cc115 administ oral to subject with advanc solid tumor and hematolog malign
1842,NCT02431260,an openlabel doseescal studi of incb054329 in patient with advanc malign,['incb054329 monotherapy'],"['1', '2']",a phase 12 openlabel doseescalation safeti and toler studi of incb054329 in subject with advanc malign
1843,NCT00719849,donor umbil cord blood transplant in treat patient with advanc hematolog cancer or other diseas,"['cyclophosphamide', 'cyclosporine', 'fludarabine phosphate', 'mycophenolate mofetil']",['2'],transplant of unrel donor umbil cord blood in patient with hematolog malign use a nonmyeloabl prepar regimen
1845,NCT02711137,openlabel safeti and toler studi of incb057643 in subject with advanc malign,"['incb057643', 'gemcitabine', 'paclitaxel', 'rucaparib', 'abiraterone', 'ruxolitinib', 'azacitidine']","['1', '2']",a phase 12 openlabel doseescalationdoseexpansion safeti and toler studi of incb057643 in subject with advanc malign
1846,NCT00719472,a studi of rituximab altern dose rate in patient with previous untreat diffus larg bcell or follicular nonhodgkin lymphoma rate,"['rituximab', 'chop ', 'cvp ', 'analgesic']",['3'],a phase iii multicenter openlabel studi of rituximab altern dose rate in patient with previous untreat diffus larg bcell or follicular nonhodgkin lymphoma
1849,NCT01705847,a phase 1b studi evalu gs9820 in subject with lymphoid malign,['gs-9820'],['1'],a phase 1b studi evalu the safety pharmacokinetics pharmacodynamics and clinic activ of gs9820 in subject with lymphoid malign
1851,NCT00742495,pharmacokinet studi of forodesin in children with relaps or refractori tcell or bcell precursor acut lymphoblast leukaemia or tcell non hodgkin lymphoma,['forodesine'],"['1', '2']",a phase iii pharmacokinet studi of intraven and oral forodesin in children with relaps or refractori tcell or bcell precursor acut lymphoblast leukaemia or tcell nonhodgkin lymphoma
1853,NCT00251394,studi of dynavax 1018 iss follow rituxan in patient with bcell follicular lymphoma,"['rituxan', '1018 iss']",['2'],a phase 2 openlabel studi of the efficacy safety and toler of dynavax immunostimulatori phosphorothiol oligodeoxyribonucleotide 1018 iss follow rituxan rituximab treatment in patient with cd20 bcell follicular nonhodgkin lymphoma
1856,NCT01005979,a phase i trial use cyclophosphamide rituximab and revlimid cr2 for the treatment of relapsedrefractori bcell chronic lymphocyt leukemia bcll and small lymphocyt lymphoma sll,"['lenalidomide', 'rituximab,', 'cyclophosphamide']",['1'],a phase i trial use cyclophosphamide rituximab and revlimid cr2 for the treatment of relapsedrefractori bcell chronic lymphocyt leukemia bcll and sll
1858,NCT01990534,a studi of brentuximab vedotin in particip with relaps or refractori hodgkin lymphoma,['brentuximab vedotin'],['4'],a singlearm studi of brentuximab vedotin in patient with relaps or refractori hodgkin lymphoma who are not suitabl for stem cell transplant or multiag chemotherapi
1859,NCT01126502,alvespimycin hydrochlorid in treat patient with relaps chronic lymphocyt leukemia small lymphocyt lymphoma or bcell prolymphocyt leukemia,['alvespimycin hydrochloride'],['1'],a phase i studi of the hsp90 inhibitor 17dmag alvespimycin in patient with relaps chronic lymphocyt leukemia cllsmall lymphocyt lymphoma sll and bcell prolymphocyt leukemia bpll
1861,NCT02556346,pharmacokinet pk pharmacodynam pd safety toler of multipl dose regimen of mt3724 for the treatment of patient with relaps chronic bcell lymphocyt leukemia or small lymphocyt lymphoma,['mt-3724'],['1'],pharmacokinetics pharmacodynamics safeti and toler of multipl dose regimen of mt3724 for the treatment of patient with relaps chronic bcell lymphocyt leukemia or small lymphocyt lymphoma
1862,NCT01153971,a studi of induct and mainten treatment with mabthera rituximab in patient with indol bcell nonfollicular lymphoma,['rituximab'],['2'],an openlabel studi of fludarabin and cyclophosphamid plus mabthera follow by mainten with mabthera on failurefre surviv in treatmentnaïv patient with advanc indol bcell nonfollicular lymphoma
1863,NCT00365274,sgn30 and combin chemotherapi in treat patient with newli diagnos anaplast larg cell lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'vincristine sulfate', 'prednisone', 'sgn-30']",['2'],a phase ii studi of sgn30 in combin with chop in anaplast larg cell lymphoma
1864,NCT00103779,a safeti studi of sgn40 in patient with nonhodgkin lymphoma,['sgn-40 '],['1'],a phase i multidos studi of sgn40 antihucd40 mab in patient with nonhodgkin lymphoma
1865,NCT00825149,a studi of obinutuzumab in combin with chemotherapi in particip with cd20 bcell follicular nonhodgkin lymphoma,"['bendamustine', 'cyclophosphamide', 'doxorubicin', 'fludarabine', 'obinutuzumab', 'prednisone', 'vincristine']",['1'],an openlabel multicentre randomised phase ib studi to investig the safeti and efficaci of ro5072759 given in combin with chop fc or bendamustin chemotherapi in patient with cd20 bcell follicular nonhodgkin lymphoma
1866,NCT01685008,studi of fcoptim anticd19 antibodi mor00208 to treat nonhodgkin´ lymphoma nhl,['mor00208 '],['2'],a phase iia openlabel multicent studi of singleag mor00208 an fcoptim anticd19 antibodi in patient with relaps or refractori nonhodgkin´ lymphoma nhl
1867,NCT01289223,a trial to investig the efficaci of bendamustin in patient with indol nonhodgkin lymphoma nhl refractori to rituximab,['bendamustine iv'],['3'],a randomised open label multicentre phase iii studi to investig the efficaci of bendamustin compar to treatment of physician choic in the treatment of subject with indol nonhodgkin lymphoma nhl refractori to rituximab
1868,NCT02315118,pilot studi of autolog t lymphocyt with adcc in patient with cd20posit bcell malign,"['t-cell therapy', 'rituximab', 'il']","['1', '2']",pilot studi of autolog t lymphocyt with antibodydepend cell cytotox in patient with cd20posit bcell malign
1869,NCT00724984,studi of the safeti and toler of pci24781 in patient with lymphoma,['pci-24781'],"['1', '2']",phase iii doseescal studi of the panhiston deacetylas hdac inhibitor pci24781 in lymphoma
1871,NCT00377104,alvocidib in treat patient with bcell chronic lymphocyt leukemia or small lymphocyt lymphoma,['alvocidib'],['1'],a phase i doseescal studi of flavopiridol nsc 649890 administ as a 30 minut load dose follow by a 4hour infus in patient with bcell chronic lymphocyt leukemia cllsmall lymphocyt lymphoma sll follow cytoreduct with chemotherapi
1872,NCT01273090,imetelstat sodium in treat young patient with refractori or recurr solid tumor or lymphoma,['imetelstat sodium'],['1'],a phase 1 studi of imetelstat a telomeras inhibitor in children with refractori or recurr solid tumor and lymphoma
1876,NCT01589302,pci32765 ibrutinib in treat patient with relaps or refractori chronic lymphocyt leukemia small lymphocyt lymphoma or bcell prolymphocyt leukemia,['ibrutinib'],['2'],a phase 2 studi of the bruton tyrosin kinas btk inhibitor pci32765ibrutinib in relaps and refractori patient with chronic lymphocyt leukemia cllsmall lymphocyt lymphoma sll and bcell prolymphocyt leukemia bpll
1878,NCT01744626,safeti studi of cc292 and rituximab in subject with chronic lymphocyt leukemiasmal lymphocyt lymphoma,"['cc-292', 'rituximab']",['1'],a phase 1b multicenter open label studi to determin the safeti and activ of cc292 in combin with rituximab in subject with relaps or refractori chronic lymphocyt leukemia  small lymphocyt lymphoma
1880,NCT02488512,peptid receptor radionuclid therapi with 90ydotatoc in relapsedrefractori diffus larg b cell and mantl cell lymphoma,['90y-dotatoc'],['2'],peptid receptor radionuclid therapi with 90ydotatoc in relapsedrefractori diffus larg b cell dlbcl and mantl cell lymphoma mcl
1883,NCT00602836,rituximab pentostatin cyclophosphamide and lenalidomid in treat patient with previous untreat bcell chronic lymphocyt leukemia or small lymphocyt lymphoma,"['cyclophosphamide', 'lenalidomide', 'pentostatin']",['2'],phase ii trial of pentostatin cyclophosphamide and rituximab follow by consolid with lenalidomid for previous untreat bchronic lymphocyt leukemia cll or small lymphocyt lymphoma sll
1884,NCT02309515,lenalidomid in improv immun respons to vaccin therapi in patient with chronic lymphocyt leukemia small lymphocyt lymphoma or monoclon b cell lymphocytosi,['lenalidomide'],['2'],impact of short term lenalidomid on immun respons to prevnar 13® in individu with chronic lymphocyt leukemia cll small lymphocyt leukemia sll and monoclon b cell lymphocytosi mbl
1885,NCT02406742,a phase 12 openlabel dose find studi to evalu cc122 in combin with ibrutinib and obinutuzumab in subject with chronic lymphocyt leukemiasmal lymphocyt lymphoma,"['cc-122', 'ibrutinib', 'obinutuzumab']","['1', '2']",phase 12 studi to determin the safety pharmacokinetics and efficaci of singl agent cc122 and the combin cc122 and ibrutinib and cc122 and obinutuzumab in subject with chronic lymphocyt leukemiasmal lymphocyt lymphoma
1886,NCT00058240,flavopiridol in treat patient with previous treat chronic lymphocyt leukemia or lymphocyt lymphoma,['alvocidib'],"['1', '2']",a doseescal studi of flavopiridol nsc 649890 administ as a 30 minut load dose follow by a 4hour infus in patient with previous treat bcell chronic lymphocyt leukemia cllsmall lymphocyt lymphoma sll
1887,NCT00646750,transplant with ybritumomab tiuxetan zevalin plus beam regimen in patient with refractori larg bcell difuss lymphom,['ybritumomab tiuxetan '],['2'],autolog transplant of haematopoiet stem cell with condit includ zevalin  beam to patient suffer from refractori larg bcell diffus lymphom
1888,NCT00385125,treatment of patient with relaps or primari refractori aggress b cell nhl,"['bendamustine', 'rituximab']",['2'],phase ii studi for treatment of patient with relaps or primari refractori aggress b cell nhl and anthracyclin chemotherapi pretreatment who receiv or did not qualifi for autolog stem cell transplantation
1891,NCT00049413,combin chemotherapi and rituximab in treat patient with chronic lymphocyt leukemia or lymphocyt lymphoma,"['cyclophosphamide', 'pentostatin']",['2'],pentostatin cyclophosphamid and rituximab pcr for bcell chronic lymphocyt leukemia cll and small bcell lymphocyt lymphoma sll four phase ii trial with patient stratif base on prior therapi
1892,NCT02013128,ublituximab  ibrutinib in select bcell malign,"['ublituximab', 'ibrutinib']","['1', '2']",a multicent phase ii studi with safeti runin evalu the efficaci and safeti of ublituximab in combin with ibrutinib in patient with select bcell malign
1894,NCT01732861,safeti studi of cc292 and lenalidomid in subject with chronic lymphocyt leukemia small lymphocyt lymphoma,"['cc-292', 'lenalidomide']",['1'],a multicenter phase 1b openlabel studi to determin the safeti and activ of cc292 in combin with lenalidomid in subject with relaps andor refractori chronic lymphocyt leukemia  small lymphocyt lymphoma
1895,NCT02290951,a phase 1 studi to investig the safeti and toler of regn1979 in patient with cd20 bcell malign,['regn1979 multiple dose levels'],['1'],an openlabel multicent phase 1 studi to investig the safeti and toler of regn1979 an anticd20 x anticd3 bispecif monoclon antibody in patient with cd20 bcell malign previous treat with cd20direct antibodi therapi
1896,NCT00504972,phase i trial of anticd74 hll1 antibodi therapi in b cell malign,['hll1'],['1'],phase i trial of anticd74 hll1 antibodi therapi in b cell malign
1897,NCT02006485,ublituximab in combin with tgr1202  ibrutinib or bendamustin in patient with bcell malign,"['ublituximab', 'tgr', 'ublituximab', 'tgr', 'ublituximab', 'tgr']",['1'],a phase iib studi evalu the efficaci and safeti of ublituximab a thirdgener anticd20 monoclon antibody in combin with tgr1202 a novel pi3k delta inhibitor and ibrutinib or bendamustine in patient with bcell malignancies
1898,NCT00151320,phase iii trial of velcad  choprituximab in untreat dlcbl or mantl cell nhl,"['bortezomib', 'chop', 'rituximab']","['1', '2']",phase iii trial of velcade choprituximab in patient with previous untreat diffus larg b cell or mantl cell nonhodgkin lymphoma
1899,NCT00398112,sunitinib in treat patient with relaps or refractori chronic lymphocyt leukemia or small lymphocyt lymphoma,['sunitinib malate'],['2'],a phase ii studi of sunitinib malat for treatment of patient with relapsedrefractori chronic lymphocyt leukemia cll or small lymphocyt lymphoma sll
1902,NCT00816595,pentostatin cyclophosphamide and rituximab with or without bevacizumab in treat patient with bcell chronic lymphocyt leukemia or small lymphocyt lymphoma,"['cyclophosphamide', 'pentostatin']",['2'],random phase ii trial of pentostatin cyclophosphamide and rituximab with or without concurr avastin® for previous untreat bchronic lymphocyt leukemia cll
1905,NCT01116193,repeatdos studi of lenalidomid revlimid ® plus dexamethason in patient with lymphoblast leukemia,"['lenalidomide', 'dexamethasone']",['2'],a phase ii multicenter openlabel repeatdos studi of lenalidomid revlimid ® plus lowdos dexamethason in patient with refractori b cell lineag acut lymphoblast leukemia or in relaps after 2 line of treatment
1907,NCT01076556,cyclophosphamide alvocidib and rituximab in treat patient with high risk bcell chronic lymphocyt leukemia or small lymphocyt lymphoma,"['alvocidib hydrochloride', 'cyclophosphamide']",['1'],a phase i feasibl trial of cyclophosphamide alvocidib flavopiridol and rituximab car in patient with high risk bcell cllsll
1908,NCT01430390,in vitro expand allogen epsteinbarr virus specif cytotox tlymphocyt ebvctls genet target to the cd19 antigen in bcell malign,['cyclophosphamide-based chemotherapy'],['1'],a phase i dose escal trial use in vitro expand allogen epsteinbarr virus specif cytotox tlymphocyt ebvctls genet target to the cd19 antigen in bcell malign
1909,NCT00005977,combin chemotherapi in treat patient with nonhodgkin lymphoma or acut lymphocyt leukemia,"['cyclophosphamide', 'cytarabine', 'dexamethasone', 'doxorubicin hydrochloride', 'etoposide', 'ifosfamide', 'leucovorin calcium', 'methotrexate', 'vincristine sulfate']",['3'],a pilot studi of dose intensif of methotrex in patient with advancedstag iiiiv small noncleav cell nonhodgkin lymphoma and bcell all
1910,NCT02268851,a phase iib safeti and efficaci studi of the pi3kdelta inhibitor tgr1202 and ibrutinib in patient with cll or mcl,"['tgr-1202', 'ibrutinib']",['1'],a multicent phase iib studi evalu the efficaci and safeti of the novel pi3k delta inhibitor tgr1202 in combin with ibrutinib in patient with select bcell malign
1911,NCT01570049,safeti and efficaci studi of bendamustin to treat nonhodgkin lymphoma,['bendamustine'],['3'],a multicenter singl arm clinic trial in patient with rituximab refractori bcell indol lymphoma
1912,NCT00864942,trial of bendamustine lenalidomid and rituximab in chronic lymphocyt leukemia cll and nonhodgkin lymphoma nhl,"['bendamustine', 'lenalidomide', 'bl-nhl', 'blr-cll', 'blr-nhl']",['1'],phase i clinic trial of bendamustine lenalidomid and rituximab in bcell lymphoid malign
1913,NCT00003217,combin chemotherapi in treat children with stage iii or stage iv nonhodgkin lymphoma or acut lymphoblast leukemia,"['cyclophosphamide', 'cytarabine', 'dexamethasone', 'doxorubicin hydrochloride', 'methotrexate', 'vincristine sulfate']",['1'],a pilot studi of dose intensif of methotrex and cyclophosphamid in patient with advancedstag iiiiv small noncleav nonhodgkin lymphoma and bcell all a limit institut phase iii pilot studi
1914,NCT00334438,bortezomib rituximab and yttrium y 90 ibritumomab tiuxetan in treat patient with relaps or refractori lowgrade follicular or mantl cell nonhodgkin lymphoma,['bortezomib'],['1'],a phase i studi evalu combin zevalin ibritumomab tiuxetan and valcad bortezomib in relapsedrefractori lowgrad or follicular bcell and mantl cell lymphoma
1916,NCT01403948,bi 836826 dose escal in patient with relaps or refractori nonhodgkin lymphoma nhl,['bi 836826'],['1'],a phase i openlabel doseescal trial with bi 836826 in patient with relaps or refractori nonhodgkin lymphoma of b cell origin
1917,NCT00918723,vorinostat fludarabin phosphate cyclophosphamide and rituximab in treat patient with previous untreat chronic lymphocyt leukemia or small lymphocyt lymphoma,"['fludarabine phosphate', 'cyclophosphamide', 'vorinostat']","['1', '2']",a phase iii studi of fludarabine cyclophosphamide rituximab and vorinostat follow by rituximab and vorinostat mainten therapi in patient with previous untreat bcell chronic lymphocyt leukemia cll or small lymphocyt lymphoma sll
1920,NCT00735930,lenalidomid and alvocidib in treat patient with relaps or refractori bcell chronic lymphocyt leukemia or small lymphocyt lymphoma,"['alvocidib hydrochloride', 'lenalidomide']",['1'],phase 1 trial of flavopiridol in combin with lenalidomid in patient with relaps or refractori bcell cllsll
1922,NCT00039351,combin chemotherapi in treat older patient with nonhodgkin lymphoma,"['cyclophosphamide', 'prednisone', 'vincristine sulfate']",['2'],diffus larg b cell and peripher tcell nonhodgkin lymphoma in the frail elderly progress and cautious treatment strategi in poor status patients a phase ii trial with emphasi on geriatr assess and qualiti of life
1924,NCT00005631,rituximab and combin chemotherapi in treat patient with relaps or refractori larg cell lymphoma,"['carboplatin', 'etoposide', 'ifosfamide']",['2'],cytoreduct and stem cell mobil with rituximab and ice for patient with refractori or relaps cd20 bcell igl elig for asct the rice protocol
1925,NCT00060385,combin chemotherapi with or without etoposid in treat older patient with nonhodgkin lymphoma,"['chop regimen', 'epoch regimen', 'cyclophosphamide', 'doxorubicin hydrochloride', 'etoposide', 'prednisone', 'vincristine sulfate']","['2', '3']",diffus larg b cell and peripher t cell nonhodgkin lymphoma nhl in the elderly influenc of prolong oral etoposid ad to chop combin chemotherapi in patient with good physiolog status an eortc random phase iiiii trial includ geriatr assess and qualiti of life
1928,NCT02651662,studi of regn2810 and regn1979 in patient with lymphoma,"['regn2810', 'regn1979']",['1'],a phase 1 studi to assess safeti and toler of regn1979 an anticd20 x anticd3 bispecif monoclon antibody and regn2810 an antiprogram death1 monoclon antibody in patient with bcell malign
1929,NCT02456350,anticd19 chimer antigen receptor cartransduc t cell therapi for patient with b cell malign,"['fludarabine', 'cyclophosphamide']",['1'],genet engin t cell express an anticd19 chimer antigen receptor for treatment of patient with b cell malign
1930,NCT00107380,s0433 iodin i 131 tositumomab rituximab and combin chemotherapi in treat older patient with stage ii stage iii or stage iv nonhodgkin lymphoma,"['cyclophosphamide', 'doxorubicin hydrochloride', 'prednisone', 'vincristine sulfate']",['2'],iodine131label monoclon antib1 antibodi i131 tositumomab in combin with cyclophosphamide doxorubicin vincristine prednison and rituximab therapi for patient ≥ age 60 with advanc stage diffus larg bcell nhl a phase ii studi
1933,NCT02328014,acp196 in combin with acp319 for treatment of bcell malign,"['acp-196', 'acp']","['1', '2']",a phase 12 proofofconcept studi of the combin of acp196 and acp319 in subject with bcell malign
1934,NCT00003658,pentostatin cyclophosphamide and rituximab in treat patient with chronic lymphocyt leukemia or other bcell cancer,"['cyclophosphamide', 'pentostatin']",['2'],a phase iii studi of pentostatin with cyclophosphamid for previous treat patient with intermedi and highrisk chronic lymphocyt leukemia
1936,NCT00873457,perifosin in relaps or refractori chronic lymphocyt leukemiasmal lymphocyt lymphoma,['perifosine'],['2'],phase ii trial of perifosin in patient with relaps or refractori chronic lymphocyt leukemiasmal lymphocyt lymphoma
1939,NCT01120457,first in human studi to determin the safety toler and preliminari efficaci of an anticxcr4 antibodi in subject with acut myelogen leukemia and select bcell cancer,['bms-936564 '],['1'],a phase 1 openlabel multicent studi of bms936564 mdx1338 in subject with relaps acut myelogen leukemia and select bcell malign
1940,NCT00669318,pentostatin alemtuzumab and rituximab in treat patient with relaps or refractori chronic lymphocyt leukemia or small lymphocyt lymphoma,"['pentostatin', 'sargramostim']",['2'],treatment of relapsedrefractori chronic lymphocyt leukemiasmal lymphocyt lymphoma cll with pentostatin alemtuzumab and low dose rituximab a phase ii clinic trial
1941,NCT01515176,ofatumumab and dinaciclib in treat patient with relaps or refractori chronic lymphocyt leukemia small lymphocyt lymphoma or bcell prolymphocyt leukemia,['dinaciclib'],"['1', '2']",phase 1b2 studi of dinaciclib sch 727965 and ofatumumab in relaps and refractori cllsllbpll
1942,NCT02662296,ibrutinib or idelalisib in treat patient with persist or relaps chronic lymphocyt leukemia small lymphocyt lymphoma or nonhodgkin lymphoma after donor stem cell transplant,"['ibrutinib', 'idelalisib']",['2'],a phase ii nonrandomized singl institution clinic trial of signal transduct inhibitors ibrutinib or idelalisib to treat patient with persist or relaps bcell malign follow allogen hematopoiet cell transplant
1943,NCT00905398,nilotinib with chemotherapi for the treatment of philadelphia chromosom posit acut lymphoblast leukemia,['nilotinib'],"['1', '2']",estudo da eficácia do nilotinib concomitant à quimioterapia no tratamento de pacient com leucemia linfoblástica aguda filadélfia positiva recémdiagnosticada
1944,NCT02518750,reinduct therapi for relaps pediatr tcell acut lymphoblast leukemia or lymphoma,"['dexamethasone', 'panobinostat', 'liposomal vincristine', 'mitoxantrone', 'peg-asparaginase', 'bortezomib', 'intrathecal triples', 'high-dose methotrexate', '6-mercaptopurine', 'high-dose cytarabine', 'nelarabine', 'cyclophosphamide', 'etoposide', 'clofarabine']",['2'],a phase ii studi incorpor panobinostat bortezomib and liposom vincristin into reinduct therapi for relaps pediatr tcell acut lymphoblast leukemia or lymphoma
1945,NCT01212380,studi of carfilzomib in chronic lymphocyt leukemia cll small lymphocyt lymphoma sll or prolymphocyt leukemia pll,['carfilzomib'],['1'],a phase i studi of carfilzomib in chronic lymphocyt leukemia cllsmall lymphocyt lymphoma sllprolymphocyt leukemia pll
1946,NCT01886859,lenalidomid and ibrutinib in treat patient with relaps or refractori chronic lymphocyt leukemia or small lymphocyt lymphoma,"['ibrutinib', 'lenalidomide']",['1'],a dose escal studi of ibrutinib with lenalidomid for relaps and refractori chronic lymphocyt leukemiasmal lymphocyt lymphoma
1947,NCT02369653,a studi of the safeti and effect of apixaban in prevent blood clot in children with leukemia who have a central venous cathet and are treat with asparaginas,['apixaban'],['3'],a phase iii randomized open label multicent studi of the safeti and efficaci of apixaban for thromboembol prevent versus no system anticoagul prophylaxi dure induct chemotherapi in children with newli diagnos acut lymphoblast leukemia all or lymphoma t or b cell treat with asparaginas
1948,NCT01217749,efficaci and safeti studi of pci32765 combin with ofatumumab in cll,"['pci-32765', 'ofatumumab']","['1', '2']",an openlabel phase 1b2 safeti and efficaci studi of the bruton tyrosin kinas btk inhibitor pci32765 and ofatumumab in subject with relapsedrefractori chronic lymphocyt leukemiasmal lymphocyt lymphoma and prolymphocyt leukemia
1950,NCT02258529,idelalisib in combin with rituximab for previous untreat follicular lymphoma and small lymphocyt lymphoma,['idelalisib'],['2'],a phase 2 singl arm studi evalu the safeti and efficaci of idelalisib in combin with rituximab for previous untreat follicular lymphoma and small lymphocyt lymphoma
1951,NCT00500058,a phase i doseescal studi to assess the safeti and biolog activ of recombin human interleukin18,"['sb-485232', 'rituximab']",['1'],a phase i doseescal studi to assess the safeti and biolog activ of recombin human interleukin18 sb485232 administ by intraven infus in combinationwith rituximab in adult patient with b cell nonhodgkinslymphoma
